Large scale total synthesis of apoptolidinone and progress towards the total synthesis of ammocidin by Liu, Qingsong
  
 
LARGE SCALE TOTAL SYNTHESIS OF APOPTOLIDINONE AND PROGRESS 
TOWARDS THE TOTAL SYNTHESIS OF AMMOCIDIN 
 
 
 
A Dissertation 
by 
QINGSONG LIU 
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
 
December 2006 
 
 
 
Major Subject: Chemistry 
  
 
LARGE SCALE TOTAL SYNTHESIS OF APOPTOLIDINONE AND PROGRESS 
TOWARDS THE TOTAL SYNTHESIS OF AMMOCIDIN 
 
A Dissertation 
by 
QINGSONG LIU 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
Approved by: 
 
Chair of Committee, Gary A. Sulikowski 
Committee Members,  Daniel Romo 
   Daniel A. Singleton 
   Heather H. Wilkinson 
Head of Department, Emile Schweikert    
 
 
 
December 2006 
 
Major Subject:  Chemistry 
 
 
 iii 
ABSTRACT 
Large Scale Total Synthesis of Apoptolidinone and Progress Towards the Total Synthesis 
of Ammocidin. 
(December 2006) 
Qingsong Liu, B.S., Nankai University, P. R. China 
Chair of Advisory Committee: Dr. Gary Sulikowski 
 
Apoptolidin 1.1 was isolated in 1997 by Hayakawa and co-workers from a soil 
bacterium Nocardiopsis sp. during screening for specific apoptosis inducers.  The 
primary biological test revealed that this polyketide macrolide induced apoptosis in cells 
transformed with the adenovirus type E1A oncognene, but not normal cells. This 
dissertation describes the latest studies in understanding of apoptolidin’s biological 
activity mechanism and previous contributions towards its total synthesis. Synthesizing 
apoptolidinone 1.26 by an intra-molecular Horner-Wadsworth-Emmons approach 
featuring a Suzuki coupling, cross metathesis and two diastereoselective aldol reactions is 
discussed. 15 mg apoptolidinone is prepared via our previously developed intramolecular 
Suzuking coupling approach.  
Ammocidin 3.1, which was found to induce apoptosis in Ba/F3-v12 cells in an IL-
3 free medium, is a specific apoptosis inducer discovered by Hayakawa and co-workers 
in 2001 from Saccharothrix sp. AJ9571.  A strategy featuring Suzuki coupling, cross 
metathesis, Yamaguchi macrolactonization and three asymmetric aldol reactions was 
applied to the total synthesis of ammocidinone 3.6, the aglycone of ammocidin.  The 
preparation of the key building blocks was discussed in the following chapter: aldehyde 
3.8 (C14-C19) was synthesized via Sharpless asymmetric epoxidation; ethyl ketone 3.9’ 
 iv 
(C20-C28) was prepared via Kobayashi and Crimmins’s asymmetric aldol 
methodologies; aldehyde 3.14 (C7-C13) was generated by Brown crotylation and cross 
metathesis.   
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 1 
 CHAPTER I  
INTRODUCTION TO APOPTOLIDIN: ISOLATION, BIOLOGICAL ACTIVITY 
AND PREVIOUS SYNTHESES  
1.1 Apoptolidin: isolation and structure elucidation 
 Apoptosis, originated from Greek words apo and ptosis, meaning from and 
fallings respectively, was first introduced in the early 1970’s to describe programmed cell 
death.1 In contrast to necrosis, which is usually caused by injury, apoptosis is one of the 
most common regulated processes of cell death and essential to multi-cellular tissue’s 
development and health. The main function of apoptosis is to dispose of unwanted cells 
including damaged and old cells without causing damage or effect of neighboring cells.  
Quite a few factors like DNA damage and oxidative stress can stimulate the apoptosis 
process by sending signals to the cell via special enzymes known as caspases through 
very complicated mechanisms that are still unclear. Apoptosis is an essential 
counterbalance to cellular proliferation.  Defects in apoptosis can result in cancer, 
autoimmune diseases and spreading of viral infections.  It has been shown that 
neurodegenerative disorders, AIDS and ischaemic diseases are caused or enhanced by 
apoptosis failure.2 Therefore, a more detailed study of the mechanism of apoptosis could 
lead to significant advance in the clinical treatment of disease including cancer.  a 
Selective apoptosis inducers can lead only certain types of tumor cells to apoptosis 
without affecting any other healthy ones and have attracted extensive attention in drug 
discovery in the past decade.  In 1997, as a result of continuing efforts to discover  
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cytotoxic agent: apoptolidin 1.1 from a culture of soil bacterial Nocardiopsis sp (Figure 
1.1).3 
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Figure 1.1 Structure of apoptolidin 1.1 and deoxy sugars 1.2-1.4 
 
 The structure of apoptolidin was assigned based on the extensive NMR analysis 
and chemical degradation studies by Hayakawa in 1998.4 A 218 mg sample of 
apoptolidin was isolated from fermentation culture broth of Nocardiopsis sp as a white 
powder.  High resolution FABMS revealed that the molecular formula was C58H96O21.  
Methanolysis of apoptolidin under acidic condition (1% HCl-MeOH, 50 °C, 30 min) led 
to the identification of three sugar units: 6-deoxy-4-O-methyl-L-glucose 1.2, a 
disaccharide containing L-olivomycose 1.3 and D-oleandrose 1.4 attached at C(9) and 
C(27) respectively by comparing their derived methyl acetals to authentic samples.  The 
aglycone structure was determined to consist of a 20-membered macrolactone and a fully 
substituted pyranose ring.  The relative stereochemistry assignment of the aglycone was 
based on extensive two-dimensional NMR analysis. The aglycone absolute 
 3 
stereochemistry at C(9) and C(27) were assigned through observed NOE enhancement 
between 1’-H and 9-H, C1’’-H and C27-H.  
 
1.2 Isolation of iso-apoptolidin and apotolidin B&C 
 In 2002 the Sulikowski and Wender groups independently identified a second 
major fermentation product in the apoptolidin culture broth, which was assigned the 
structure isoapoptolidin 1.5 (Figure 1.2).5 Initially our group considered the possibility 
that isoapoptolidin was the C21 epimer of apoptolidin.  However, following extensive 
two-dimensional NMR analysis we concluded that isoapoptolidin was actually a C(19) to 
C(20) acyl migration product.  Both Wender’s and Sulikowski’s study showed that there 
existed an equilibrium between apoptolidin and isoapoptolidin.  Our study showed that 
treatment of apoptolidin with methanolic triethylamine led to a 1.4:1 mixture of isomers.  
1.5 isoapoptolidin
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Figure 1.2 Structure of isoapoptolidin 1.5 
 
Wender demonstrated that in a cell environment apoptolidin and isoapoptolidin likey 
existe as an equilibrium mixture. In 2005, Wender’s group reported the isolation of two 
new apoptolidin congeners, which they designated apoptolidin B and C (Figure 1.3).6 
 4 
These newly discovered compounds were produced in amounts of 2-5 mg per liter of 
culture. High-resolution mass spectrometric analysis indicated the molecular formulas of 
apoptolidin C58H96O20 and C58H96O19 for apoptolidin B and C, respectively.  The structure 
of these two compounds was established by two-dimensional NMR studies (COSY, 
TOCSY, HMQC, HMBC, ROSEY).  Apoptolidin B proved to be a C(16), C(20) dideoxy 
derivative of apoptolidin and apoptolidin C a C(20) deoxy derivative.  A study of the base 
liability of apotolidin B showed that it established an equilibrium (6:4 mixture) similar to 
apoptolidin (Dulbecco’s phosphate-buffered saline pH 7.4) despite requiring two times 
longer to reach equilibrium relative to apoptolidin.  Apoptolidin C, under the same 
conditions isomerized to a completely new compound, which has not been fully 
characterized.  
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1.7 ApoptolidinC  
Figure 1.3 Structure of apoptolidin B (1.6) and C (1.7) 
 
1.3 Biological activity study of apoptolidin and derivatives 
1.3.1 Hayakawa’s primary biological study of apoptolidin 
 As indicated by its name, apoptolidin is an apoptosis inducer. The primary 
biological assay conducted by Hayakawa showed that apoptolidin induced apoptotic cell 
 5 
death in E1A and E1A/E1B19K transformed rat glial cells while not proving cytotoxic to 
normal cells including glial cells or H-ras- and v-src-transformed cells (Table 1.1).3  
 
Table 1.1 Cytotoxicity of apoptolidin against normal and transformed cells3 
Cell line Oncogene IC50 (ng/mL) 
Glia  >100,000 
RG-E1A-7 E1A 11 
RG-E1A19K-2 E1A, E1B19K 10 
RG-E1A54K-9 E1A, E1B54K 13 
RG-E1-4 E1A, E1B19K, E1B54K 10 
3Y1  >100,000 
Ad12-3Y1 E1A, E1B19K, E1B54K 17 
HR-3Y1 H-ras >100,000 
SR-3Y1 v-src >100,000 
SV-3Y1 SV40 large T antigen >100,000 
 
 
1.3.2 Khosla’s biological target directed study of apoptolidin 
 Drugs that can selectively induce cancer cells to undergo apoptosis could play an 
important role in the development of new cancer therapy protocols.  After apoptolidin’s 
selective apoptosis ability was discovered, it drew extensive attention from researchers.  
To understand the mechanism of apopotosis of apoptolidin, Khosla and co-workers at 
Stanford University conducted a series of molecular and cell-based pharmacological 
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assays and proposed that apoptolidin’s selective apoptosis activity was associated with its 
inhibition of F0F1-ATPase.7 Their experiments showed that cell death induced by 
apoptolidin was independent of p53 status, which means it either acts downstream or 
independent of p53. In addition, the inhibition of apoptosis by BCL-2 and a caspase-9 
specific inhibitor suggested that a mitochondria-dependent pathway was involved during 
the cell death signaling.7b To identify the target of apoptolidin, a structure comparison 
study was launched and revealed that apoptolidin’s aglycone structure, apoptolidinone, 
has significant similarity with oligomycin A (1.8) and bafilomycin (1.9), which are both 
known ATPase inhibitors (Figure 1.4).7c  These results prompted evaluation of the 
inhibition of apoptolidin against F0F1-ATPase, which led to the conclusion that F0F1-
ATPase was the molecular target of apoptolidin.  
 
OH OHOH O
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O OMe
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MeO
OH OH O O OH OH
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O OH O OH O
Apoptolidin Aglycone
Oligomycin A
OH
Bafilomycin
OH OH OH
OMe
O OH
OMe
O O
(1.8)
(1.9)  
Figure 1.4 Structural similarity among apoptolidin, oligomycin and bafilomycin  
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 Khosla proposed a metabolism-driven mechanism to explain the selective 
apoptosis induction of apoptolidin.7a   According to his hypothesis, apoptolidin functions 
through inhibition of mitochondrial F0F1-ATPase in cells that demand a high level of 
ATP hydrolysis, which depends on mitochondrial activity.  This model can explain the 
selectivity of apoptolidin in transformed cells over normal cells.  Presumably, 
transformed cells demanding a high level of ATP require a higher aerobic mitochondrial 
metabolism can be signaled through the reduced mitochondrial ATP synthase caused by 
apoptolidin.  While normal cells and transformed cells that require low level of ATP are 
resistant to apoptolidin-induced apoptosis.  Further study of the mechanism of apoptosis 
is required to fully understand apoptolidin’s biological activity.  
 During Khosla’s structure comparison study, they found that apoptolidin 
derivative 1.10 (Figure 1.5) retained considerable activity against mitochondrial ATPase 
(one order less active than apoptolidin) but lost cellular cytotoxicity in vivo (1% active as 
apoptolidin).  This observation suggests an alternative mechanism that apoptolidin may 
induce apoptosis by interfering with a secondary target.7c 
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Figure 1.5 Structure of truncated apoptolidin 1.10 
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1.3.3 Wender’s study of biological activity of apoptolidin derivatives 
  Since 2002, Wender’s group has extensively investigated the biological activity of 
apoptolidin and its derivatives.  Rresults of their study are summarized in the Table 1.2.8   
 
Table 1.2: Summary of apoptolidin and derivatives biological activities in F0F1-ATPase 
and E1A transformed cells8 
Compounds 
GI50(µM) 
Ad12-3Y1 
GI50(µM) 
3Y1 
IC50(µM) 
F0F1-ATPase 
1.1 (apoptolidin) 0.0065 >1.0 0.7 
1.11 (C2’-OBz) 0.0036 >1.0 0.3 
1.12 (C4’’’-OAc,C23-OAc) 0.0095 >0.6 0.4 
1.13 (C4’’’-OAc) 0.0098 >1.0 0.8 
1.14 (C16-OAc) 0.056 >1.0 0.8 
1.15 (3’-OAc) 0.0027 >1.0 0.4 
1.16 (C20-OAc) 0.011 >1.0 1.1 
1.17 (C20-OMe) 0.012 >1.0 2.8 
1.18 (C21-OMe) 0.016 >1.0 2.3 
1.5 (isoapoptolidin) 0.009 >1.0 17 
1.19 (macrolide, C20-OH) 5.4 >7.0 13 
1.20 (macrolide, C20-OMe) 1.4 >5.0 16 
1.21 (macrolide, C20-OBz) 2.4 >5.0 16 
1.22 (δ-lactone) >12 >12 190 
1.23 (Diels-Alder adduct) 3.2 >5.0 2.3 
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Figure 1.6 Structure of apoptolidin derivatives 1.11-1.23 
 
 As described above, Khosla has proposed a hypothesis that apoptolidin’s 
biological target is mitochondrial F0F1-ATPase and provided evidence to explain the 
relationship of cytotoxicity to this metabolic pathway.  To explore the mechanism of 
apoptolidin and improve its therapeutic potential, Wender group prepared a series of 
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analogues 1.11-1.23 through chemical modification of apoptolidin, which is readily 
obtained by fermentation (Figure1.6).8  The preliminary in vitro assay with F0F1-ATPase 
showed that modifications of hydroxyl groups with esters (1.11-1.15) and ethers (1.16-
1.18) did not significantly effect the activity (Table 1.2).  The greatest effect on activity 
observed across this series of analogs in this assay were methyl ethers C(20) (1.17) or 
C(21) (1.18).  Isoapoptolidin (1.5) demonstrated a significant decrease in enzyme 
inhibitions with an over all 24-fold reduced potency.  Although not as active as 
apoptolidin, derivatives 1.19-1.21 still retain activity compared to isoapoptolidin.  
However, the simple lactone 1.22 derived from oxidative cleavage of apoptolidin lost 
significant inhibition activity.  To evaluate the importance of hydroxyl groups, Wender’s 
group prepared compound 1.23 a Diels-Alder reaction product.  Evaluation of 1.23 
against F0F1-ATPase indicated that it was only 3 fold less active than apoptolidin and 
comparable to methyl ether 1.17 and 1.18.  Considering F0F1-ATPase assay is a cell free 
system and the unusual insensitivity of activity to widely varied structural change, they 
established a cell assay with normal 3Y1 and E1A and E1B transformed Ad12-3Y1 cells 
(identical to the same cell lines used by the Seto-Hayakawa group). In this assay 
apoptolidin showed its potency toward transformed Ad12-3Y1 cell (6.5 nM) and no 
effect on normal 3Y1 cell.  While in cell free F0F1-ATPase inhibition test, it is much less 
potent (IC50 = 0.7 µM).  They reasoned the 2-order magnitude difference in activity might 
reflect a difference in cellular uptake, chemical modification or cumulative effects in the 
3 days cell-based assay.  Acyl derivatives 1.11-1.16 were much more active in cell 
proliferation assay than in the cell free enzyme test.  Furthermore, these analogues 
showed only a small difference relative to apoptolidin in terms of potency except 1.14 
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(56 nM)  (containing a C(16) Acetate). This exception (1.14) could be explained by one 
of three reasons: C(16) hydroxyl is important for activity; the increased steric demand 
affects the action of apoptolidin, or C(16) acetate might be a poor lipase substrate.  The 
methyl ether 1.17 and 1.18 retained the same trend in the cell assay with the F0F1-ATPase 
enzyme assay, which demonstrated 3-4 fold less potency to apoptolidin.  Surprisingly, 
isoapoptolidin 1.5 demonstrated almost the same activity against transformed cells with 
apoptolidin (9 nM vs 6.5 nM) while a great difference was observed in the enzymatic 
assay.  This result is consistent with the observation that there is a facile equilibration 
between apoptolidin and isoapoptolidin.  Without pyranose and disaccharide part, 
compounds 1.19-1.21 are about 20 fold less active than parent compounds in the 
enzymatic assay, while in E1A transformed cell they are almost 1000 times less potent 
than apoptolidin.  Lactone 1.22 lost potency to both transformed cell and F0F1-ATPae.  
Diels–Alder adduct was 500 less active in transformed cells, however, it retained almost 
full activity against F0F1-ATPase.  This indicated that the loss of activity in 1.19-1.21 was 
due to the binding affinity change to the biological target rather than a loss of cellular 
uptake.  Based on these data, Wender proposed that there might be a relevant secondary 
biological target of apoptolidin.8c  
 Wender also tested apoptolidin A, B and C in H292 cell line.  The results are 
summarized below in Table 1.3.  Apoptolidin B is more active than A to H292 cell. 
Apoptolidin C is less potent than B but more active than A.  
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Table 1.3 Growth inhibition assay result with H292 cells 
Compounds GI50(µM) 
Apoptolidin A (1.1) 0.032 + 0.003 
Apoptolidin B (1.6) 0.007 + 0.004 
Apoptolidin C (1.7) 0.024 + 0.005 
 
1.3.4 Nicolaou’s biological study of apoptolidin and analogues 
 Nicolaou and co-workers at Scripps accomplished the first total synthesis of 
apoptolidin and investigated the biological activity of apoptolidin and some synthetic 
intermediates (Figure 1.7).9 As summarized in Table 1.4, apoptolidin is the most active 
compound among these analogues.  All the other analogues significantly lost their 
activity compared to apoptolidin (Table 1.4). These observations provide further evidence 
to Khosla’s hypothesis that aglycone structure contributes the biological activity and 
carbohydrate side chain help cellular transport or binding to the cellular target.  
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Table 1.4 Cytotoxicity of synthesized apoptolidin analogues against 1A9 human ovarian 
carcinoma cells  
Entry Compound IC50 (µM) 
1 Apoptolidin (1.1) 0.24 
2 1.24 11.5 
3 1.20 20.0 
4 1.25 45.0 
 
1.4 Previous studies toward total synthesis of apoptolidin 
 The complex structure and interesting biological activity of apoptolidin have 
drawn extensive attention from synthetic community.  To date two total syntheses of 
apoptolidin and three total synthesis of apoptolidinone (aglycone structure) have been 
accomplished and multiple fragment syntheses have been reported.  Some of these efforts 
will be discussed in this section.  
 
1.4.1 K. C. Nicolaou’s total synthesis of apoptolidin 
In 2001, Nicolaou group completed the total synthesis of apoptolidin.  Later in 
2003, a revised synthesis route based on the same strategy was disclosed leading to an 
efficient total synthesis.10 The total synthesis features a Stille coupling, Yamaguchi 
macrolactonization and a dithiane coupling reaction (later changed to a Horner-
Wadsworth-Emmons reaction) to construct the 20-membered macrolactone ring (Scheme 
1.1).  The three sugar units were introduced at a very late stage of the total synthesis.  The 
disconnection between C1 lactone and C11-C12 revealed 1.31 and 1.32 as key building 
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blocks.  1.32 was first prepared from 1.33 and 1.34 via dithiane coupling and later in the 
second generation it was constructed by Horner-Wadsworth-Emmons reaction.   
 
Scheme 1.1 Nicolaou’s retrosynthetic analysis of apoptolidin 1.1 
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The first generation synthesis of trienoate 1.31 was based on a strategy that 
utilized consecutive Wittig reactions (Scheme 1.2).   Starting from known propargylic 
aldehyde 1.35, Brown’s asymmetric crotylation, TBS protection followed by ozonolysis 
of the terminal olefin and subsequent Wittig olefination provided ethyl ester 1.37.  
DIBAL-H reduction, Ley oxidation followed by a Horner-Wadsworth-Emmons reaction 
afforded dienoate 1.38.  A second standard three-step sequence including reduction, 
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oxidation and HWE reaction furnished trienoate 1.39.  Finally deprotection followed by 
Pd(0) catalyzed hydrostannylation finished up the synthesis of 1.31. 
 
Scheme 1.2 Nicolaou’s first generation synthesis of trienoate 1.31 
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 In 2003 the Nicolaou group reported a revised synthesis route to 1.31 based on a 
Suzuki coupling strategy (Scheme 1.3). This shorter sequence began with aldehyde 1.40, 
which is available from the first generation synthesis.  One carbon homologation with 
Ohira-Bestmann reagent 1.41 followed by methylation of terminal acetylene generated 
diyne 1.42.  Chemoselective hydroboration with catecholborane followed by aqueous 
hydrolysis afforded vinyl boronic acid 1.43.  The counterpart of the Suzuki coupling 
vinyl bromide 1.46 was prepared from known compound 1.44 with Wittig olefination.  
Trienoate 1.47 was obtained by coupling 1.43 and 1.46 together.  Further elaboration 
introduced the vinyl tin moiety to afford 1.31.  
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Scheme 1.3 Nicolaou’s secondary generation synthesis of 1.31 
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 Nicolaou’s first generation synthesis of fragment 1.32 (C12-C28) was based on a 
dithiane coupling reaction.  Although two synthetic routes were developed to prepare the 
aldehyde part required for the dithiane coupling, only the more efficient synthetic 
sequence is summarized here (Scheme 1.4).  The synthesis of aldehyde 1.33 began with 
commercial available (+)-glycidol 1.48.  Protection of the free hydroxyl group followed 
by epoxide opening with allenylmagnesium bromide, silylation of the newly generated 
hydroxyl group and methylation of the resultant terminal acetylene afforded compound 
1.49.  DDQ removal of the PMB protecting group, Ley oxidation of the corresponding 
alcohol, asymmetric allylation followed by methylation of the newly formed hydroxyl 
group afforded 1.50.  Sharpless asymmetric dihydroxylation and benzylidene formation 
provided 1.51.  Finally, a reduction and oxidation sequence furnished desired aldehyde 
1.33.   
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Scheme 1.4 Nicolaou’s synthesis fragment 1.33 
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 Dithiane 1.34 was prepared starting from the glycidol methyl ether 1.52.  1,3-
dithiane opening of the epoxide, PMB protection and dithiane hydrolysis afforded 
aldehyde 1.53 (Scheme 1.5).  Brown asymmetric crotylation, silylation of the newly 
formed hydroxyl group followed by oxidative cleavage of the terminal alkene furnished 
aldehyde 1.54.  Evan’s asymmetric aldol reaction and Weinreb amide displacement of the 
auxiliary generated amide 1.56.   Then TMS protection, DIBAL-H reduction, dithiane 
formation followed by silylation provided dithiane 1.34.  
 
Scheme 1.5 Nicolaou’s synthesis fragment 1. 34 
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 As designed, aldehyde 1.33 and dithiane 1.34 were coupled together by treatment 
with base (tBuLi) to provide a 1.5:1 mixture of diastereomers 1.57 (Scheme 1.6).  Both of 
the disastereomers were taken forward.  Hence, desilylation with TBAF, dithiane 
hydrolysis with Stork-Zhao’s method and resilylation with TBSOTf afforded 1.58.  At 
this stage the stereochemistry of the C20 was assigned by converting 1.58 to C20-C21 
carbonate with triphosgene. Then both isomers were protected as orthoester with 
trimethyl orthoacetate and the alkyne moiety was subjected to hydrozirconation and Zr-I 
exchange to furnish vinyl iodide 1.59.  At this point the unwanted C20 epimer was 
inverted through a standard oxidation-reduction sequence.  Oxidative removal of DMB 
and PMB protecting groups followed by protection of the diol with triphosgene and 
silylation afforded southern part of the apoptolidin 1.32.  
 
Scheme 1.6 Nicolaou’s completion synthesis of fragment 1.32 
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An alternative route to synthesis of fragment A32 based on Horner-Wadsworth-
Emmons reaction was later developed and summarized in Scheme 1.7.  Weinreb amide 
1.61, which was an intermediate in the synthesis of fragment 1.34, was converted to  
phosphonate 1.62 via a three-step sequence including phosphonate installation, 
desilyation and resilylation.  HWE reaction between 1.62 and aldehyde 1.63, which is 
readily available from 1.50 via oxidative cleavage of the terminal alkene, proceeded 
smoothly to form the trans olefin. Sharpless asymmetric dihydrolxyation, desilylation- 
cyclization, methylation of the newly formed hemiacetal and protection of the diol with 
                 
                   Scheme 1.7 Nicolaou’s HWE strategy to synthesis of fragment 1.32 
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triphosgene furnished 1.64.   Silylation with TBSOTf, hydrozirconation and Zr-I 
exchange, reprotection of the diol with triphosgene, replacing the PMB group with TES 
protecting group afforded fragment 1.32.  
With both key fragment 1.32 and 1.31 in hand, Stille coupling connected them 
together and afforded ployene 1.65 (Scheme 1.8).  Kahne’s glycosylation with sugar 1.27 
followed by KOH hydrolysis of C19–C20 carbonate and selective Yamaguchi 
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macrolactonization furnished macrolide 1.66.  Protection of the C20 hydroxyl followed 
by selective desilylation of C27 TES group provided 1.67 and set up the stage for the 
second glycosylation.  Disaccharide 1.28 was attached to C27 via a Ti(II) mediated 
glycosylation.  Finally, global desilylation with HF.Pyr, acetate saponification and acetal 
hydrolysis afforded the target molecule apoptolidin 1.1. 
 
 
Scheme 1.8 Nicolaou’s completion synthesis of apoptolidin 1.1 
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1.4.2 Koert’s total synthesis of apoptolidin 
 In 2001 Ulrich Koert accomplished the total synthesis of the aglycone structure of 
apoptolidin, apoptolidinone.11 Three years later, they reported their total synthesis of 
apoptolidin.12 Their synthesis feactures a strategy similar to Nicolaou’s approach to 
construct the 20-membered macrolactone, which disconnected the macrolide from  
 
Scheme 1.9 Koert’s restrosynthetic analysis of apoptolidin 1.1 
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lactone part and C11-C12 bond.  Regarding incorporation of the sugar moieties, they 
selected to introduce the sugar residues early during the course of the fragment synthesis.  
This strategy revealed northern half 1.68 and southern half part fragment 1.69 as key 
building blocks (Scheme 1.9). The synthesis of trienoate 1.68 was based on three 
consecutive Wittig type olefination reactions as Nicolaou applied in his first generation 
synthesis of trienoate 1.31 (Scheme 1.10).  Starting from β-hydroxyl lactone 1.70,  
silylation with TBSOTf, lactone reduction with DIBAL-H and Wittig olefination 
followed by silylation with TESCl provided bissilylated diol 1.71. Then a standard three-
step sequence including reduction, oxidation and Wittig olefination afforded dienoate 
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1.72.  Selective removal of TES silyl ether with CSA, oxidation with Dess-Martin 
periodinane followed by Takai reaction introduced E-vinyl iodide 1.73. The ethyl ester 
was reduced and the corresponding alcohol was acetylated.  Desilylation followed by 
Kahne glycosylation with sulfoxide 1.78 afforded 1.68.  The glycosyl sulfoxide 1.78 was 
prepared from acetonide-protected L-rhamnose thioglycoside 1.76.  Methylation of the 
free hydroxyl, removal of the acetonide with PTSA, selective protection 4-hydroxyl as 
  
Scheme 1.10 Koert’s synthesis of fragment 1.68 
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TBS ether and Dess-Martin oxidation generated ketone 1.77.  Diastereoselective 
reduction of the ketone and desilylation furnished a diol, which was then transformed into 
SIBA-protected glycosylsulfoxide 1.78 by protection and oxidation. 
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The southeastern disaccharide was prepared from L-rhamnose 1.79 and D-glucal 
1.82 (Scheme 1.11).  methyl acetal formation  followed by benzylidene protection of the 
3,4-diol and treatment of excess MeLi afforded branched sugar 1.80.  Selective acylation 
of the secondary alcohol, protection of the tertiary alcohol as TES silyl ether followed by 
removal of the acetate protecting group furnished the left part of disaccharide 1.85.   The 
synthesis of the remaining sugar started from 1.82 and protection of the 4,6-diol.  
Methylation of the allylic alcohol, desilylation, tosylation followed by silylation again 
 
 Scheme 1.11 Koert’s synthesis of disaccharide 1.85 
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generated 1.83.  The precursor of the glycosyl donor 1.84 was obtained through a three-
step reaction sequence including treatment of the 1.83 with PhSCl, Ag2CO3(aq) and  
NaH, Cl3CCN subsequently.  Finally, TMSOTf mediated coupling of 1.81 and 1.84 
produced a disaccharide, which was reduced to afford 1.85.  
The synthesis of the southern half of apoptolidin began with β-ketoester 1.86, 
which was subjected to Noyori’s ruthenium catalyzed asymmetric hydrogenation, 
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silylation, DIBAL-H reduction to afford aldehyde 1.87 (Scheme 1.12). Evans aldol 
reaction with 1.88 produced alcohol 1.89.  Subsequently, anti-1,3-reduciton,  
  
                                 Scheme 1.12 Keort’s synthesis of fragment 1.69  
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displacement of auxiliary with Weinreb amide and silylation of the free hydroxyl 
furnished 1.90.  Benzyl protected glycidol 1.91 was converted to E-vinyl iodide 1.92 via 
a four-step sequence including epoxide opening, methylation, desilylation, 
hydrozirconation and Zr-I exchange.  After Lithium-Iodine change, compound 1.92 was 
coupled with Weinreb amide 1.90 to produce the corresponding ketone, which was 
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desilylated to cyclize to methyl hemiactal 1.93.  Silylation of the C27 hydroxyl group 
followed by Sharpless asymmetricdihydroxylation and acylation of the newly formed diol 
provided 1.94.  After desilylation, the disaccharide 1.85 was introduced to furnish 1.95 
via NIS activation followed by reductive elimination of the iodide.  Finally, reductive 
debenzylation, Dess-Martin oxidation, chelation-controlled Grignard addition and acetate 
hydrolysis provided C12-C28 fragment 1.69.  
A copper (I) mediated Stille reaction coupled fragments 1.68 and 1.69 to provide 
1.97, which was then subjected to cyanomethyl ester hydrolysis and Yamaguchi 
macrolactonization to close the 20-membered macrolide (Scheme 1.13).  Global 
deprotection with H2SiF6 completed the total synthesis of apoptolidin.  
 
Scheme 1.13 Keort’s completion synthesis of apoptolidin 1.1 
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1.4.3 Crimmins’s total synthesis of apoptolidinone and sugars 
 In late 2005 Crimmins and co-workers reported their total synthesis of 
apoptolidinone and later the individual sugar units.13 Apoptolidinone, the aglycone of 
apoptolidin, was considered as a check-point en route to the total synthesis of 
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apoptolidin.   In contrast to Nicolaou and Koert’s synthesis, Crimmins disconnected the 
                         Scheme 1.14 Crimmins’ retrosynthesis of apoptolidinone 1.26 
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macrolide at the C10-C11 bond, which was proposed to be formed via a cross metathesis 
reaction.  In the synthesis of lower part they adopted the same strategy as employed by 
Nicolaou, which introduced the C20–C21 diol by Horner-Wadsworth-Emmons 
olefination and Sharpless asymmetric dihydroxylation.  The highlight of this synthesis 
was constructing 8 of 12 stereocenters via thiazolidinethione aided asymmetric 
methodology.  The retrosynthesis of apoptolidinone is illustrated in Scheme 1.14. 
Crimmins’ synthesis of trenoate 1.98 was similar to Koert’s synthesis, which 
applied three consecutive Wittig type olefination reactions (Scheme 1.15).  Starting from  
 
Scheme 1.15 Crimmins’ synthesis of trienoate 1.98 
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known anti-aldol adduct 1.101, silylation, reductive cleavage of the auxiliary and Wittig 
reaction afforded 1.103.  A sequence of two standard three-step reaction including 
reduction, oxidation and olefination completed the trienoate.  Finally, desilylation with 
H2SiF6 delivered the upper fragment of apoptolidinone: 1.98.  
 
Scheme 1.16 Crimmins’ synthesis of fragment 1.99 
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 The synthesis of aldehyde 1.99 commenced with glycolyl amide 1.104 (Scheme 
1.16).  Asymmetric alkylation followed by reductive cleavage of the auxiliary and Swern 
oxidation of corresponding alcohol afforded aldehyde 1.105.  Titanium mediated 
allylation provided a syn-diol via chelation-control.  After silylation of the newly formed 
hydroxyl, ruthenium catalyzed hydroboration followed by acylation introduce the acetate 
in the right part of 1.99.  Finally, ozonolysis of the left terminal alkene finished up the 
synthesis of aldehyde 1.99. 
The preparation of ketophosphonate 1.100 began with chiral auxiliary 1.106 
(Scheme 1.17).  Asymmetric alkylation, reduction of auxiliary and subsequent 
methylation of the corresponding alcohol introduced the C27 stereocenter and terminal 
methyl ether.  Asymmetric aldol with chiral thazolidinethione auxiliary 1.108 followed 
by silylation and reduction afforded aldehyde 1.109.  A second aldol reaction with 1.108 
and silylation set up the stereocenter at C22 and C23.  Finally, keotphosphonate 1.100 
was obtained by displacement of the auxiliary with lithiodimethyl methylphosphonate. 
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Scheme 1.17 Crimmins’ synthesis of fragment 1.100 
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 With all the building blocks in hand, they turned to the attention to the key 
coupling reactions.  HWE reaction between aldehyde 1.99 and phosphonate 1.100 
followed by desilyation afforded pyranose 1.110 (Scheme 1.18).  Silylation followed by  
 
Scheme 1.18 Crimmins’ completion synthesis of apoptolidinone 1.26 
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dihydroxylation introduced C20 and C21 diol, which was subsequently protected as a 
carbonate.  Converting benzyl ether to the more labile TES silyl ether was accomplished 
through two steps to furnished intermediate 1.111.  Hydrolysis of acetate followed by 
Swern oxidation set the stage for introducing diene required for cross metathesis.  A 
Horner-Wadsworth-Emmons reaction followed by a Wittig reaction afforded diene 1.112, 
which was then coupled with trienoate 1.98 via cross metathesis to form the C10-C11 
bond.  Silylation of the C9 hydroxyl with TBSOTf provided polyene intermediate 1.113.  
Hydrolysis of the ethyl ester and C20-C21 carbonate followed by selective Yamaguchi 
macrolactonization closed the 20-membered macrolactone.  Finally, global deprotection 
with H2SiF6 completed the total synthesis of apoptolidinone 1.26.  
 Each of the three monosaccharide in apoptolidin is 6-deoxy sugar (scheme 1.19).  
Both Nicolaou’s and Koert’s synthesis took an approach to modify natural carbohydrates.  
In contrast, Crimmins group applied his anti glycolate aldol methodology to establish the 
C4 and C5 stereocenter in all sugar units and prepared them from simple building 
blocks.14   
Scheme 1.19 Crimmins’ retrosynthesis of sugar units  
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 The preparation of sugar 1.114 commenced with an anti glycolate aldol reaction 
between o-methyl glycolyloxazolidinethione 1.118 and acetaldehyde (Scheme 1.20).  
After silylation and reductive removing of the auxiliary, the aldol adduct was converted 
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into primary alcohol 1.119.  Swern oxidation followed by Horner-Wadsworth-Emmons 
reaction provided α,β-unsaturated methyl ester, which in turn was subjected to Sharpless 
asymmetric dihydroxylation and afforded diol 1.120.  Desilylation simultaneously led to 
cyclization and furnished lactone, which was then resilylated and reduced to afford 
protected 1.114: 1.121.  
 
Scheme 1.20 Crimmins’ synthesis of sugar 1.114 
O
OTES
MeO
Me
TESO
1.121
O N
S
Bn
OMe
O
1) TiCl4, (-)-sparteine
     CH3CHO
2) TESOTf,2,6-Lutidine
3) LiBH4, MeOH
HO Me
OMe
OTES
1) (COCl)2, DMSO, Et3N
2) (MeO)2P(O)CH2CO2Me
3)AD-mix-!,t-BuOH/H2O
Me
OMe
OTES
MeO2C
OH
OH
1) TBAF
2) TESOTf,2,6-Lutidine
3) DIBAL-H
O
OH
MeO
Me
HO
1.114
(5:1)
1.118
1.119
1.120
75% 70%
74%
OH OH
 
 Disaccharide 1.115 is comprised of monosaccharide 1.116 and 1.117.  The 
synthesis of monosaccharide 1.116 began with allyl protected glycolyloxazolidinethione 
1.122 (Scheme 1.21).  Titanium chloride mediated anti aldol reaction with acetaldehyde 
set up the anti-1,2-diol, which was in turn converted to Weinreb amide.  After silylation 
of the free hydroxyl group, methyl Grignard addition introduced methyl ketone 1.123.  
The tertiary carbinol center was set up by chelation-controlled allylation with 
allyltributylstannane.  Then the allyl protection group was replaced by TES silyl ether 
and afforded 1.124.  Oxidative cleavage of the terminal alkene followed by formation of 
benzyl acetal and desilylation provided the left hand of disaccharide 1.116.  The synthesis 
of right hand of 1.115 utilized the same strategy as 1.116.  Starting from aldol adduct  
 31 
Scheme 1.21 Crimmins’ synthesis of disaccharide 1.115  
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1.125, which was obtained from ent-1.122 and acetaldehyde, was first protected as TBS 
silyl ether.  Reductive removal of auxiliary followed by oxidation of the corresponding 
alcohol furnished aldehyde 1.126.  Chelation-controlled allylation and methylation of the 
corresponding homoallylic alcohol generated homoallylic methyl ether, which in turn 
was deallylated.  Oxidative cleavage of the terminal alkene delivered hemiacetal 
1.128.Formation of the benzyl hemiacetal with BnOH followed by silylation and 
debenzylation provided the right part of the disaccharide 1.117.  Exposure of the 
hemiacetal 1.117 to Me3SiBr generated glycosyl bromide, which was then coupled with 
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1.116 to form the disaccharide.  Silylation followed by hydrogenolysis gave protected 
disaccharide 1.115: 1.118. 
 
1.4.4 Toshima’s synthesis of C1-C21 macrolide fragment and C12-C28 fragment 
 In 2001 Toshima and co-workers disclosed their synthesis of C1-C21 macrocyclic 
lactone 1.129 of apoptolidin.15 Not surprisingly, Toshima selected a retrosynthetic 
disconnections form at the C1 lactone position and C11-C12 bond, which in the forward 
sense were to be formed by Yamaguchi macrolactonization and Stille coupling 
respectively.  This synthetic strategy revealed intermediate 1.130 and 1.131 as key 
building blocks (Scheme 1.22).  
Scheme 1.22 Toshima’s retrosynthesis of macrolide C1-C21 1.129 
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 Toshima’s preparation of upper part of the 1.129 started from aldehyde 1.132, 
which was obtained from methyl R-3-hydroxy-2-methylpropionate (Scheme 1.23).   
Addition of the lithium anion derived from trimethylsilylacetylene generated Cram-
adduct as a major isomer (2:1), which was subjected to basic hydrolysis to remove TMS 
protective group. The propargyl alcohol was protected as TIPS silyl ether and the primary 
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Scheme 1.23 Toshima’s synthesis of fragment 1.130 
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alcohol was released by removing trityl protection group under acidic condition to 
provided 1.133.  Swern oxidation followed by Wittig reaction introduced the first olefin 
of the trienoate.  The resulting ethyl ester was then converted into aldehyde 1.134 via a 
standard two-step reaction sequence. Wittig olefination, reduction and oxidation 
introduced the second double bond and afforded aldehyde 1.135.  A Horner-Wadsworth-
Emmons reaction completed the trienoate moiety.  Palladium catalyzed regio- and 
stereoselective hydrostannylation introduced the E-vinyl tin required by Stille coupling.  
Finally, hydrolysis of the ethyl ester provided the desired acid 1.130.  
The construction of the lower part of the macrolide 1.131 began with alcohol 
1.136, which is readily prepared from diethyl L-tartrate (Scheme 1.24).   One carbon 
homologation from 1.136 to 1.137 was accomplished via a three-step sequence consisting 
of Dess-Martin oxidation, Wittig olefination and hydroboration reaction.  The syn-diol at 
C16 and C17 was introduced by MgBr2 mediated crotylation of the corresponding 
aldehyde, which was obtained from oxidation of 1.137.  Then hydroboration of the alkene, 
tosylation of the corresponding alcohol and substitution of the tosylate with lithium anion 
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Scheme 1.24 Toshima’s completion of macrolide 1.129 
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of acetylene afforded terminal alkyne 1.139.  Methylation of the terminal alkyne with 
MeI followed by hydrozirconation and Zr-I exchange introduced E-vinyl iodide regio- 
and stereoselectively.  Oxidative removal of MPM protecting group released the 
C20hydroxyl group and afforded 1.131.  Yamaguchi macrolactonization coupled acid 
1.130 and alcohol 1.131 together to furnish 1.141, which was then subjected to 
desilylation and intramolecular Stille coupling to complete the synthesis of macrolide 
1.129. 
In 2004 Toshima’s group reported their synthesis of fragment C12-C28 of 
apoptolidin featuring a tin (II) mediated highly diastereoselective aldol reaction.16 This 
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Scheme 1.25 Toshima’s retrosynthesis of fragment C12-C28 1.141 
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aldol approach led to the disconnection between C22 and C23 to reveal key building 
blocks ethyl ketone 1.142 and aldehyde 1.143 (Scheme 1.25).  
 
                      Scheme 1.26 Toshima’s synthesis of ethyl ketone 1.142  
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The preparation of ethyl ketone 1.142 commenced on dimethyl acetonide 1.144, 
which was prepared from diethyl L-tartrate (Scheme 1.26).  Hydroboration of the 
terminal, benzylation of the corresponding alcohol and disylation afforded 1.145.  The 
ethyl ketone 1.142 was obtained through Dess-martin oxidation, ethyl Grignard addition 
and reoxidation. 
Scheme 1.27 Toshima’s synthesis of aldehyde 1.143 
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The construction of aldehyde 1.143 began with paramethoxybenzylidene acetal 
1.146, which was readily available from D-malic acid (Scheme 1.27).  Methylation of the 
primary alcohol with MeI introduced C28 methyl ether.  DIBAL-H reduction of the  
acetal released secondary alcohol, which was protected as a TBS ether.  Finally oxidative 
debenzylation with DDQ afforded alcohol 1.147.  Swern oxidation followed by Evan’s 
asymmetric aldol reaction set up the stereocenter at C24 and C25.  Auxiliary was then 
replaced by Weinreb amide and free hydroxyl group resulting from aldol reaction was 
protected as PMB ether.  At last the aldehyde 1.143 was obtained through reduction of 
Weinreb amide with DIBAL-H.  
 
Scheme 1.28 Toshima’s completion of fragment C12-C28 1.141 
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With fragment A143 and A144 in hand, they then exploited the aldol reaction.  
After several different Lewis acid-base combinations were screened, they found that 
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Sn(OTf)2 with Hunig’s base provided the best result to afford the anti-Feilkin-Anh 
product (Scheme 1.28).  The aldol adduct A149 was exposed to DDQ to remove the PMB 
ether and the resulting alcohol simultaneously cyclized to form pyranose, which was in 
turn protected as TBS silyl ether. Hydrogenolysis of benzyl ether followed by Dess-
Martin oxidation afforded aldehyde A150. To introduce the C16 and c17 syn-diol, they 
adopted the same strategy as applied in their synthesis of C1-C21 macrolide that utilized 
MgBr2 mediated crotylation.  The newly formed allylic alcohol was methylated and the 
terminal alkene was subject to hydroboration-oxidation to furnish the primary alcohol, 
which was subsequently tosylated to give A151.  Then the tosylate was replaced by 
lithium anion of acetylene.  Methylation of the terminal alkyne, hydrozirconation and Zr-
I exchange afforded E-vinyl iodide A142.  
 
1.4.5 Fuchs’ synthesis of C21-C26 fragment of apoptolidin 
 
Scheme 1.29 Fuchs’ retrosyntesis of C21-C26 pyranose 1.151 
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 In 2002 Fuchs group at Purdue University disclosed an approach to synthesis 
C21-C26 fragment of apoptolidin via an alkylative oxidation strategy.17 The C21-C26 
pyranose 1.151 could be obtained from epoixde 1.154 as shown in Scheme 1.29.  
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 Fuch’s synthesis started from R-pulegone A156.  Basic epoxidation of A156 
followed by treatment of sodium thiophenoxide provided α-ketosulfide, which was in 
turn oxidized to the corresponding sulfoxide (Scheme 1.30).  Pummerer elimination 
introduced the vinyl sulfide, which was subjected to Luche reduction and oxone 
oxidation to provided vinyl sulfone 1.156.  Double bond isomerization with DBU, 
epoxidation with m-CPBA followed by sequential treatment of MsCl and LHMDS 
afforded 1.154. Considering the inefficiency of the synthesis, an alternative route was 
developed that began with dienyl sulfone 1.157.  Basic epoxidation followed by addition 
of LHMDS, MeLi, (PhS)2 and TMSOTf sequentially generated a dienyl sulfide 
compound, which was finally treated with Mo(CO)6 to afforded 1.154 in three operations. 
 
Scheme 1.30 Fuchs’s synthesis of C21-C26 fragment 
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Comparing the initial study, the second approach is much shorter and more efficient.  
Treatment of epoxide 1.154 with trimethyl aluminum introduced the methyl group in a 
1,4-addition mode.  Mitsunobu reaction reversed the stereocenter at C25.  Silylation of 
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the diol followed by selectively removing the less hindered C25 protecting group 
introduced the TBS silyl ether at C23.  Finally, ozonolysis gave aldehyde, which was 
reduced to alcohol 1.158 for the storage purpose.    
 
1.4.6 Loh’s synthesis of C1-C11 fragment 
In 2003 Loh reported a synthesis of fragment C1-C11 based on a strategy that 
introduced stereocenter at C8 and C9 diastereoselectively with Tin mediated allylation.18 
Their synthesis started from aldehyde 1.159, which was readily available from D-
mannitol (Scheme 1.31).  A non chelation-controlled allylation give the anti relationship 
at the newly formed C-C bond, which was the required stereochemistry at C9.  Hence, 
 
Scheme 1.31 Loh’s synthesis of C1-C11 fragment 1.164 
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allylation of 1.159, benzylation of the newly formed hydroxyl group followed by 
oxidative cleavage of the terminal alkene provided aldehyde 1.160.   The trienoate moiety 
was constructed by three sequential Wittig type olefination.  As a result, Horner-
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Wadsworth-Emmons reaction with 1.161, DIBAL-H reduction of the resulting methyl 
ester and oxidation of the corresponding alcohol followed by another Wittig olefination 
with 1.162 generated diene 1.163.  Finally, another three-step sequence including 
reduction, oxidation, and HWE reaction completed the synthesis of C1-C11 fragment and 
provided methyl trienoate 1.164.  
 
1.4.7 Taylor’s synthesis of fragment C1-C11 1.173 
 In 2004 Taylor at Norte Dame University disclosed a new route to prepare C1-
C11 trienoate based on an iterative thionyl chloride rearrangement/oxidation strategy.19  
 
Scheme 1.32 Taylor’s synthesis of trienoate 1.173 
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His synthesis began with Evans asymmetric aldol reaction with aldehyde 1.165 and 
auxiliary 1.166 (Scheme 1.32).  Silylation of the aldol adduct followed by reductive 
removal of auxiliary and oxidation of the resulting alcohol provided aldehyde 1.167.  
Addition of the vinyllithium reagent generated from 2-bromopropene afforded the 
secondary allylic alcohol.  Thionyl chloride allylic rearrangement developed by Young in 
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the 1950s is a known method that can convert secondary allylic alcohols to their isomeric 
primary allylic chlorides strereospecifically.  Hence, applying this methodology, the 
secondary allylic alcohol obtained from vinyllithium addition was treated with thionyl 
chloride and generated desired primary allylic chloride, which was subsequently oxidized 
to aldehyde 1.169 via Ganem oxidation.   A second same three-step reaction sequence 
delivered aldehyde 1.170.  Finally, a Horner-Wadsworth-Emmons reaction with 
phosphonate 1.172 completed the synthesis of methyl trienoate 1.173.  
 
1.4.8 Vogel’s synthesis of C1-C11 fragment 1.174 
 
Scheme 1.33 Vogel’s retrosynthesis of C1-C11 fragment 
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In 2005 Vogel at Switzerland disclosed a sulfur dioxide based approach to make 
C11-C12 fragment.20 They envisioned that the trienoate moiety could be built up by the 
methodology that is sulfur dioxided mediated one pot, four-component synthesis of 
polyfunctional ε-alkanesulfonyl-γ,δ-unsaturated ketones developed by this group.  This 
strategy revealed intermediate 1.175 as key building block, which can be converted to 
1.174 via dehydration and Ramberg-Backlund reaction (Scheme 1.33). 
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Exposure of the diene 1.176 to SO2 in the presence of Lewis acid generated Diels-
Alder type adduct, which was then sequentially subjected to aldol reaction with silyl enol 
ether 1.177, desilsylation and sulfone alkylation with 1.178 to provide stereomixture of 
1.179 (Scheme 1.34).  Acidic dehydration introduced C2-C3 double bond.   The methyl 
ester 1.181 was obtained via oxidative cleavage of the α-hydroxyl ketone, which was 
generated by Silylation of the primary alcohol and Rubottom oxidation, followed by 
esterification of the corresponding carboxylic acid.  Dess-Martin oxidation of the primary 
 
Scheme 1.34 Vogel’s synthesis of C1-C11 fragment 1.174 
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alcohol followed by lithium anion addition of the TES protected acetylene afforded 1.182.  
After silylation of the secondary hydroxyl group resulting from the acetylene addition, 
under Chan’s condition, Ramberg-Backlund reaction provided fragment 1.174 
stereospecifically by losing SO2.  
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1.5 Sulikowski’s previous studies towards the total synthesis of apoptolidin  
 Our group’s efforts towards a total synthesis of apoptolidin started in 1998.  As 
described earlier, apoptolidin has a propensity to isomerize to iso-apoptolidin.  To avoid 
this instability, we selected pseudoapoptolidinone 1.175 as our first synthetic target, a 
stable derivative of apoptolidinone and good candidate for chemical correlation with 
synthetic material.  The preparation of pseudoapoptolidinone from apoptolidin is shown  
  
Scheme 1.35 Sulikowksi’s preparation of pseudoapoptolidinone 1.175 
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in Scheme 1.35.  Acylation of the free hydroxyl groups afforded apoptolidin 
hexacetate,which was then subjected to selective methanolysis under acidic condition to 
remove the bottom disaccharide.5a At last acylation again to protect the C27 hydroxyl 
group resulting from hydrolysis to give 1.175. 
Retrosynthetically, we disconnected the C9 sugar bond first, which was going to 
be attached at proper time by chemical glycosylation (Scheme 1.36).  The 20-membered 
macrolactone was disconnected into three major fragments (1.176, 1.178 and 1.179), 
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which were going to be assembled together via three Suzuki couplings and Yamaguchi 
macrolactonization.  The pyranose 1.179 was derived from1.181.  Further disconnection 
of 1.181 at C19-C20 bond and C22-C23 bond revealed aldehyde 1.182, 1.184 and silyl 
enol ether 1.183 as key building blocks.   In a forward synthesis sense, a 
diastereoselective Mukaiyama aldol reaction and a lithium enolated mediated 
diastereoselective aldol reaction was going to assemble fragment 1.182, 1.183 and 1.184 
together and established the required stereochemistry. 
Scheme 1.36 Sulikowski’s retrosynthesis pseudoapoptolidinone 1.175 
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1.5.1 Sulikowski’s synthesis of C12-C28 fragment: 1.179  
 Our synthesis of C12-C28 fragment commenced with synthesis of aldehyde1.182 
(Scheme 1.37).  Exposure of the epoxide 1.52 to lithium anion of 1,3-dithiane followed 
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by silylation of the resulting secondary alcohol with TBS generated dithiane compound, 
which was in turn hydrolyzed to adehyde 1.87 with MeI.  A Crimmins syn aldol with 
chiral auxiliary 1.185 established the C24-C25 stereocenter.  The aldol adduct was 
converted into aldehdye 1.182 via a three-step sequence involving silyation of the 
hydroxyl group resulting from aldol reaction, reductive cleavage of the auxiliary and  
 
Scheme 1.37 Sulikowski’s secondary generation synthesis of C12-C28 fragment 1.179 
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Swern oxidation of the corresponding primary alcohol.  The preparation of aldehyde 
1.184 began with epichlorohydrin 1.186, which was subjected to epoxide opening with 
1,3-dithiane followed by PMBOH opening of resulting epoxide to afford alcohol 1.187.   
Methylation of the remaining secondary alcohol, oxidative removal of the PMB ether 
with DDQ and Swern oxidation of the corresponding primary alcohol provided aldehyde 
1.188.  Here we adopted Ulrich Koert’s strategy to establish the C16-C17 syn diol type 
stereochemistry via a chelating controlled Grignard addition.  To that end, we prepared 
vinyl tin 1.96 based on Koert’s procedure.  Following Kocienski’s procedure, 1,2-
dihydrofuran 1.189 was converted to alcohol 1.190, which was then transformed to 
bromide 1.96 via a standard two-step Finkelstein reaction sequence.   With both bromide 
1.96 and aldehyde 1.188 in hand, we then coupled them together via a chelation-
controlled mode to afford a syn diol type product in a single isomer, which was in turn 
silylated and exposed to iodine to provide vinyl iodide 1.193.   Careful hydrolysis of 
dithiane gave aldehyde 1.184.  We then reached to the point to explore the Mukaiyama 
aldol reaction, which called for silyl enol ether 1.183 as a reaction partner.  1.183 was 
prepared from 1,2-butanediol 1.191, which was first selectively silylated in the primary 
alcohol and afforded secondary alcohol 1.192.   Swern oxidation converted alcohol to 
ketone, which was then enolated with LDA and quenched with TMSCl to provide silyl 
enol ether 1.183.  Lewis acid BF3.OEt2 promoted diastereoselective Mukaiyama aldol 
reaction furnished 4:1 mixture of two diastereomers, which could be separated in the later 
stage by normal flash chromatography or HPLC.  TBS protection of the newly formed 
hydroxyl group generated ethyl ketone 1.194.  Then a double diastereoselective lithium 
enalote mediated aldol reaction proceeded smoothly to afford ketone 1.181 as a sole 
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isomer to establish C24-C25 stereocenter.  Finally, global deprotection with HF.pyr 
completed the synthesis of C12-C28 fragment 1.179.  
 
1.5.2 Sulikowski’s synthesis of fragments 1.176 and 1.178 
 Our preparation of aldehyde 1.176 began with propargyl alcohol 1.195, which 
was first protected as TMS silyl ether (Scheme 1.38).22, 23 Hydroboration followed by 
acidic desilylation using Vaultier’s procedure provided allylic alcohol 1.196 in 30% yield 
stereo- and regioselectively.  Dess-Martin oxidation of alcohol afforded aldehyde 1.197, 
which then underwent Crimmins asymmetric aldol reaction to provide 1.198 with Evans 
syn stereoselectivity.   Silylation of the aldol adduct with TBSCl, reductive removal of 
the auxiliary and Dess-martin oxidation gave aldehyde 1.176 in 50% yield over 3 steps.  
 
Scheme 1.38 Sulikowski’s synthesis of aldehyde 1.176 
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 The synthesis of dienoate boronate 1.178 commenced on 2-methyl diethyl 
malonate 1.199 (Scheme 1.39).  Alkylation with iodoform afforded 1.200, which was 
subjected to decarboxylation and hydrolysis to give acid 1.201.  Reduction of acid 
furnished allylic alcohol 1.202, which was subsequently oxidized and exposed to Wittig 
reaction to provide methyl ester 1.203.   Then the methyl ester was replaced by 
 48 
trimethylsilylethyl ester, which was coupled with bis(pinacolato)diborane to give 
dienoate boronate 1.178. 
 
Scheme 1.39 Sulikowksi’s synthesis of dienoate boronate 1.178 
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1.5.3 Sulikowski’s model study of sequential Suzuki coupling  
As designed, our end game strategy called for a sequential Suzuki coupling 
reaction to assemble those key building blocks together (Scheme 1.40).  To explore this 
approach, we did a model study with a simplified lower vinyl iodide part 1.190, which 
was an intermediate during the synthesis of vinyl tin 1.96.   Iodine-tin exchange followed 
by protection of the primary alcohol with TBS silyl ether afforded vinyl iodide 1.204.  
With Roush modified Suzuki coupling condition, 1.204 coupled with vinyl boronate 
1.176 smoothly to provided aldehyde 1.205, which was then converted to vinyl 
dibromide 1.206.  The second Suzuki coupling attached vinyl boronate 1.178 to 1.206 
strereoselectively to afford polyene 1.207.  Finally the third Suzuki coupling was carried 
out to methylate the C6 bromide with Me-9-BBN and furnished the desired trienoate 
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1.208.  The sequential Suzuki coupling strategy with simple substrate proved to be 
successful.  
Scheme 1.40 Sulikowski’s model study of sequential Suzuki coupling 
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1.5.4 Sulikowski’s studies toward first generation total synthesis of 
pseudoapoptolidinone 
The model study described above indicated that the sequential Suzuki coupling 
approach might be effective in our total synthesis of pseudoapoptolidinone.  At this point, 
we carried out the first Suzuki coupling between vinyl iodide 1.179 and vinyl boronate 
1.176 and successfully obtained the coupling adduct, which was homologated to 1,1-
geminal dibromide 1.209 in 72% yield over 2 steps (Scheme 1.41).  After removal of C9 
TES protecting group, glycosylation with sugar unit 1.180 upon activation with NIS and 
TESOTf afforded 1.210.   However, all attempts of the second Suzuki coupling between 
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vinyl boronate 1.178 and vinyl bromide1.210 failed.  We envisioned that the sugar in the 
C9 position might increase the steric effect.  Therefore, a Suzuki coupling was carried out 
between 1.209 and 1.178 and the reaction proceeded smoothly to afford the coupled 
product 1.211.  However, all efforts to remove the C9 silyl protection group failed, 
probably due to the instability of the trienoate moiety. This failure led to our secondary 
generation total synthesis of apoptolidinone, which is going to be described in the next 
chapter.  
 
Scheme 1.41 Sulikowski’s studies towards completion synthesis of 
pseudoapoptolidinone 1.175 
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CHAPTER II 
LARGE SCALE TOTAL SYNTHESIS OF APOPTOLIDINONE 
2.1 Studies towards total synthesis of apoptolidinone: Horner-Wadsworth-Emmons 
approach 
 As described in the last chapter, the failed synthesis of pseudoapoptolidinone led 
us to reconsider our synthetic strategy directed toward apoptolidin itself.  Based on the 
observation by K. C. Nicolaou and Ulrich Koert during their total synthesis of 
apoptolidin and our group’s efforts to identify the isomerization product of apoptolidin, 
we realized that chemical glycosylation to attach the two sugar units would be  
 
Scheme 2.1 Retrosynthetic analysis of apoptolidinone 2.2 
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challenging.  Therefore, biological glycosylation was considered, which would utilize 
glycosyltransferase in vivo.23 This strategy revealed apoptolidinone 2.2 as our primary 
synthetic target.  In contrast to our previous sequential Suzuki coupling approach, 
intramolecular Horner-Wadsworth-Emmons olefination, cross metathesis and Suzuki 
coupling reactions would serve as key transformations in the construction of the 20-
membered macrolactone ring (Scheme 2.1).  As before, C12-C28 was synthesized via our 
previous strategy, which featured a diastereoselective Mukaiyama aldol reaction and a 
lithium enolate mediated double diastereoselective aldol reaction.21 These disconnections 
led to key intermediates aldehyde 2.3, methacrolein 2.4, phosphonate 2.5, aldehyde 2.6 
and silyl enol ether 2.7.  Fragment 2.6 and 2.7 were prepared following the procedure 
described in Chapter I.   Further disconnection of fragment 2.3 called for a Suzuki 
coupling reaction and a Grignard addition reaction as key transformations. The syn-diol 
type stereochemistry at C16–C17 position was envisioned to be established via Grignard 
mediated addition of bromide 2.11 to aldehyde 2.12 in a chelation controlled fashion.11 A 
palladium mediated cross coupling, either a Suzuki coupling24 or a Stille coupling25, 
would establish the C11-C12 bond employing building blocks 2.8-2.10, which varies in 
the terminal groups.   
 
2.2 A new approach to prepare aldehyde 2.12 
 The initial synthesis of fragment 2.12 began with (S)-epichlorohydrin 1.186, 
which is very expensive.  Therefore, a more practical method was required to enable the 
synthesis scalable. Hence, inexpensive (S)-malic acid 2.13 was considered as an 
alternative starting material.  Fisher esterification of 2.13 provided dimethyl ester 2.14 in 
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85% yield (Scheme 2.2).  β-hydroxy lactone 2.15 was obtained by NaBH4 catalyzed 
broane regioselective reduction of dimethyl ester 2.1426a, which was followed by in situ 
acid mediated cyclization via the 1,2-diol intermediate.26b  Next, an efficient methylation 
method was required to introduce the C17 methyl ether. Concerns here include  
 
    Scheme 2.2 New approach to aldehyde 2.12 
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Table 2.1 Exploring methylation of 2.15 
Entry Reaction Conditions 2.16 
1 NaH (1.5 equiv), MeI (2 equiv), THF, 0°C-rt, 12h Decomposed 
2 NaH (1 equiv), MeI (1.5 equiv), THF, 0°C-rt, 5h Decomposed 
3 Me3O+BF4-, CH2Cl2, rt, 5h No reaction 
4 MeI (8 equiv), Ag2O (1.1 equiv), CH3CN, 80°C, 12h 17% 
5 MeI (8 equiv), Ag2O (1.1 equiv), CH3CN, 40°C, 12h 34% 
6 MeI (neat), Ag2O (1.0 equiv), 40 °C, 12h 70% 
 
potential for competing α-methylation of the lactone and competing beta elimination of  
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hydroxyl group.  Initially, traditional basic conditions employing excess NaH and MeI 
were attempted (Table 2.1, Entry 1).  Unfortunately, the reaction led to decomposition.   
Therefore, exactly one equivalent of base was used and the reaction was conducted at 
room temperature for 5 h instead of 12 h (Entry 2).  However, again no product was 
obtained.  Then our attention was turned to acidic conditions. Unfortunately, exposure of 
2.15 to Meerwein’s salt for 5 h at room temperature yielded only starting material (Entry 
3).   Therefore, mild neutral conditions were considered.  Treatment of 2.15 with MeI and 
Ag2O in refluxing acetonitrile at 80 °C for 12 h furnished 17% desired product (Entry 
4).27 It was suspected that the low yield might be due to the elevated reaction temperature, 
hence, the reaction was repeated and the temperature maintained at 40 °C. Under these 
conditions the yield improved (34%) with some starting material recovered (Entry 5).28 
To drive the reaction to completion, a neat reaction was examined, again maintaining a 
reaction temperature of 40 °C (Entry 6).29 Under these conditions, a satisfactory yield 
(70%) was obtained.   With methyl ether 2.16 in hand, the next goal was to prepare 
alcohol 2.17.  Reduction of lactone 2.16 with DIBAL-H followed by acetal formation 
with 1,3-propanedithiol afforded desired 2.17 in 60% yield over 2 steps.30 Finally, Swern 
oxidation provided aldehyde 2.12 in 80% yield.  In summary, this new approach started 
from inexpensive (S)-malic acid and furnished fragment 2.12 in 5 isolated steps with 20% 
overall yield.  Later, we found that β-hydroxy lactone 2.15 was commerially available in 
kilogram quantities at a relatively low price (1 $/g, Louston International, Inc.).  Thus our 
current approach to fragment 2.12 started from 2.15 instead of 2.13.  
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2.3 Preparation of vinyl metal reagents 2.8, 2.9 and 2.10 
2.3.1 Preparation of vinyl boronate 2.8 
The synthesis of vinyl boronate 2.8 was based on a crotylation strategy.  In the 
previous synthesis, aldehyde 2.21 was prepared from propargyl alcohol by hydroboration 
with pinacolborane.  Long reaction time (4 days) and separation difficulty introduced by 
multiple stereoisomers from hydroboration prompted us to examine Hall’s method for the 
preparation of 2.21, 31 which started from propargyl aldehyde diethyl acetal 2.20.  The 
synthesis commenced with acrolein 2.18, which was brominated and protected in situ as 
the diethyl acetal with triethyl orthoformate to provided dibormide 2.19 (Scheme 2.3).32  
Double elimination of dibromide afforded acetylene 2.20 in 68% yield.  Then aldehyde  
 
Scheme 2.3 Preparation of vinyl boronate 2.8 
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2.21was obtained in 45% yield following Hall’s procedure via stereo- and regioselective 
hydroboration, borane oxiation, boronate ester hydrolysis and pinacol boronate 
formation.31 As planned, the stereogenic centers at C8 and C9 were installed using 
Roush’s asymmetric crotylation reaction.33 Under typical crotylation reaction conditions 
(3M NaOH for work up) no desired product was generated. It was envisioned that the 
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crotylation intermediate might not be stable enough to treatment with a 3M NaOH 
solution.  Instead, 1 M NaOH was used in the hydrolysis process and analysis of the 
crude 1HNMR showed the desired product was generated.   However, after flash column 
chromatography purification, no product was obtained.  This result 
indicated that the homoallylic alcohol resulting from crotylation was not stable in either 
strong basic conditions or weak acidic conditions.  Finally, silylation of the resultant 
alcohol in situ with TESOTf led to isolation of the desired 2.8 in 44% yield over 2 steps 
without any apparent decomposition.  Enantiomeric excess of 2.8 was determined to be 
80% by chiral gas chromatography after converting vinyl boronate to vinyl iodide 2.10 
(Scheme 2.4).34  It was considered  that Brown’s asymmetric crotylation might improve 
the enantioselectivity of the addition process.35  However, it was envisioned that 3M 
NaOH and H2O2 used in Brown’s work up procedure might prove problematic due to the 
apparent instability of vinyl boronate under strongly basic condition.   
 
Scheme 2.4 Synthesis of 2.10 from 2.8 
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2.3.2 Preparation of vinyl tin 2.9 
The synthesis of vinyl stannane 2.9 adopted the same strategy as the preparation 
of vinyl boronate 2.8.  The synthesis began with known aldehyde 2.23, which was readily 
available from propargyl alcohol via hydrostannylation.36 Under typical Roush 
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asymmetric crotylation condition, homoallylic alcohol 2.24 was afforded in 86% yield, 
 
  Scheme 2.5 Preparation of vinyl tin 2.9 
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which was subsequently silylated to give 2.9 (Scheme 2.5).  Again, the enantiometric 
excess of 2.9 was determined by chiral GC to be 33% after converting vinyl tin to vinyl 
iodide 2.10 via tin-iodine exchange.  Although this route was more practical, the 
observed low enantioselectivity of the crotylation reaction rendered the procedure less 
useful. 
 
2.3.3 Preparation of vinyl iodide 2.10 
 A new synthesis of vinyl iodide 2.10 was considered that still based on a 
crotylation strategy to establish the C8 and C9 stereogenic center.  Starting from methyl 
propiolate 2.25, hydroiodonaiton provided β-iodo methyl acrolate 2.26 in 80% yield 
(Scheme 2.6).37 Carefully controlled DIBAL-H reduction of the methyl ester afforded  
 aldehyde 2.27, which in turn was subjected to isomerization in the presence of BF3.OEt2 
to generate E isomer of β-iodo acrolein 2.28 (E:Z = 10:1).38  Neat aldehyde 2.28 
underwent polymerization very quickly, therefore, after basic work up (NaHCO3), 2.28 
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was subjected to crotylation immediately in a solution of CH2Cl2 and protected from 
 
Scheme 2.6 Preparation of vinyl iodide 2.10 
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light.  After silylated in situ with TESOTf, the desired vinyl iodide 2.10 was isolated in 
40% yield over 4 steps from 2.26.  The enantiomeric excess was determined to be 26% 
by chiral GC.  Brown’s asymmetric crotylation provided a higher yield from 2.26 (67% 
over 4 steps) and high enantiomeric excess (90%).38 Currently, 15 grams of 2.10 is 
produced using Brown’s procedure.  
 
2.4. Preparation of Suzuki coupling protocol 2.31 
 Triene aldehyde 2.3 was to be assembled using a standard Suzuki Cross coupling 
reaction and thus required vinyl iodide 2.31 as a reaction partner.  Aldehyde 2.31 was 
prepared utilizing previously described chelation-controlled Grignard addition to 
establish the C16-C17 syn diol relationship.21 Exposure of alkyl bromide 2.11  
to magnesium metal in the presence of 1,2-diboromoethane followed by addition of 
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aldehyde 2.12 generated alcohol 2.29 in 63% yield as a sole isomer (Scheme 2.7). 
Our previous synthesis used 7 equivalents 2.11.  On larger scale (ca. 5 grams), we have 
successfully decreased 2.11 to 3 equivalents and maintained the high yield and  
 
                                    Scheme 2.7 Preparation of aldehyde 2.31 
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diastereoselectivity.  Iodine-tin exchange followed by in situ silylation of the secondary 
alcohol resulted vinyl iodide 2.30 in 90% yield over 2 steps.  Hydrolysis of dithiane 2.30 
with MeI and K2CO3 in the presence of pH=7 buffer was highly dependent on the 
reaction concentration.39 After optimization, we determined a reaction concentration of 
0.07 M at room temperature provided an 85% yield of aldehyde 2.31.  
 
2.5 Exploration of the cross coupling reaction to prepare aldehyde 2.3 
2.5.1 Suzuki coupling between 2.31 and 2.8 
Suzuki coupling between vinyl iodide 2.31 and vinyl boronate 2.8 proved 
challenging (Scheme 2.8 & Table 2.2).  Under typical Roush modified Suzuki coupling 
reaction condition, which utilized TlOEt as base and Pd(Ph3P)4 as catalyst, both desired 
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product 2.3 and β-elimination product 2.32 were obtained (Entry1).40 Presumably, this β- 
 
Scheme 2.8 Suzuki coupling between 2.31and 2.8 
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Table 2.2 Exploration of Suzuki coupling between 2.31 and 2.8 
Entry Reaction conditions 2.3 2.32 2.31 
1 
TlOEt(1.5 eq), Pd(PPh3)4, THF/H2O(3:1),0.02 M, rt, 
20 min,100 mg 
44% 15% 0% 
2 
TlOEt(1.25 eq), Pd(PPh3)4, THF/H2O(3:1),0.03 M, 0 
°C, 40 min, 50 mg 
89% 0% 0% 
3 
TlOEt(1.25 eq), Pd(PPh3)4, THF/H2O(3:1),0.03 M, 0 
°C, 2 h, 350 mg 36% 6% 28% 
4 
TlOEt(1.25 eq), Pd(PPh3)4, THF/H2O(3:1),0.03 M, 0 
°C for1.5 h then rt 5 min, 200 mg 45% 4% 20% 
5 
TlOEt(2.5 eq), Pd(PPh3)4, THF/H2O(3:1),0.1 M, 0 °C 
for3 h then rt 10 min, 200 mg 
25% 18% 16% 
6 
TlOEt(1.25 eq), Pd(PPh3)4, THF/H2O(3:1),0.02 M,rt, 
15 min,200 mg-1g 
82% 0% 0% 
7 Tl2CO3, Pd(PPh3)4, THF/H2O(3:1), 0.02 M, rt, 1 h 37% 0% 0% 
8 Tl2CO3, Pd(PPh3)4, THF, 0.02 M, rt, 1 h 0% 0% 100% 
9 Tl2CO3, Pd(PPh3)4, THF/H2O(3:1), 0.02 M, 0 °C, 2 h 19% 28% 0% 
10 Tl2CO3, Pd(PPh3)4, THF/H2O(3:1), 0.02 M, 10 °C, 1 h 30% 18% 0% 
11 Tl2CO3, Pd(PPh3)4, THF, 0.02 M, 50 °C, 12 h 0% 0% 0% 
12 Tl2CO3, PdCl2(dppf)2•CH2Cl2, THF, 0.02 M, rt, 2 h 0% 0% 100% 
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Table 2.2 (continued) 
Entry Reaction conditions 2.3 2.32 2.31 
13 
Tl2CO3, PdCl2(dppf)2•CH2Cl2, THF/H2O(3:1), 0.02 M, 
rt, 20 h 
42% 0% 0% 
14 
Tl2CO3, PdCl2(dppf)2•CH2Cl2, THF/H2O(3:1), 0.02 M, 
MW 50W, 5 min 
0% 0% 100% 
15 
Tl2CO3, PdCl2(dppf)2•CH2Cl2, THF/H2O(3:1), 0.02 M, 
50 °C, 20 h 32% 0% 0% 
16 TlOAc, Pd(PPh3)4,THF/H2O(3:1), 0.02 M, rt,12 h 0% 0% 100% 
17 KOAc, PdCl2(dppf)2•CH2Cl2, DMSO, 80 °C,2 h 0% 0% 0% 
 
 
elimination was initiated by deprotonation of the acidic α-proton of the 2.3 aldehyde 
followed by elimination of β-methoxy group generating thermodynamically stable α,β-
unsaturated aldehyde.   To suppress this side reaction, the reaction was then conducted at 
lower temperature with a decreased amount of base.  To our satisfaction the desired 
product was produced in 89% yield without the β-elimination byproduct (Entry 2).  
However, scaling up the reaction under the same condition resulted in incomplete 
coupling.  Furthermore, extended reaction times resulted in β-elimination (Entry 3, 4).  
Attempts to increase the equivalents of base (1.25 equiv. – 2.5 equiv.) and reaction 
concentration (0.02 M – 0.1 M) provided the same result (Entry 5).  Surprisingly, it was 
found that by decreasing the amount of base and lowering reaction concentration, good 
yield (87%) could be achieved by shortening the reaction time (less than 15 min).  This 
condition worked well for reaction scales ranging from 200 mg to 1 g.  This observation 
suggests that the coupling reaction occurs first and afterward the remaining base 
participates the elimination reaction. Tl2CO3 was also examined as a base.  The advantage 
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of Tl2CO3 over TlOEt is that this weaker base is soluable in organic solvents.41 It was 
hoped that β-elimination side reaction could be avoided with weaker base.  However, 
these conditions resulted in no reaction for these substrates either at room temperature or 
at elevated temperatures (Entry 8 and 11).  In aqueous THF, the yield of 2.3 increased 
with increasing temperature (Entry 7, 9 and 10).  Unfortunately, in these reactions, β-
elimination could not be suppressed and the yield of the desired product was 
unacceptable.  Screening Pd catalyst Pd(Ph3P)4 and PdCl2(dppf)2•CH2Cl2 led to no 
reaction (Entry 12 and 14).  Although it provided the desired product 2.3 without any 
byproduct in aqueous THF system at either room temperature or higher temperature, the 
low yield excluded these options (Entry 13 and 15).  Microwave assisted reactions led to 
recovery of starting material (Entry 14).   Changing base to TlOAc and using Pd(Ph3P)4 as 
catalyst in aqueous THF led to no reaction (Entry 16).37 More harsh conditions, such as 
KOAc and PdCl2(dppf)2•CH2Cl2 at 80 °C, resulted in decomposition of starting material.24  
In summary, entry 6 proved to be a mild and practical method to prepare large scale of 
fragment 2.3.  
 
2.5.2 Stille coupling between 2.31 and 2.9 
 In order to develop an efficient method to prepare fragment 2.3 we also explored 
Stille coupling reaction, which both Nicolaou and Koert applied in their total syntheses of 
apoptolidin.  It was envisioned that Stille coupling would not require a base and β-
elimination side reaction could be avoided.  Under typical Stille condition  
PdCl2(dppf)2•(CH3CN)2 as catalyst in DMF at room temperature no reaction was observed 
and starting material 2.31 was recovered (Scheme 2.9).25  It was also reported that a free 
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alcohol in the molecule could be tolerated during Stille coupling and sometimes it 
facilitates the reaction.  To examine the feasibility of this route, compound 2.33 was 
 
Scheme 2.9 Stille coupling between 2.31 and 2.9 
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prepared via a diastereoselective Mukaiyama aldol reaction with silyl enol ether 2.7.  
Unfortunately, Stille cross coupling did not take place on this substrate.  One possible 
reason was that the trisubstituted olefin 2.31 or 2.33 was too hindered to react.  
 
2.5.3 Suzuki coupling between 2.31 and 2.10 
 With aldehyde 2.31 and boronate ester 2.8 we had developed an efficient method 
to prepare fragment 2.3.  However, the low yield and enantioselectivity of reaction 
leading to 2.8 prevented scaling up of the synthesis.  In order to make the synthesis more 
practical and suitable for large-scale synthesis, vinyl iodide 2.10 was prepared from  
methyl propiolate 2.25 in more than 50% yield over 5 steps as described above. 
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Converting vinyl iodide 2.10 to the vinyl boronic acid 2.35 was realized by lithium- 
 
Scheme 2.10 Suzuki coupling between 2.31 and 2.10 
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iodine exchange followed by in situ trapping with triisopropyl borate (Scheme 2.10).42 
Under Roush modified Suzuki coupling conditions, fragment 2.3 was generated in 70% 
yield on 100 mg to 1gram scale in 10 minutes without any β-elimination product 
observed.  This observation supported our hypothesis that the β-elimination side reaction 
takes place after the Suzuki coupling.  Therefore, the route starting from methyl 
propiolate 2.25 proved to be the most efficient approach to prepare aldehyde 2.3 on large 
scale.  
 
2.6 End game strategy: exploring intramolecular Horner-Wadsworth-Emmons 
(HWE) reaction 
 In order to examine a unique approach to form the macrolactone of apoptolidin 
we planned to examine an intramolecular Horner-Wadsworth-Emmons reaction (HWE) 
that required preparation of phosphonate 2.37.  To this end, a second-generation synthesis 
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of C12-C28 fragment was adopted, which utilized diastereoselective Mukaiyama aldol 
reaction to establish the C16 and C17 stereocenters.  Under the same conditions, BF3.OEt2 
mediated aldol reaction coupled aldehyde 2.3 and vinyl silyl enol ether 2.7 together and 
formed aldol adduct 2.34 in 45%-76% yield (dr: 5:1) (Scheme 2.11).21 Acid 2.5, which 
 
 Scheme 2.11 Preparation of fragment 2.37 
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was prepared from methyl vinyl carbinol, was then attached to alcohol 2.34 by 
Yamaguchi esterification and afforded phosphonate 2.36 in 50%-75% yield. Finally, a 
cross metathesis with methacrolein 2.4 in the presence of Grubbs secondary generation 
catalyst introduced the α,β-unsaturated aldehyde 2.37 (E:Z = 10:1) to complete the HWE 
substrate.43  
 With aldehyde 2.37 in hand, the intramolecular Horner-Wadsworth-Emmons 
reaction was then investigated (Scheme 2.12).   Treatment with n-BuLi in the presence of 
HMPA at a concentration of 0.01 M at 0 °C did not provided any desired product 
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(Entry1).  Diluting the reaction mixture to 0.001 M still led to no reaction.  Masamune-
Roush modified condition, which utilized LiCl and DBU, yielded mostly the starting 
material (Entry 3).44 Changing base to NaH resulted in no reaction or only a trace amount 
of product (Entry 4 and 5).  When applying KOt-Bu as base, again no desired product 
was observed.  In order to create a concentrated base environment, 2.37 was added to a 
solution of KOt-Bu by syringe pump over 12 h.  This procedure still did not generate any 
cyclized product 2.38 (Entry 8). The reverse addition also failed (Entry 9).  In all cases 
after base was added, color change was observed, indicating that deprotonation took 
place.  Presumably, the failure of the cylization might be due to a conformational and/or 
stereo barrier.  
 
Scheme 2.12 Horner-Wadsworth-Emmons reaction 
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Table 2.3 Intramolecular Horner-Wadsworth-Emmons reaction conditions 
Entry Reaction condition 2.38 
1 n-BuLi, HMPA, THF, 0.01 M, 0 °C, 12 h 0% 
2 n-BuLi, THF, 0.001 M, 0 °C, 12h 0% 
3 LiCl, DBU, CH3CN, 0.0005 M, rt, 36 h No reaction 
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Table 2.3 (continued) 
Entry Reaction condition 2.38 
4 NaH, THF, 0.005M, 0 °C 30 min then rt 3 h 0% 
5 
NaH, THF, 0.005M, 0 °C 30 min then rt 12 h 
Trace 
amount 
6 KOt-Bu, THF, 0.005 M, 0 °C 30 min then rt 3 h 0% 
7 KOt-Bu, THF, 0.005 M, 0 °C 30 min then rt 12 h 0% 
8 KOt-Bu, THF, rt, sm was added to a solution of base over 12 h 0% 
9 KOt-Bu, THF, rt, base was added to a solution of sm over 12 h 0% 
 
 
2.7 Large scale synthesis of apoptolidinone: intramolecular Suzuki coupling 
approach 
 Failure of the intramolecular Horner-Wadsworth-Emmons approach forced 
examination of the previous intramolecular Suzuki coupling approach, which proved 
successful on small scale by Wu.45 This strategy is similar to the intramolecular HWE 
approach. The only difference was that C5-C6 bond was to be formed by Suzuki coupling 
with fragment vinyl iodide 2.40 and vinyl boronate 2.39 in an intramolecular fashion.  
This retrosynthesis revealed aldehyde 2.3, vinyl boronate 2.39, carboxylic acid 2.40, 
aldehyde 2.6 and silyl enol ether 2.7 as major building blocks (Scheme 2.13).   Based on 
our previous studies, all these fragments could be prepared on multi-gram scale from 
readily available starting materials. This highly convergent route makes our goal of 
preparing 15-25 mg of apoptolidinone practical.  
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Scheme 2.13 Retrosynthetic analysis of apoptolidinone 2.2 based on intramolecular 
Suzuki coupling 
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 The synthesis began with a Mukaiyama aldol reaction between aldehyde 2.3 and 
silyl enol ether 2.7, which afforded diol type product 2.34 in 75% yield as an inseparable 
mixture of stereoisomers (Scheme 2.14). Yamaguchi esterification with acid 2.40, which 
was obtained from hydrolysis of methyl ester 1.203, provided ester 2.41 in 83% yield.  At 
this stage three fractions were observed by TLC and were able to be separated by flash 
chromatograph column.  The quantitative measurement demonstrated that the three 
isomers were produced in a ratio of 75:15:10.  The NMR study indicated that the major 
isomer was the anit, syn-diastereomer 2.34.  Fraction C was determined to be a 1:1 
mixture of two diastereomers based on NMR analysis.  Minor fractions B and C were not 
fully characterized.  Hence, the Mukaiyama aldol reactions between 2.3 and 2.7 
generated all four possible stereoisomers in a ratio of 75:15:5:5.  A lithium enolate 
mediated double diastereoselective aldol reaction between 2.41 and aldehyde 2.6 
afforded aldol adduct 2.42 as a single isomer in 50% yield with 20% recovered starting 
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Scheme 2.14 Completion of the synthesis of apoptolidinone 2.2 
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material. After silylation of the newly formed secondary hydroxyl group as TES ether, 
intermediate 2.43 was subjected to cross metathesis with vinyl boronate 2.39 in the 
presence of Grubbs secondary generation catalyst 2.44 and furnished vinyl pinacol 
boronate 2.45 in 50% yield (E:Z=10:1). Under Roush modified Suzuki coupling 
condition, the macorlide 2.46 was afforded.  Finally, global deprotection delivered 
apoptolidinone 2.2. Previously, HF.Pyridine was chosen as desilylation reagent, which 
afforded 40%-60% yield.  Considering the instability of apoptolidinone under acidic 
conditions, a milder reagent, H2SiF6, was applied and the reaction afforded reproducible 
80% yield.46  
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In summary this highly convergent synthesis provided apoptolidinone in 11 linear 
steps with 2.6% overall yield.  With this synthesis route 15 mg apoptolidinone was 
prepared. The biological glycosylation study and biological activity test are in progress.   
 
2.8 Experimental section 
General procedures. Reagents were obtained from commercial suppliers, and where 
appropriate were purified prior to use.  All reactions were carried out under a nitrogen or 
argon atmosphere using dry glassware that had been flame-dried under a stream of 
nitrogen, unless otherwise noted.  All solvents were purified prior to use.  
Tetrahydrofuran and ethyl ether were distilled from sodium/benzophenone; 
dichloromethane and benzene were distilled from calcium hydride.  Chloroform was 
washed twice with water, dried over potassium carbonate, refluxed, and distilled from 
phosphorus pentoxide. Triethylamine was distilled from calcium hydride and stored over 
sodium hydroxide.  Reactions were monitored by thin-layer chromatography (TLC) using 
0.25-mm E. Merck precoated silica gel plates.  Visualization was accomplished with UV 
light and aqueous ceric ammonium molybdate solution, anisaldehyde stain or KMnO4 
followed by charring on a hotplate.  Flash chromatography was performed with the 
indicated solvents using silica gel 60 (particle size 230-400 mesh) with the indicated 
solvent.  Yields refer to chromatographically and spectroscopically pure compounds 
unless otherwise stated.  Melting points are uncorrected unless otherwise noted.  1H and 
13C NMR spectra were recorded on Bruker 400, and 500 MHz spectrometers at ambient 
temperature.  1H and 13C NMR data are reported as δ values relative to tetramethylsilane 
or chloroform.  Enantionmeric excess was determined by chiral GC analysis by Varian 
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3900 with chiral column (BETA DEX 120, 30 M x 0.25 mm, 0.25 µm film, column : # 
17411-02B).  High-resolution mass spectra were obtained at Texas A&M University 
Mass Spectrometry Service Center by Dr. Shane Tichy on an API QSTAR Pulsar 
Instrument. The single-crystal X-ray diffraction analysis was performed by Dr. Joseph 
Reibenspies at Texas A&M University using a Bruker Smart 1000 CCD single crystal X-
ray diffractometer. 
O
O
MeO
2.16  
To a solution of 2.15 (5.23 g, 51.30 mmol) in MeI (50 mL) at room temperature 
was added Ag2O (11.9g, 51.3 mmol, 1 equiv).  The resultant mixture was stirred at 40 °C 
for 36 h, filtered through a celite pad, washed with ether, and concentrated in vacuo.  The 
residue was purified by flash chromatography (Hexane/EtOAc 1:8-1:5) to afford 3.73g 
(63%) 2.16 as a colorless oil with 1.04 g (20%) recovered 2.15: Observed physical 
properties were identical with those previously reported: 27 1H NMR (400 MHz, CDCl3): δ 
4.37 (d, J = 3.2 Hz, 2H), 4.16 (m, 1H), 3.35 (s, 3H), 2.73 (dd, J = 18, 6.4 Hz, 2H) 
 
S
S
OH
OMe
2.17  
To a solution of lactone 2.16 (730 mg, 6.29 mmol, 1 equiv) in CH2Cl2 (25 mL) at 
–78 °C was added DIBAL-H (1.68 mL, 9.5 mmol, 1.5 equiv) in CH2Cl2 (10 mL) 
dropwise.  The resulting solution was stirred at –78 °C for 30 min before quenched with 
MeOH (5 mL).  The mixture was allowed to warm to room temperature, poured into a 
saturated solution of potassium sodium tartrate (50 mL) and CH2Cl2 (200 mL) was added 
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to the solution.  The mixture was stirred for 2 h two layers were separated and the 
aqueous solution was extracted with CH2Cl2 (50 mL x 3).  The combined organic layers 
were dried over Na2SO4.  The solvent was evaporated at 0 °C in vacuo and the residue 
was dissolved in CH2Cl2 (25 mL).  1,3 propanedithiol (2.45 mL, 25.16 mmol, 4 equiv) 
and BF3.OEt2 (0.95 mL, 7.55 mmol, 1.2 equiv) were then added sequentially dropwise.   
The resulting solution was stirred at room temperature for 4 h.  The reaction was 
quenched with H2O (10 mL), and the aqueous layer was extracted with CH2Cl2 (20 mL x 
3).  The combined organic layers were dried over Na2SO4, filtered, and concentrated in 
vacuo. The residue was purified by flash chromatography (hexane/EtOAc, 2:1) to afford 
0.785 g (60%) of the alcohol 2.17 as colorless oil: [α]D25 +14.4° (c 5.2, CHCl3); IR( neat) 
3448, 2981,1425, 1113 cm-1; 1H NMR (300 MHz, C6D6): δ 4.18 (dd, J = 8.1, 6.3 Hz, 1H), 
3.82 (ddd, J= 11.4, 6.0, 3.6 Hz, 1H), 3.65-3.50 (m, 2H), 3.47 (s, 3H), 2.99-2.82 (m, 4H), 
2.21-2.04 (m, 2H), 1.96-1.83 (m, 2H); 13C NMR (125MHz, C6D6): δ 78.1, 63.6, 57.8, 
43.9, 37.1, 30.6, 30.4, 26.1; HRMS(ESI) m/z 231.0500 [(M+Li)+ calculated for 
C8H16O2S2Na: 231.0483]. 
 
B
OTES
O
O
2.8  
To as solution of tBuOK (48.5g, 433 mmol, 1.3 equiv) in THF (230 mL) at -78 °C 
was added cis-2-Butene (35.6 mL, 400 mmol, 1.2 equiv) through a cannula.  After 5 min, 
n-BuLi (177 mL of 2.5 M solutions in hexanes, 333 mmol, 1 equiv) was added slowly so 
as to keep the internal temperature below -65°C. The reaction mixture was stirred at -78 
°C for 1 h then -25 °C for 45 min before it was cooled down to -78°C.  B(O-iPr)3 (76.5 
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mL, 333 mmol, 1 equiv) was added slowly.  The resultant solution was stirred at -78 °C 
for 30 min before quenched with 1 N HCl (130 mL).  After warmed to rt, 1N HCl (460 
mL) was added and stiring continued for 20 min. The solution was extracted with EtOAc 
(300 mL X 3).  The combined organic layer was added 4 Å molecular sieves (50 g) and 
diethaolamine (25 mL, 266 mmol, 0.8 equiv).  The resultant mixture was stirred under 
argon overnight and filtered.  Solvents were removed in vacuo and white solid was 
obtained.   Benzene (100 mL) was added to remove the unreacted diethanol amine.  
Recrystalization in ether-CH2Cl2 system afforded crotyl diethanol amine boronate 
complex 17.5 g (31%) as a white crystalline solid.  
To a solution of the complex prepared above (765mg, 4.5 mmol, 4 equiv) in ether 
(10 mL) at room temperature was added diisopropyl tartrate (920 µL, 4.5 mmol, 4 equiv).  
After 15 min stirring, brine (10 mL) was added and the resultant solution was stirred at 
room temperature for 30 min before diluted with ether (10 mL), separated and extracted 
with ether (20 mL X 3).  The combined organic layer was dried over Na2SO4 and 
concentrated in vacuo to afforded crude product of 2.22.  The crude 2.22 was dissolved in 
toluene (12 mL) at room temperature and powdered 4 Å molecular sieves (4 g) were 
added.  After 10 min, the mixture was cooled down to –78 °C and a solution of aldehyde 
2.21 (220 mg, 1.2 mmol) in toluene (2 mL) was added dropwise.  The resulting mixture 
was stirred at –78 °C for 12h.  1N NaOH solution (25 mL) was then added and the 
mixture was stirred for 2h at room temperature.  The resultant cloudy mixture was diluted 
with brine (30 mL) and extracted with ether (50 mL x 3).  The combined organic layers 
were dried (MgSO4), filtered and concentrated in vacuo.  The residue was dissolved in 
dichloromethane (8 mL) and cooled to –78 °C.  2,6-lutidine (0.2 mL, 1.6 mmol, 1.2 equiv) 
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was added followed by TESOTf (0.28 mL, 1,2 mmol, 1 equiv).  The reaction was stirred 
at –78 °C for 2 h before quenched with H2O (2 mL) and extracted with dichloromethane 
(3 x 10 mL).  The combined organic layer were dried (Na2SO4), filtered and concentrated 
in vacuo.  The residue was purified by flash chromatography (hexane: EtOAc, 50:1) to 
afford 0.18g (43%) of homoallylic ether 2.8 as a colorless oil: [α]D25 +7.0° (c 2.0, CHCl3); 
IR (neat) 3018, 2953, 1738, , 1636, 1360, cm-1; 1H NMR (500 MHz, C6D6): δ 6.92 (dd, J 
= 18.0, 5.5 Hz, 1H), 5.96 (dd, J = 18.0, 1.0 Hz, 1H), 5.91-5.80 (m, 1H), 4.97-4.95 (m, 
1H), 4.94-4.93 (m, 1H), 4.06 (dt, J = 6.0, 1.0 Hz, 1H), 2.31-2.25 (m, 1H)1.03 (s, 12H), 
1.01 (d, J = 7.0 Hz, 3H), 0.96 (t, J = 8.0 Hz, 9H), 0.56 (dq, J = 8.0, 2.5Hz, 6H); 13C NMR 
(125MHz, C6D6): δ 154.8, 141.1, 114.4, 83.0, 78.5, 44.3, 42.8, 42.7, 14.6, 7.1, 5.3; 
HRMS(ESI) m/z 359.2792 [(M+Li)+ calculated for C19H37BLiO3Si: 359.2765]. 
 
BO
O
OTES
I
OTES
2.8 2.10  
To a solution of 2.8 (40 mg, 0.11 mmol) in THF (2 mL) at room temperature was 
added NaOH (0.11 mL, 0.33 mmol of 3M solution, 3 equiv).  After 10 min vigorous 
stirring, I2 (0.11 mL, 0.22 mmol, 2 M, 2 equiv) in THF was added dropwise.  The 
resultant solution was stirred for 2 h at room temperature before quenched with Na2S2O3, 
extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4, filtered and concentrated in vacuo.  
The residue was purified by flash chromatography (Hexane/EtOAc 150:1) to afford 24 
mg (62%) 2.10 as a colorless oil: [α]D25 -16.9° (c 1.4, CHCl3); IR (neat) 2955, , 1455, 
1238, 1072cm-1; 1H NMR(500 MHz, C6D6): δ 6.46 (dd, J = 14.5, 7 Hz, 1H), 6.02 (dd, J = 
14.5, 1 Hz, 1H), 5.73 (m, 1H), 4.95 (m, 2H), 3.71 (ddd, J = 7, 5.5, 1 Hz, 1H), 2.12 (m, 
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1H),  0.93 (m, 12H), 0.51 (q, J = 7.5Hz, 6H); 13C NMR (125MHz, C6D6): δ 147.85, 
140.20, 114.99, 79.17, 77.00, 44.10, 14,68, 7.01, 5.18. The enantiomeric excess of A216 
was determined by chiral GC analysis of vinyl iodide 2.10 to be 80% (starting from 80 °C, 
20 °C/min to 100 °C, then hold for 10 min, 0.5 °C/min to 120 °C, hold for 5 min, 0.1 
°C/min to 139 °C, hold for 0 min, 20 °C/min to 220 °C hold for 0 min, totally 250 min, 
major isomer showed up at 61.06 min, minor isomer showed at 61.80 min starting from 
80 °C, 20 °C/min to 100 °C, then hold for 10 min, 0.5 °C/min to 120 °C, hold for 5 min, 
0.1 °C/min to 139 °C, hold for 0 min, 20 °C/min to 220 °C hold for 0 min, tonally 250 
min, major isomer showed up at 61.06 min, minor isomer showed at 61.80 min) 
Bu3Sn
OH
2.24  
To a solution of 2.22 (360 mg, 1.2 mmol, 4 equiv) in toluene (5 mL) at room 
temperature, which was prepared following the procedure described in synthesis of 2.8 , 
was added 4 Å molecular sieves (1g).  After 10 min, the reaction mixture was cooled 
down to –78 °C and 2.23 (103 mg, 0.3mmol) in toluene (2 mL) was added dropwise.  The 
resultant solution was stirred at –78 °C for 16 h, quenched with 1N NaOH (8 mL) at –78 
°C.  The mixture was allowed to warm up to room temperature and continued to stir 1 h. 
After separated, it was extracted with ether, washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo.  The residue was purified by flash chromatography 
(Hexane/EtOAc 30:1) to afford 104 mg (86%) 2.24 as a colorless oil: IR (neat) 3498, 
2956, 1375cm-1; 1H NMR (500 MHz, CDCl3): δ 6.18 (dd, J = 19.0, 1.0 Hz, 1H), 6.03 (dd, 
J= 19.0, 5.5 Hz, 1H), 5.80 (m, 1H), 5.12-5.08 (m, 2 H), 4.0 (q, J = 5.0 Hz, 1 H), 2.41-2.37 
(m, 1H), 1.65 (d, J = 5.5 Hz, 1H), 1.53-1.47(m, 6H), 1.35-1.27 (m, 6H), 1.04 (d, J = 7 Hz, 
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3H), 0.92-0.888 (m, 15H); 13C NMR (125MHz, CDCl3): δ148.2, 140.2, 128.9, 115.6, 78.1, 
43.5, 29.1, 27.3, 14.6, 13.7, 9.5; HRMS (ESI) m/z 409.2108[(M+Li)+ calculated for 
C19H38OSn 409.2105] 
 
Bu3Sn
OTES
2.9  
To a solution of 2.24 (100 mg, 0.25 mmol) in CH2Cl2 (5 mL) at –78 °C was added 
2,6-lutidine (90 µL, 0.75 mmol, 3 equiv) followed by TESOTf (113 µL, 0.50 mmol, 2 
equiv.).  The resultant solution was stirred at –78 °C for 1 h, quenched with saturated 
NaHCO3 (5 mL), extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4, filtered and 
concentrated in vacuo.  The residue was purified by flash chromatography 
(Hexane/EtOAc 100:1) to afford 104 mg (86%) 2.9 as colorless oil: IR (neat) 2924, 1376, 
1005cm-1; 1H NMR (500 MHz, CDCl3): δ 6.04 (d, J = 19 Hz, 1H), 5.93 (dd, J = 19, 6.5 
Hz, 1H), 5.85-5.79 (m, 1H), 4.99 (dd, J =14, 1 Hz, 2H), 3.88 (t, J = 6.5Hz, 1H), 2.28-2.24 
(m, 1H), 1.53-1.47 (m, 6H), 1.33-1.28 (m, 6H), 1.00 (d, J = 7 Hz, 3H), 0.95 (t, J = 8 Hz, 
9H), 0.91-0.86 (m, 15H), 0.59 (qd, J = 8, 1 Hz, 6H); 13C NMR (125MHz, CDCl3): δ 149.8, 
141.1, 128.3, 113.9, 80.5, 44.3, 29.1, 27.3, 15.0, 13.7, 9.5, 6.9, 5.0; After converting the 
vinyl tin to vinyl iodide 2.10 by treatment of iodine and NaHCO3, the enantiomeric 
excess was determined to be 33% by chiral GC analysis (starting from 80 °C, 20 °C/min 
to 100 °C, then hold for 10 min, 0.5 °C/min to 120 °C, hold for 5 min, 0.1 °C/min to 139 
°C, hold for 0 min, 20 °C/min to 220 °C hold for 0 min, totally 250 min, major isomer 
showed up at 61.06 min, minor isomer showed at 61.80 min) 
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I
OTES
2.10  
A) Roush Crotylation33  
To a solution of 2.26 (1.13 g, 5 mmol) in CH2Cl2 at –78 °C was added DIBAL-H 
(1.0 mL, 6 mmol, 1.2 equiv) dropwise.  The resultant solution was stirred at –78 °C for 
30 min, quenched with MeOH (1 mL).  Then the solution was poured into saturated 
Rochelle’s salt (sodium potassium tartrate) solution (50 mL), diluted with CH2Cl2 (50 mL) 
and stiring continued for 1.5 h.   The mixture was separated, aqueous layer was extracted 
with CH2Cl2 (50 mL x 3), and combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo to about 30 mL.  BF3.OEt2 (0.85 mL, 6.7 mmol, 1.34 equiv) 
was added to this solution at room temperature and stirred 1.5 h while protected from 
light.  The reaction was quenched with NaHCO3, extracted with CH2Cl2, washed with 
NaHCO3, brine, dried over Na2SO4, concentrated at 0 °C while kept off light in vacuo to 
about 5 mL.  Then the solution was diluted with toluene (30 mL) and 4 Å molecular 
sieves (3 g) were added.  After 10 min, the reaction was cooled to –78 °C and a solution 
of 2.22 (4.47 g, 15 mmol, 3 equiv) in toluene (10 mL) was added dropwise.  The resultant 
slurry was stirred for 16 h before quenched with 1N NaOH (120 mL).  After 1 h stirring, 
the mixture was diluted with brine (200 mL), extracted with ether, dried over Na2SO4, 
filtered and concentrated in vacuo.  The residue was dissolved in CH2Cl2 (10 mL) at 0 °C 
and 2,6-lutidine (0.87 mL, 7.5 mmol, 1.5 equiv) was added.  After 5 min, TESOTf (1.12 
ml, 5 mmol) was added dropwise.  The resultant solution was stirred at 0 °C for 1 h, 
quenched with H2O, extracted with CH2Cl2, dried over Na2SO4, filtered and concentrated 
in vacuo, The residue was purified by flash chromatography (Hexane/EtOAc 100:1 to 
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40:1) to afford 0.7g (40% over 4 steps) 2.10 as colorless oil.  The enantiomeric excess 
was determined by chiral GC (starting from 80 °C, 20 °C/min to 100 °C, then hold for 10 
min, 0.5 °C/min to 120 °C, hold for 5 min, 0.1 °C/min to 139 °C, hold for 0 min, 20 
°C/min to 220 °C hold for 0 min, totally 250 min, major isomer showed up at 61.06 min, 
minor isomer showed at 61.80 min) to be 26%.  
B) Brown Crotylation35 
To a solution of 2.26 (5.18 g, 23 mmol) in CH2Cl2 (50 mL) at –78 °C was added 
DIBAL-H (4.5 mL, 25.2 mmol, 1.1 equiv) dropwise.  The resultant solution was stirred at 
–78 °C for 30 min, quenched with MeOH (5 mL).  Then the solution was poured into 
saturated Rochelle’s salt (sodium potassium tartrate) solution (200 mL), diluted with 
CH2Cl2 (150 mL) and continued to stir for 1.5 h.   The mixture was separated, aqueous 
layer was extracted with CH2Cl2 (150 mL x 3), and combined organic layer was dried 
over Na2SO4, filtered and concentrated in vacuo to about 30 mL.  BF3.OEt2 (3.8 mL, 30 
mmol, 1.3 equiv) was added to this solution at room temperature and stirred 1.5 h 
protected from light.  The reaction was quenched with NaHCO3, extracted with CH2Cl2 
(100 mL x 3), washed with NaHCO3, Brine, dried over Na2SO4, concentrated at 0 °C 
while kept off light in vacuo to about 10 mL containing 2.28. A solution of t-BuOK (3.7g, 
33 mmol, 1 equiv) in THF (40 mL) at –78 °C was added cis-2-butene (10 mL, 20 equiv).  
After 5 min, n-BuLi (13.2 mL, 33 mmol) was added.  The mixture was warmed up to –45 
°C for 15 min.  It was cooled down to –78 °C again and (Ipc)2BOMe (12.50 g, 39.50 
mmol, 1.2 equiv) in ether (20 mL) was added.  The resultant solution was stirred at –78 
°C for 30 min then BF3.OEt2 (5.6 mL, 44.2 mmol, 1.34 equiv) was added.  After 15 min 
stirring, a solution of 2.28 was added in THF (10 mL) dropwise.   The resultant solution 
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was stirred at –78 °C for 16 h before warmed up to room temperature.  NaOH (40 mL, 
115 mmol, 3M) and H2O2 (30%, 20 mL) were then added and the mixture was refluxed 
for 2 h.   After separated, the aqueous layer was extracted with ether, dried over Na2SO4, 
concentrated in vacuo, The residue was purified by flash chromatography 
(Hexane/EtOAc 20:1) to afford 2.6 g product as colorless oil.  It was then dissolved in 
CH2Cl2 (20 mL) at 0 °C.  2,6-lutidine (2.5 mL, 22 mmol, 2 equiv) was added followed by 
TESOTf (3.7 mL, 16.4 mmol, 1.5 equiv).  The resultant solution was stirred at 0 °C for 1 
h, quenched with H2O (5 mL), extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4, 
filtered and concentrated in vacuo.  The residue was purified by flash chromatography 
(Hexane/EtOAc 100:1) to afford 3.1 g (38% over 4 steps) 2.10 as colorless oil. 
Enantiomeric excess was determined by chiral GC (starting from 80 °C, 20 °C/min to 100 
°C, then hold for 10 min, 0.5 °C/min to 120 °C, hold for 5 min, 0.1 °C/min to 139 °C, 
hold for 0 min, 20 °C/min to 220 °C hold for 0 min, totally 250 min, major isomer 
showed up at 61.06 min, minor isomer showed at 61.80 min) to be 90%. 
H
OOMe
OTES
I
2.31  
To a solution of 2.3045 (2.26 g, 4.37 mmol) in CH3CN (48 mL) and pH=7 buffer 
(12 mL) at 0 °C was added K2CO3 (1.5 g, 11 mmol, 2.5 equiv) and MeI (2.7 mL, 43.7 
mmol, 10 equiv).  The resulting solution was stirred at 26.5 °C for 48 h before diluted 
with EtOAc (40 mL), washed with brine and dried over Na2SO4.  The organic layer was 
filtered, concentrated, and residue was purified by flash chromatography (hexane:EtOAc, 
20:1) to afford 1.58 g (85%) of the alcohol 2.31 as colorless oil: [α]D25 –15.0° (c 5.4., 
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CHCl3); IR( neat) 2953, 1724, 1375 cm-1;  1H NMR(500 MHz, C6D6): δ 9.47 (s, 1H), 
6.14-6.10 (m, 1H), 3.68-3.62 (m, 2H), 3.04 (s, 3H), 2.31 (ddt, J=12.0, 3.5, 1.0Hz, 1H), 
2.16-2.12 (m, 1H), 2.11 (s, 3H), 2.04-1.96 (m, 1H), 1.79-1.71 (m, 1H), 1.54-1.47 (m, 1H), 
1.16-1.09 (m, 1H), 0.90 (t, J=8.0Hz, 9H), 0.50 (q, J = 8.0Hz, 6H); 13C NMR (125MHz, 
C6D6): δ199.2, 141.0, 93.9, 78.8., 71.3, 57.5, 43.6, 30.9, 27.3, 27.2, 6.9, 5.2; HRMS(ESI) 
m/z 427.1131 [(M+Li)+ calculated forC16H32IO3Si: 427.1166]. 
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To a solution of aldehyde 2.31 (1.02 g, 2.4 mmol) and vinyl boronate 2.8 (1.3 g, 
3.6 mmol, 1.5 equiv) in THF/H2O (120 mL, 3:1, degassed by freezing in liquid nitrogen 
under vacuum followed by warmed up to room temperature and repeated three times) at 
room temperature was added Pd(Ph3P)4 (280 mg, 0.24 mmol, 0.1 equiv).  The mixture 
was stirred for 5 min, and TlOEt (210 µL, 3 mmol, 1.25 equiv) was added via syringe.  
The reaction was kept at room temperature for 15 min, and then quenched with saturated 
NaHCO3.  The aqueous layer was extracted with EtOAc (100 mL x 3), and the combined 
organic layers were washed with brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo.  The residue was purified by flash chromatography 
(Hexanes:EtOAc, 30:1) to afford 1.03 g (82%) of 2.3 as a colorless oil: [α]D25 –11.0° (c 
1.2 , CHCl3); IR (neat) 2960, 1731cm-1; 1H NMR (500 MHz C6D6): δ 9.53 (s, 1H), 6.27 
(d, J = 15.5 Hz, 1H), 6.04-5.97 (m, 1H), 5.64 (dd, J = 15.5, 7.5 Hz, 1H), 5.51 (t, J = 7.0 
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Hz, 1H), 5.07-5.02 (m, 2H), 4.08 (t, J = 6.0 Hz, 1H), 3.83-3.79 (m, 1H), 3.72-3.68 (m, 
1H), 3.10 (s, 3H), 2.42-2.37 (m, 2H), 2.36-2.29 (m, 1H), 2.21 (ddd, J = 16.5, 8.0, 2.0 Hz, 
1H), 2.14 –2.06 (m, 1H), 1.74 (s, 3H), 1.73-1.66 (m, 1H), 1.36-1.28 (m, 1H), 1.11 (d, J = 
6.5 Hz, 3H), 1.02 (t, J = 8.0 Hz, 9H), 0.95 (t, J = 8.0 Hz, 9H), 0.64 (dq, J = 8.0, 1.5 Hz, 
6H), 0.56 (q, J = 8.0 Hz, 6H); 13C NMR (125 MHz, C6D6): δ 199.5, 141.3, 135.6, 133.8, 
132.2, 128.8, 114.2, 78.9, 78.0, 71.6, 57.6, 45.1, 43.7, 31.6, 25.2, 15.1, 12.6, 7.1, 7.0, 
5.4, 5.3; HRMS (ESI) m/z 531.3869 [(M+Li)+ calcd for C29H56O4Si2Li: 531.3877]. 
OTES
O
H
TESO
2.32  
 The byproduct of the Suzuki coupling was determined to be 2.32 as a colorless 
oil: [α]D25 +19.2° (c 1.1, CHCl3); IR (neat) 1696, 1457cm-1; 1H NMR (500 MHz, CDCl3): 
δ 9.59 (d, J = 8 Hz, 1H), 6.82 (dd, J = 15.5, 5 Hz, 1H), 6.31 (qd, J = 8, 1 Hz, 1H), 6.10 
(d, J = 16 Hz, 1H), 5.87-5.80 (m, 1H), 5.54 (dd, J = 15.5, 7 Hz, 1H), 5.39 (t, J = 7 Hz, 
1H), 5.0-4.97 (m, 2H), 4.47 (q, J = 5.5 Hz, 1H), 3.99 (t, J = 6.5 Hz, 1H), 2.31 (m, 1H), 
2.23 (q, J = 7.5 Hz, 2H), 1.71 (s, 3H), 1.69 (q, J = 6.5 Hz, 2H), 1.0 (d, J = 7 Hz, 3H), 
0.98 (q, J = 8 Hz, 18H), 0.64 (m, 12H); 13C NMR (125 MHz, CDCl3): δ 193.5, 159.6, 
141.0, 134.9, 134.0, 130.8, 130.7, 128.77. 114.1, 77.5, 71.1, 44.7, 37.0, 23.6,15.0, 12.6, 
6.8, 6.7, 5.0, 4.8; HRMS (ESI) m/z 499.3617  [(M+Li)+ calcd for C28H52O3Si2Li: 
499.3615] 
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To a solution of 2.10 (140 mg, 0.4 mmol, 1.5 equiv) at –78 °C in THF (5 mL) was 
added n-BuLi (0.24 mL of 2.5 M solution in hexanes, 0.6 mmol, 2.25 equiv).  After 2 h, 
B(O-iPr)3 (140 µL, 0.6 mmol, 2.25 equiv) was added.  The reaction mixture was warmed 
up to room temperature slowly and continued to stir overnight.  The reaction was 
quenched with H2O (5 mL), extracted with ether (10 mL x 3), dried over Na2SO4.  The 
organic layer was filtered, concentrated in vacuo.  The residue was added to a solution of 
2.31 (110 mg, 0.27 mmol) in THF/H2O (8 mL, 3:1) at room temperature.  The resultant 
solution was degassed (by freezing in liquid nitrogen under vaccum followed by warming 
up to room temperature and repeated three times) and Pd(PhP3)4 (31 mg, 0.027 mmol, 0.1 
equiv) was added.  After 10 min, TlOEt (23 µL, 0.34 mmol, 1.25 equiv) was added.  
After 15 min the reaction was quenched with saturated NaHCO3 (10 mL).  The mixture 
was filtered through a celite pad, washed with EtOAc (20 mL), dried over Na2SO4.  The 
organic layer was filtered and concentrated in vacuo and residue was purified by flash 
chromatography (Hexane/EtOAc, 20:1) to afford 100 mg (70%) of the alcohol 2.3 as 
colorless oil. 
TESO
OTES
OMe
O
O
O
TES
O
P
O
OEt
OEt
2.36  
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To a solution of 2.34 (154 mg, 0.21 mmol) in toluene (5 mL) was added 2.5 (100 
mg, 0.4 mmol, 1.3 equiv).  The reaction solution was then cooled to –78 °C and DMAP 
(384 mg, 3.15 mmol, 15 equiv), Et3N (322 µL, 2.31 mmol, 11 equiv) and tricholro 
benzyl chloride (328 µL, 2.1 mmol, 10 equiv) was added sequentially.  After 10 min, the 
reaction slurry was warmed up to room temperature and continued to stir overnight.  The 
reaction was quenched with NaHCO3 (10 mL), extracted with EtOAc (15 mL x 3), dried 
over Na2SO4.  The organic layer was filtered, concentrated, and residue was purified by 
flash chromatography (Hexane/EtOAc, 3:1) to afford 150 mg (75%) of 2.36 as colorless 
oil: 1H NMR (500 MHz C6D6): δ 6.99 (m, 1H), 6.30 (dd, J = 16, 4.4 Hz, 1H), 6.03 (m, 
1H), 5.83 (m, 1H), 5.67 (dd, J = 15.6, 7.2Hz, 1H), 5.56 (m, 1H), 5.10-5.05 (m, 2H), 
4.32(d, J = 4 Hz, 1H), 4.09 (t, J = 6.8Hz, 1H), 3.99-3.86 (m, 6H), 3.36-3.25 (m, 4H), 
2.92-2.80 (m, 1H), 2.69-2.57 (m, 1H), 2.50-2.36 (m, 2H), 2.28-2.18 (m, 2H), 2.0 (m, 
2H), 1.92-1.86 (m, 2H), 1.78 (s, 3H), 1.64 (s, 1H), 1.62-1.52 (m, 1H), 1.37 (s, 2H), 1.35-
1.20 (m 4H), 1.15-0.95 (m, 40H), 0.71-0.58 (m, 18H); HRMS (ESI) m/z 
965.6133[(M+Li)+ calcd for C49H95O10PSi3 965.6131]. 
TESO
OTES
OMe
O
O
O
TES
CHO
O
P(O)(OEt)2
2.37  
To a solution of 2.36 (144 mg, 0.15 mmol) in CH2Cl2 (5 mL) at room 
temperature was added methacrolein 2.44 (62 µL, 0.75 mmol, 5 equiv) and Grubbs 
secondary generation catalyst (7 mg, 7.5 µmol, 0.05 equiv).  The resultant solution was 
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refluxed at 45 °C (bath temperature) overnight.  After cooled to room temperature, 
solvent was removed in vacuo.  The residue was purified by flash chromatography 
(Hexanes:EtOAc, 4:1 to 2:1) and afforded 110 mg (73%) of 2.37 as colorless oil: 1H 
NMR (400 MHz C6D6): δ 9.35 (s, 1H), 7.01-6.87 (m, 1H), 6.35 (m, 1H), 6.11 (m, 1H), 
5.68 (m, 1), 5.54 (m, 3H), 4.31 (dd, J = 13.2, 3.2Hz), 4.13-3.77 (m, 8H), 3.54-3.42 (m, 
1H), 3.68-3.20 (m, 6H), 2.73-2.54 (m, 3H), 2.47-2.10 (m, 6H), 2.0 (m, 2H), 1.91-1.79 
(m, 6H), 1.76-1.73 (m, 9H), 1.64-1.54 (m, 2H), 1.15-0.97 (m, 52H), 0.71-0.57 (m, 12H); 
HRMS (ESI) m/z 1007.6259[(M+Li)+ calcd for C51H97O11PSi3 1007.6236]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85 
CHAPTER III 
STUDIES TOWARDS THE TOTAL SYNTHESIS OF AMMOCIDINONE 
3.1 Ammocidin: isolation and structure elucidation 
 Uncontrolled cell growth and differentiation in human tissues lead to cancer.  
Genetically, few mechanisms that lead to uncontrolled cell division and proliferation 
have been characterized.  One such mechanism is that of a mutant gene, which is known 
as an oncogene leading to hyperactive cell growth.  One example involves the gene Ras, 
found on chromosome 11, that functions like a switch in normal cells to regulate cell 
growth.  When the receptor on the cell surface is initiated, it will be activated and 
transduce signals to initiate cell growth.  When the ras signal is off, the cell growth cycle 
will stop.  A mutant Ras will keep the cell growing regardless whether the receptor is 
stimulated or not, which may finally lead to the development of a cancerous cell.  30% of 
human cancers, especially colon and pancreas cancer are due to Ras mutations.   In 
certain conditions, Ras can suppress an apoptosis process, which leads to programmed 
death of immortalized cells thus terminating the proliferation disorder and circumventing 
tumor formation.  Therefore, a selective apoptosis-inducing reagent may be a useful 
anticancer drug to cells expressing mutant Ras.  During their effort in searching for active 
apoptosis inducers with Ras dependent cell lines, a new promising cell-selective 
cytotoxic agent ammocidin 3.1 (Figure 3.1) was discovered.  
In the course of screening for apoptosis inducer with Ras dependent Ba/F3-V12 
cells, Hayakawa and co-workers isolated ammocidin from the culture broth of 
Saccharothrix sp. AJ9571 in 2001.47 From a 10 liter culture broth 387 mg of ammocidin 
was isolated as a colorless powder.  The molecular formula was determined to be 
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C59H96O22 by high-resolution FAB-MS. Extensive NMR analysis and chemical 
degradation revealed the connectivity of the molecular structure of ammocidin.  
Furthermore, methanolysis of ammocidin under acidic conditions led to the identification 
of two sugar units:  6-deoxy-L-glucoside 3.2 a sugar determined to be located at C9 of 
the ammocidin aglycone, a disaccharide attached at C24 containing D-digitoxoside 3.3 
and D-olivomycoside 3.4 interconnected through an alpha-glycoside linkage (Figure 3.1).  
The identity and absolute stereochemistry of three sugars units: 3.2, 3.3, and 3.4 were 
assigned by comparison to their derived methyl acetals to authentic samples.  
Unfortunately, the aglycone (ammocidinone) apparently did not survive the acidic 
degradation conditions.  The HMQC, COSY, HMBC studies revealed that ammocidin 
consisted of a highly unsaturated 20-membered macrolactone containing two 
trisubstituted triene moieties and a fully substituted hemiketal pyranose.48 The chemical  
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Figure 3.1 Structures of ammocidin 3.1 and deoxy sugars 3.2-3.4 
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shifts of the five allylic methyl carbons and NOE correlations led to the configuration 
assignment of the two triene moieties as E.  The complete relative and absolute 
stereochemistry of the aglycone (ammocidinone) was determined by two-dimensional 
NMR techniques.  The absolute configuration of C9, assigned an S configuration, was 
determined by the observed NOE between C1' methine of the 6-deoxy-L-glucose sugar 
3.2 (Figure 3.2).49 The structural comparison studies between apoptolidin and ammocidin 
indicated that these two molecules share some similarities in terms of stereochemistry, 
specifically, the C8, C9 and C20 positions have the same absolute  
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Figure 3.2 NOE studies of ammocidin structure 
 
stereochemistry.  Furthermore, the relative stereochemistry of C17-C19 and C21-C25 
were determined to be identical, both the C22 methoxy in ammocidin and C22 methyl in 
apoptolidin occupy an equatorial position and both C24 methyl groups hold an axial 
orientation (Figure 3.2).   However, the relative stereochemistry between C16-C17 in 
apoptolidin, have a syn relationship, while in ammocidin, they are anti to each other 
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(Figure 3.3).  Unfortunately, the relationship of the C9, C17 and C21 positions remain 
unassigned.  
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Figure 3.3 Structural similarities between apoptolidin 2.1 and ammocidin 3.1 
 
 With the absolute configuration of C9, C17 and C21 unknown, 4 different 
stereoisomer of ammocidin were plausible.  Based on the results obtained from the  
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Figure 3.4 Proposed structure of ammocidin 
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spectroscopic studies conducted in Hayakawa group, and the known stereochemistry of 
apoptolidin, ammocidin was tentatively assigned the structure 3.5 (Figure 3.4). 
 
3.2 Ammocidin: biological activity 
In IL-3 free medium the IL-3-dependent Ba/F3 pro-B cells undergoes apoptosis 
rapidly on treatment with ammocidin.  However, Ras-dependent Ba/F3-V12 cells, 
bearing dexamethasone-inducible v-H-Ras, survive in the medium containing 
dexamethasone (Dex) in the absence of IL-3 when treated with ammocidin.50 The primary 
biological assay showed that in an IL-3-free medium containing Dex (2 x 10-7 M) 
ammocidin induced apoptosis in Ba/F3-v12 cells with an IC50 of 66 ng/mL.  However, in 
the presence of IL-3 and less than 100 µg/mL of ammocidin, only inhibition of the Ras-
dependent Ba/F3-v12 cells growth was observed rather than apoptosis.45 The anti-
apoptotic function of Ras in Ba/F3 cells is believed to be mediated by mitogen-activated 
protein kinase (MAPK) and S6 kinase (S6K) pathway.51 It is known that the 
phosphorylation of MAPK an S6K is induced by Ras.  However, only 1 µg/mL of 
ammocidin could significantly reduce the phosphorylation lever of MAPK and S6K.  
These results indicated that the anti-apoptotic function of ammocidin in Ras-dependent 
cells is mediated by simultaneous inhibition of MAPK and S6K phosphorylaiton.48  
 
3.3 Ammocidinone:  a new synthetic target  
 The complex structure of ammocidin including two tri-substituted triene moieties 
and highly substituted pyranose unit combined with an interesting biological profile 
suggests ammocidin to be a worthy synthetic target. With the assignment of the absolute 
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stereochemistry of ammocidin incomplete, a highly convergent and flexible synthetic 
strategy was required that would allow for access to variable stereochemistry within its 
structure.  As the first step toward the total synthesis of ammocidin we selected to 
develop a chemical synthesis of ammocidinone 3.6, which can be further elaborated to 
ammocidin 3.5 by bioglycosylation with glycosyltranferase (Scheme 3.1).  
 
Scheme 3.1 Bio-glycosylation of ammocidinone 3.6 
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Our primary goal of a projected total synthesis of ammocidin was assembly of the 
tentatively assigned structure of ammocidinone.  Later work would focus on the utility of 
the natural product and it’s derivatives to probe the mechanism of the selective apoptotic 
function of ammocidin and develop ammocidin related anticancer agents.  To that end a 
highly convergent, efficient and flexible synthetic strategy was required for the chemical 
synthesis of ammocidinone.  Retrosynthetically, the first three disconnections were 
identified at the lactone bond and C13-C14 and C19-C20 bonds (Scheme 3.2), which 
identified polyenoate 3.7 (C1-C13), vinyl iodide 3.8 (C14-C19) and ethyl ketone 3.9 
(C20-C28) as key building blocks.  In the forward sense, these three fragments will be 
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coupled through a diastereoselective aldol reaction between C19-C20, a Suzuki coupling 
between C13-C14, and a Yamaguchi macrolactonization.  Fragment 3.7 would be derived 
from dienoate 3.10 by employing a Brown asymmetric crotylation methodology, a cross 
metathesis and Horner-Wadsworth-Emmons olefination reactions.  Aldehyde 3.8 would  
 
Scheme 3.2 Retrosynthetic analysis of ammocidinone 3.6 
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be prepared from epoxide 3.11, which could be obtained by a known Sharpless 
asymmetric epoxidation of 3-hydroxyl-1,4-pentadiene.52 The pyranose ring in ammocidin 
would be introduced via ethyl ketone 3.9.  The four stereogenic centers in fragment C20-
C28 would be established by two auxiliary based asymmetric aldol reactions.  Crimmins 
glycolyloxazolidinethions 3.12 mediated aldol reaction will set up the syn diol at C22 and 
C23.53 The anti diol and quaternary center at C24 position would be realized with 
Kobayashi’s super-quats 3.13 aided aldol chemistry.54 The flexibility of the synthetic 
route enable us to prepare the alternate isomers of fragments 3.8 and 3.9 if proven 
necessary.  
 
3.4 Synthetic studies of fragment 3.7 (C1-C13) 
 
Scheme 3.3 Retrosynthetic analysis of fragment C1-C13 3.7 
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 A highlight of our synthesis of fragment 3.7 was the combination of an 
asymmetric crotylation and cross metathesis strategy to provide aldehyde 3.14 instead of 
the traditional aldol-Wittig reaction sequence.  This design identified dienoate 3.10 and 
aldehyde 3.16 as the key intermediates for assembly of aldehyde 3.14.  The 4-methoxy-
dienoate was to be introduced by a Horner-Emmons reaction with known phosphine 
oxide 3.15 obtained from intermediate 3.17 (Scheme 3.3).55 
 
3.4.1 Synthesis of aldehyde 3.14 
 
Scheme 3.4 Synthesis of homoallylic alcohol 3.27 
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 Our preparation of aldehyde 3.14 was adopted from a previously developed route 
to methyl ester 3.23 that had been developed during our synthesis of apoptolidinone 
(Scheme 3.4).56 Starting from malonate 3.18, following a known procedure, alkylation 
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with iodoform followed by basic hydrolysis with KOH provided acid 3.20.57  Reduction 
with LAH afforded allylic alcohol 3.21, which was oxidized with PCC to provide 
aldehyde 3.22.56  A Wittig olefination reaction of 3.22 generated methyl dienoate 3.23.  
With 3.23 in hand, we then focused on the introduction of the C8 and C9 stereocenters 
employing Brown’s syn selective asymmetric crotylation.  The reduction of methyl ester 
of 3.23 with DIBAL-H afforded allylic alcohol 3.24, which was oxidized with MnO2 to 
afford aldehyde 3.25.  Unfortunately, aldehyde 3.25 proved to be unstable with neat 
aldehyde undergoing rapid polymerization on exposure to light.  Therefore, without any 
purification, aldehyde 3.25 was taken through reaction under Brown’s conditions to 
afford homoallylic alcohols 3.26 in 56% yield over two steps.35 After TES protection of 
the secondary alcohol 3.26, terminal alkene 3.27 was suitably protected for the 
subsequent cross metathesis reaction.  
With terminal alkenes 3.26 and 3.27 in hand, our efforts were directed towards 
cross metathesis with methacrolein 3.16 (Table 3.1).  According to Grubbs general model 
for selectivity in olefin cross metathesis, terminal alkene 3.26 and 3.27 should be 
categorized as a type I olefin, which implies the alkene is a very reactive cross metathesis 
partners and can readily undergo homodimerization easily.58 Methacrolein is categorized 
as a type III olefin, which does not show any homodimerization tendency during the 
cross metathesis reaction.  Based on these empirical classifications, we anticipated that 
3.26 or 3.27 would undergo cross metathesis with methacrolein smoothly.  Unfortunately, 
in the presence of Grubbs secondary generation catalyst (Figure 3.5) and five equivalent 
methacrolein, 3.27 only provided 23% desired product with 30% recovered starting 
material (Entry 1). Homodimerization of 3.27 was observed during the reaction (3.31).  
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We envisioned that a silyl-protected ether might increase the steric bulk and decrease the 
activity of the terminal olefin, therefore, alcohol 3.26 was investigated.  With excess 
amount of methacrolein, 3.26 provided only 15% cross metathesis product after reflux for 
24 h in dichloromethane and the homodimer of 3.26 was not observed.  According to 
Grubb’s rule, type III olefins may require an excess amount of type I olefin partners in 
order to push the reaction to completion. One equivalent of methacrolein was then used  
 
Table 3.1 Studies of cross metathesis 
+
R =     H, 3.26
R = TES, 3.27
R =     H, 3.28
R = TES, 3.14
R =     H, 3.30
R = TES, 3.31
I
RO
I
RO
CHO
I
RO
I
OR
CHO
3.16
+
Cross metathesis
 
Entry* 3.26/3.27 3.16 Catalyst 3.14/3.28 3.30/3.31 
Recovered 
3.26/3.27 
1 3.27 5 equiv. 3.32 23% 3.14 0% 3.31 30% 3.27 
2 3.27 10 equiv. 3.33 35% 3.14 0% 3.31 60% 3.27 
3a 3.27 10 equiv. 3.33 66% 3.14 0% 3.31 10% 3.27 
4 3.26 10 equiv. 3.32 15% 3.28 0% 3.30 - 
5 3.26 1 equiv. 3.32 0% 3.28 13% 3.30 - 
6b 3.26 10 equiv. 3.32 21% 3.28 0% 3.30 - 
7 3.26 10 equiv. 3.33 20% 3.28 10% 3.30 - 
* All reactions were taken in CH2Cl2 at 40 °C for 24 h; a: yield was obtained after 3 
cycles; b: 3.26 was added via syringe pump in 12 h. 
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Figure 3.5 Structure of cross metathesis catalyst 
 
and homodimer product 3.30 was obtained in 13% without any cross metathesis product 
(Entry 5).  This result indicated that terminal alkene 3.26 is reactive during the reaction 
and excess amount of type III olefin must be used to suppress the homodimerization.  
This led to adding 3.26 via syringe pump over 12 h in order to obtain optimal 
concentration conditions.  Although the homodimerization of 3.26 was not observed, the 
reaction only afforded 21% yield with some amount of unreacted starting material (Entry 
6).  We then turned our attention to Hoveyda modified Grubbs catalyst (Figure 3.5), 
which is more reactive towards type III olefin.59 A mixture of dimer and cross metathesis 
product was provided under Hoveyda’s condition (Entry 7). This result indicated that 
catalyst 3.33 was more reactive than 3.32 for these reaction substrates.  We then applied 
3.33 to substrate 3.27 and a slightly high yield (35%) was obtained, but gratifyingly, 
dimerization was suppressed (0% 3.31) and most of the unreacted starting material was 
recovered (60%)(Entry 2).   After three cycles the yield improved to 66% (Entry 3).   
 
3.4.2 Investigation of HWE reaction to complete synthesis of fragment 3.7 
 The synthesis of fragment phosphine oxide 3.15 was based on a known procedure 
(Scheme 3.5).60 To this end, crotonaldehyde 3.34 was converted to dimethyl acetal 3.35 
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with MeOH in the presence of NH4NO3.61 Phosphine oxide 3.36 was obtained via  
 
                               Scheme 3.5 Synthesis of phosphine oxide 3.15 
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treatment of 3.35 with diphenyl phosphine chloride.  A mixture of 3.15a and double bond 
isomerized compound 3.15b was furnished by quenching the lithium anion of 3.36 with 
methyl chloroformate 3.37.  A pure sample of 3.15 was obtained by a single 
recrystalization from toluene and hexanes.  The structure of phosphine oxide 3.36 and 
3.15 were verified by single X-ray analysis (Figure 3.6). 
 
 
3.36 3.15
 
Figure 3.6 X-ray structure of 3.36 and 3.15 
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 With both aldehyde 3.14 and phosphine oxide 3.15 in hand, we were ready to 
assemble the top half part of ammocidinone 3.7.  Unfortunately, under typical Murrays’ 
reproted conditions, no reaction occurred with either LDA or NaH as base (Scheme 
3.6).60   
 
Scheme 3.6 Studies of Horner-Wadsworth-Emmons olefination 
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We then examined the generation of 3.15 in situ followed by olefination in a one pot 
reaction, which reportedly provided higher yields when compared to the corresponding 
two pot reaction sequence.  However, we once again failed to obtain any desired product 
and recovered starting material was observed. 
 In order to explore the intermolecular Horner-wadsworth-Emmons reaction, we 
then conducted a model study with benzyl aldehyde 3.38 which was reported to be 
successful in Murrays’ original publication (Scheme 3.7).62 Under the same condition, the 
reaction afforded 65% yield with 2:1 (E:Z) stereoselectivity.  We then selected 2-bromo-
benzylaldehyde 3.39 as the reaction partner and again the reaction proceeded smoothly 
and provided the desired product in 67% yield with 18:1(E:Z) stereoselectivity based on 
NMR analysis.  However, when methacrolein 3.16 or cinnamaldehyde 3.40 were 
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employed as substrates, no desired product was observed and only intermediate 3.15 was 
observed.  With these results we suspect that the methodology does not extend to α,β-
unsaturated aldehydes. 
 
Scheme 3.7 Model study of Horner-Wadsworth-Emmons reaction 
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 At this point we envisioned Murrays’ methodology might not be suitable for the 
preparation of the trienoate moiety.  Our attention was then directed to stepwise Horner-
Wadsworth-Emmons reaction (Scheme 3.8).  As has been illustrated in the total synthesis 
of bafilomycin A1 by Paterson and Roush, phosphonate 3.45 was a good starat for 
introduction of the dienoate moiety.63 Following Roush’s procedure, 3.45 was prepared 
from 3.43 by treatment of PCl5 and P(i-OPr)3 sequentially.  To our satisfactory, Horner-
Wadsworth-Emmons reaction between aldehyde 3.14 and phosphonate 3.45 afforded 
desired dienoate 3.46 in 91% yield with good stereoselectivity (95:5).  Attempts to reduce 
the methyl ester with DIBAL-H failed to provide the desired allyl alcohol.  Analysis of 
NMR data implied that some of the methyl enol ether was hydrolyzed during the work up 
procedure (sodium potassium tartrate solution was used).  Efforts to conduct the DIBAL-
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H reduction, MnO2 allylic oxidation and Wittig reaction in one pot, which was protected 
from light, also did not provide any desired product 3.7.  
 
Scheme 3.8 Stepwise HWE approach to fragment 3.7 
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At this stage, we envisioned that polyene 3.7 might not be stable to survive in the 
following reaction conditions, considering the fragment 3.7 would be introduced to target 
molecule by Suzuki coupling. Therefore, we decided to leave the elongation of 3.46 until 
the later stage of the synthesis. 
 
3.5 Synthesis of the fragment 3.8 (C14-C19) 
3.5.1 Anti-crotylation approach to preparation of diene 3.56 
A key consideration in designing a synthesis of aldehyde 3.8 was introduction of 
the anti relative stereochemistry between the C16 and C17 sbustituents.  Possible 
methods for consideration in establishing this relative stereochemistry included an anti-
aldol or crotylation reaction and nucleophilic opening of an enantiopure epoxide.  We 
initially focused on application of an anti–crotylation reaction.  Asymmetric crotylation 
reactions are well-established methods to establish two stereocenters located within a 
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homoallylic alcohol.  Both Brown’s pinene and Roush’s tartrate mediated addition of (Z)-
γ-alkoxyallylboronates to aldehydes can provide syn-diols with high selectivity.33,35 
However, due to the configurationally instability of the (E)-γ-alkoxyallyl anion, there are 
only a small number of examples reported in the literature that use crotylation 
methodology to establish anti-1,2-diols.64 
 
Scheme 3.9 Preparation of diene 3.56 
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In 1985, Hoffmann and co-workers developed a procedure to prepare (Z)-γ-
alkoxyallylboronates starting from (Z)-γ-alkoxyallylphenylsulfide (Scheme 3.9).65 Later 
Nicholas adopted this strategy to produce (E)-γ-alkoxyallyldiisopinocampheylboranes 
which he subsequently utilized in an anti-crotylation of a cobalt complex of 
propiolaldehyde.66 In the case of our projected stereoselective synthesis of 3.56, we 
required aldehyde 3.54 that was prepared from methyl propargyl alcohol 3.51 according 
to the procedure shown in Scheme 3.9.  To this end, a stereo- and regioselective
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stannylcupration of alkyne 3.51 afforded vinyl tin 3.52,67 which was in turn converted 
into vinyl iodide 3.53 via halogen-tin exchange.68 The allylic alcohol 3.53 was then 
oxidized to aldehyde 3.54 by MnO2 and used directly without purification (neat aldehyde 
3.54 undergoes rapid polymerization).   
The chiral borane reagent required by the syn selective crotylation was prepared 
from methyl propargyl ether 3.48.  Treatment of 3.48 with KOt-Bu provided methyl 
allene ether,69 which was then subjected to acid catalyzed phenyl thiol addition to afford 
 
                            Scheme 3.10 Isomerization of (E)-γ-alkoxyallylic anion 
MeO
MeOK
K
(-)-(ipc)2BOMe
MeO B(ipc)2 MeO B(ipc)2
+
-120 oC
3.57 3.58
3.59
3.60 3.61  
 
 (Z)-γ-alkoxyallylphenylsulfide 3.50.65 Under Nicholas’s conditions, crotylation followed 
by silylation of the newly formed hydroxyl group furnished fragment 3.56 as major 
isomer of an inseparable mixture of isomers.  GC analysis and NMR analysis showed that 
the diastereoselectivity of the addition reaction was approximately 5:1.  The observed 
low diastereoselectivity could be due to the instability of the (E)-γ-alkoxyallylic anion 
and/or the isomerization during quenching anion with borate 3.59 (Scheme 3.10).  
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3.5.2 Revised route to the synthesis of fragment 3.8 
 Despite the efficiency of the above route in terms of required transformations, a 
more stereoselective sequence was required to avoid production of a mixture of 
inseparable diastereomers.  An alternative approach based on an epoxide opening strategy 
was then proposed (Scheme 3.11).  Asymmetric epoxidation has been extensively studied 
and proven to be one of the most efficient methods for synthesizing chiral molecules.  
Adopting Sharpless asymmetric epoxidation (SAE) methodology to set stereocenters at 
C16 and C17,70 the synthesis started from commercially available racemic 1,4-pentadien-
3-ol 3.62.  A SAE reaction provided enantiopure α-hydroxyl-epoxide 3.63 in good 
  
                                      Scheme 3.11 Preparation of alkyne 3.66 
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yield.71 Methylation of alcohol 3.63 afforded methyl ether 3.64.72 Epoxide 3.64 was then 
treated with the ethylenediamine complex of lithium acetylide.73 Isomerization of the 
crude terminal alkyne with KOtBu afforded the thermodynamically favored internal 
alkyne 3.65 as sole product.  Crude secondary alcohol was then protected as TES silyl 
ether to afford 3.66 in 22% yield over 4 steps from 3.62. 
 Our efforts were then directed towards conversion of the alkyne group to the Z-
vinyl iodide group.  Although many methodologies exist for this transformation, 
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palladium (0) catalyzed hydrostannylation drew our attention.67 Pancrazi has 
systematically investigated addition of tin hydrides to alkynes and proposed an empirical 
model to help select proper reaction conditions.  According to his study, the palladium(0) 
catalyzed hydrostannylation reaction of propargyl alcohol derivatives bearing a R 
substituent at the α position usually leads to the thermodynamically distal isomer as the 
major product (Figure 3.7).  Based on this observation, we chose  
 
R
OR''
R'
H
SnR'''3R'
R
OR''
SnR'''3
HR'
R
OR''
distalproximal  
Figure 3.7 Model of regioselectivity of hydrostannylation 
 
PdCl2(PPh3)2 as  our palladium source and conducted the reaction at room temperature 
(Table 3.2).  Unfortunately, the reaction afforded poor regioselectivity and poor 
conversion (Entry 1).  To suppress the undesired proximal isomer P1’ the reaction 
temperature was decreased to 0 °C and Pd(Ph3P)4 was examined as the catalyst.  The 
result showed that the ratio between those two regioisomers remained the same (Entry 2).  
Considering the mechanism, the first step of the reaction was believed to be cis addition 
to the alkyne.  We speculated that by using a silyl protective group the steric bulk might 
favor the desired regioselectivity. However, with 3.66, poor regioselectivity and 
conversion was observed with either Pd(Ph3P)4 or PdCl2(PPh3)2 (Entry 3,4).  Finally we 
turned our attention to stannylcupration.  Surprisingly, using the procedure developed by 
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Pancrazi, the addition of excess MeOH (110 equiv.) provided excellent conversion, stereo 
and regioselectivity in 90% yield with 3.68 as the sole isomer (Entry 5). 
 
Table 3.2 Studies of hydrostannylation on 3.65/3.66 
OR
OMe
Bu3Sn
OR
OMe
OR
OMe
H
Bu3Sn
+
3.65 R=     H, 
3.66 R= TES,
3.67 R=     H,
3.68 R= TES,
3.69 R=     H, 
3.70 R= TES,  
*Starting material  
 
With Z-vinyl tin 3.68 in hand, we then moved forward to finish up the synthesis. 
of fragment 3.8.  Iodine–tin exchange furnished vinyl iodide 3.71 in 93% yield (Scheme 
3.12). Introduction of the aldehyde functionality was required to complete the synthesis 
Epoxide rearrangement to aldehydes or ketones catalyzed either by Lewis acid or base 
has been well studied recently.74 Among Lewis acids examined erbium(III)triflate 
catalyzed regio and stereoselective epoxide opening was appealling.75 This route called 
for regioselective epoxidation to set up the terminal epoxide. However, application of m-
CPBA to 3.71 failed to provide the desired epoxide and interpretation of the crude NMR 
Entry S.M.* Reaction Condition  3.67/3.68 3.69/3.70 S.M.* 
1 3.65 PdCl2(Ph3P)2, Bu3SnH,THF, rt 29% 9% --- 
2 3.65 Pd(Ph3P)4, Bu3SnH, THF, 0°C  18% 6% --- 
3 3.66 PdCl2(Ph3P)2, Bu3SnH,THF, rt  14% 6% 58% 
4 3.66 Pd(Ph3P)4, Bu3SnH, THF, 0°C  20% 6% 60% 
5 3.66 CuCN, Bu3SnH, nBuLi, THF, MeOH,  -78°C - -10°C 90% 
Trace 
amount 0% 
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spectroscopy revealed that epoxidation of the tri-substituted olefin was the major product. 
We then considered a hydroboration-oxidation sequence.  A regio- aand chemoselective 
hydroboration was required to differentiate the two olefins.  BH3•DMS resulted in poor 
 
Scheme 3.12 Completion synthesis of fragment 3.8 
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selectivity and poor yield.  Considering steric effects, a more bulky borane reagent was 
needed.  However, the application of 9-BBN led to an incomplete reaction and poor 
yield.  Gratifyingly, disiamyl broane demonstrated good regioselectivity and an oxidative 
work up provided 57% yield without any other isomer. 76 Finally, oxidation of the 
corresponding alcohol with Dess-Martin periodinane completed the synthesis of aldehyde 
3.8.  In summary, this synthetic route for fragment C14-C19 (3.8) was easy to conduct on 
large scale and provided the final 6-carbon aldehyde in good yield (9 linear steps, 5% 
overall yield).   
 
3.6 Synthesis of fragment 3.9 (C20-C28) 
The synthesis of fragment 3.9 C20-C28 relied on two consecutive asymmetric 
aldol reactions (Scheme 3.13).  This approach enabled us to prepare all four possible 
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stereoisomers of ammocidin in a versatile manner.  Introduction of the quaternary center 
at C24 position was considered one of the most challenging tasks in the total synthesis of 
 
 
Scheme 3.13 Retrosynthetic analysis of fragment 3.9 
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ammocidinone.   There are only a limited number of methods available to establish a diol 
bearing a quaternary center stereoselectively.  Among them the most practical approach 
is enantiolselective dihydroxylation developed by Sharpless.77 However, regarding the 
anti-diol, which is required in our proposed ammocidinone, dihydroxylation usually 
affords low enantioselectivity.  The other useful access to this kind of architecture is  
 
                  Scheme 3.14 Stereoselectivity of SuperQuats facilitated aldol reaction 
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stereoselective epoxide opening.  The quaternary center demands a tri-substituted 
epoxide, which is difficult to open stereospecifically with nucleophiles.  Recently 
Kobayashi developed an aldol reaction to prepare syn or anti diols asymmetrically 
facilitated by lactate derivatives bearing SuperQuats chiral auxiliary.54 
Diastereoselectivity of the aldol reaction could be controlled by varying the protecting 
groups of the SuperQuats auxiliary.  Benzyl ether usually leads to anti diols, while TBS 
ether leads to syn diols.  The enantioselectivity of the aldol reaction was controlled by the 
stereochemistry of phenyl substitutent in the SuperQuats auxiliary (Scheme 3.14). 
Relying on this methodology, in one single step the quaternary center at the C24 position 
and C25 hydroxyl group could be established stereoselectively.  The other syn diol at C22 
and C23 position was introduced by glycolate derivatives bearing Evans or Crimmins 
auxiliary.  The ethyl ketone will be introduced in the final step.  
 
3.6.1 Exploration of Kobayashi aldol reaction to prepare 3.90 
 
                            Scheme 3.15 Preparation of SuperQuats auxiliary 3.13 
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The preparation of the SuperQuats auxiliary 3.13 required for the Kobayashi aldol 
reaction.  The synthesis began with commercially available D-phenylglycine 3.78 
(Scheme 3.15).   The amino acid was esterified with thionyl chloride and methanol to 
give methyl ester 3.79 in good yield.78 Protection of the amine with trifluoroacetic 
anhydride afforded amide 3.80, which was then subjected to double Grignard addition 
with methylmagnesium iodide to provide tertiary alcohol 3.81.79 Hydrolysis of the 
trifluoroaceamide 3.81 under basic conditions gave rise to α-hydroxy amine 3.82, which  
 
                    Scheme 3.16 Approve stereochemistry for aldol product 3.90 
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was in turn converted into oxazolidinone 3.83 with carbonyl diimidazole (CDI).  The 
remaining part of the auxiliary came from (S)-methyl lactate.  Protection of the secondary 
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alcohol of 3.84 with BnBr gave rise to benzyl ether 3.85.80 Then the methyl ester was 
hydrolyzed to furnish acid 3.86 in nearly quantitative yield.81 Finally coupling 
SuperQuats 3.83 and acid 3.86 together provided auxiliary 3.13.53 
With SuperQuats auxiliaries in hand, the required aldehyde was needed for the 
Kobayashi aldol reaction.  The aldehyde preparation began from 1,4-butanediol 3.87 
(Scheme 3.16).  Monomethylation with methyl idodide of the sodium salt of 1,4-
butanediol afforded methyl ether 3.88 in good yield, which in turn was subjected toSwern 
oxidation to furnish aldehyde 3.89.  To our satisfaction, under the conditions developed 
by Kobayashi, the titanium enolate of SuperQuats auxiliary 3.13 coupled with aldehyde 
3.89 smoothly and provided aldol adduct 3.90 in 73% yield as the sole isomer.  The 
stereochemistry of 3.90 was determined by NOE analysis of acetonide ring 3.95.54 First, 
oxazolidinone was replaced by benzyl ester with lithium anion of benzyl alcohol.  LAH 
reduction of the benzyl ester rendered diol 3.92, which was selectively silylated with 
TBSCl to afford 3.93.  Reductive removal of the benzyl protective group by 
hydrogenolysis released the tertiary alcohol and the acetonide 3.95 was formed with 2,2-
dimethoxypropane.  The NOE analysis of acetonide B84 showed a strong signal between 
C(25) proton and C(24) methyl group,  thus confirming the product was the 2,3-anti 
stereoisomer.   
 
3.6.2 Studies towards elaboration of 3.90 to fragment 3.9 
After completion of diol product 3.90, introduction of stereocenters located at 
C22 and C23 position via Crimmins asymmetric glycolate aldol reaction was examined. 
First, the free hydroxyl group was protected as triethylsilyl ether 3.96 (Scheme 3.17). 
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Then SuperQuats auxiliary was replaced by lithium anion of ethyl thiol and afforded 
ethyl thiol ester 3.97. The most common procedure employed in this kind of 
transformation was reduction of the ester followed by mild oxidation of the resulting 
alcohol.  Unfortunately, LAH reduction of the ester 3.97 afforded diol 3.92 instead of 
3.99.  A less reactive reducing reagent, lithium borohydride, was then examined and 
alcohol 3.99 was obtained. Swern oxidation of the resulting alcohol 3.99 provided the 
desired aldehyde 3.98 in high yield.  However, a more efficient method was desired at 
this stage instead of a standard two-step sequence.  Recently, Fukuyama developed a 
selective reduction procedure to convert thiol esters to aldehydes in one step applying  
 
                                  Scheme 3.17 Preparation of aldehyde 3.98 
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Pd/C catalyzed hydrogenation in the presence of triethyl silane.82 Unfortunately, this 
method only provided 21-33% yield of product along with unreacted starting material.   
Efforts to optimize the reaction and improve the conversion failed, possibly because of 
the steric hindrance from the α-tertiary center.  Finally, we found that DIBAL-H (1.3 
equiv.) provided desired aldehyde 3.98 in good yield.  
With aldehyde 3.98 in hand, we set out to explore the Crimmins syn aldol reaction 
to set up the syn relationship at C22 and C23 position (Scheme 3.18).  The reaction was 
first conducted with Evans N-glycolyloxazolidiones 3.100, prepared from D-
phenylglycine and methoxyacetic acid, and provided aldol adduct 3.101 in good yield 
(52%-60%) Under the same reaction condition, Crimmins glycolyloxazolidinethione 
auxiliary 3.12 afforded a slightly higher yield 3.102 (60%-64%).83 Both 3.101 and 3.102 
were obtained as a single isomer based on the NMR observation.  Based on the Crimmins  
 
                                 Scheme 3.18 Crimmins syn glycolate aldol reaction 
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model, we predicted that the stereochemistry was the desired syn relationship, but single 
crystal X-ray analysis of the crystalline of 3.102 indicated that the C22-C23 stereocenters 
were actually of anti-stereochemistry (Figure 3.8). The stereochemistry of 3.101 was 
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determined to be anti relationship based on the NMR analysis comparison with 3.102. 
 
 
Figure 3.8 X-ray structure of aldol adduct 3.102 
 
This experimental observation can be rationalized based on the transition state 
models shown in Figure 3.6.  According to Crimmins model, with one equivalent of 
Lewis acid TiCl4, the reaction should proceed through a closed six-membered transition 
state and afford the desired syn aldol product 3.102a.  However, the unfavorable syn-  
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Figure 3.9 Rationalization of stereochemistry of aldol product 3.102  
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pentane interaction between the benzyoxy on the steric bulky α quaternary stereocenter 
and the methoxy probably disfavors a closed transition state. Thus, we propose that the 
reaction proceeds through an open transition state, as suggested by Heathcock, to explain 
propionate anti aldol mediated by N-acyloxazolidinones (Figure 3.9).84 
 Although at this stage we did not obtain the desired aldol product 3.102a, 
considering the generality of our synthetic strategy and the insignificance of the 
remaining chemistry on stereochemistry, we decided to continue with the undesired 
isomer 3.102 to investigate the remaining steps of the synthetic strategy.  Our efforts 
were then directed towards introducing the ethyl ketone to complete the synthesis of 
fragment 3.9’.  Our initial design of the synthetic route was to convert the auxiliary to a 
Weinreb amide and subsequently the ethyl ketone would be formed by an ethyl Grignard 
addition.  
 However, standard conditions to generate Weinreb amides led to no reaction, and 
recovery of most of the starting material was recovered (Scheme 3.19).   We then turned 
to manipulation of thioxazolidnone 3.102 because it was reported that Crimmins 
 
Scheme 3.19 Studies towards preparation of Weinreb amide 3.103 
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oxazolidithione was more labile than Evan’s oxazolidinone auxiliary and hence easier to 
be removed.  Unfortunately, Lewis acid mediated replacement (AlMe3, Weinreb salt) 
rendered aldehyde B98 and auxiliary 3.100 via a retro-aldol reaction and all efforts to 
prevent retro-aldol reaction failed.  Basic conditions developed by Crimmins provided a 
mixture of unreacted starting material and retro-aldol product.   
 
Scheme 3.20 Preparation of ethylthioester 3.105 
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These failures led to an alternative strategy to introduce the ethyl ketone, an 
organocuprate catalyzed substitution of a thioester then drew our attention.85 Protection of 
the free secondary hydroxyl group with TESOTf afforded silyl ether 3.104, which was 
subjected to substitution with the lithium thioethoxide (Scheme 3.20).  To our surprise, 
this reaction furnished desired thioester 3.105 in a low 28%-36% yield.   Exchanging the 
lithium anion for potassium anion led to no reaction at all.86 Presumably this poor yield 
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was due to the steric hindrance introduced by the TES silyl ether.  Alternatively, starting 
from 3.102, thioethoxide displacement of the auxiliary proceeded smoothly and afforded 
desired thioester 3.106 in 95% yield, which was silylated with TESOTf to provide 3.105. 
The formation of the ethyl ketone from the thiol ester 3.105 could be achieved by 
a couple of methods such as organo-cuprate catalyzed Grignard addition and 
organocuprate substitution.  We initially attempted copper (I) catalyzed Grignard  
 
Scheme 3.21 Synthesis of ethyl ketone 3.9’ 
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substitution with ethylmagnesium bromide.87 However, an over-addition product 3.107 
was generated at -15°C (Scheme 3.21).   Alternatively, we considered using of a Gilman 
reagent.  But the reaction with lithium deethyl cuprate did not proceed at -15°C.88 
However, after the reaction temperature was warmed up to 0 °C, the desired ethylketone 
3.9’ was provided in 79% yield. 
In summary, the synthesis of fragment 3.9’ featured two consecutive aldol 
reactions and one cuprate addition reaction and was completed in 8 linear steps with a 
12% overall yield (Scheme 3.22).  
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Scheme 3.22 Summary of synthesis of fragment 3.9’ 
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3.7 Conclusion: projected completion of ammocidinone 
In conclusion, we have developed a highly convergent synthetic strategy to build 
ammocidinone 3.6.  Three key building blocks were prepared efficiently: fragment 3.9’ 
(C23 epimerized C20-C28) was synthesized by two consecutive asymmetric aldol 
reactions in 8 linear steps at 12% yield; fragment 3.8 (C14-C19) was built in 9 linear 
steps at 5% overall yield featuring a Sharpless asymmetric epoxidation and regioselective 
hydroboration reaction; fragment 3.46 was achieved via a Brown asymmetric crotylation, 
cross metathesis and Horner-Wadsworth-Emmons reaction.  To complete the synthesis of 
ammoidinone 3.6, we still require correction of the C23 stereocenter proper method.  
Possible solutions include examining different lewis acids mediated syn aldol reactions 
like nBu2BOTf and Sn(OTf)2 or employing asymmetric Mukaiyama aldol reaction.89   
With all building blocks in hand,  an efficient strategy was required to assemble them 
together(Scheme 3.23).   We envisioned that an Sn(OTf)2 mediated aldol reaction would 
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couple ethyl ketone 3.108, which is derived from 3.9 via changing benzyl ether to TES 
silyl ether, and install the required stereochemistry.90 Then a Suzuki coupling will attach 
fragment 3.46 to 3.109 and afford pentaene 3.110.  At this stage a reliable method is 
required to install the trienoate unit.  Examining suitable reduction and oxidation 
conditions is necessary to avoid the unstability of the polyene system.  Subsequently, 
macrolactonization will furnish the lactone 3.111,10 which finally will be subjected to 
global deprotection and simultaneously cyclization45 to install the pyranose moiety and 
completed the total synthesis of ammocidinone.  
 
Scheme 3.23 Projected completion of ammocidinone 3.6 
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3.8 Experimental Section 
General procedures. Reagents were obtained from commercial suppliers, and where 
appropriate were purified prior to use.  All reactions were carried out under a nitrogen or 
argon atmosphere using dry glassware that had been flame-dried under a stream of 
nitrogen, unless otherwise noted.  All necessary solvents were purified prior to use.  
Tetrahydrofuran and ethyl ether were distilled from sodium/benzophenone; 
dichloromethane and benzene were distilled from calcium hydride.  Chloroform was 
washed twice with water, dried over potassium carbonate, refluxed, and distilled from 
phosphorus pentoxide. Triethylamine was distilled from calcium hydride and stored over 
sodium hydroxide.  Reactions were monitored by thin-layer chromatography (TLC) using 
0.25-mm E. Merck precoated silica gel plates.  Visualization was accomplished with UV 
light and aqueous ceric ammonium molybdate solution, anisaldehyde or KMnO4 stain 
followed by charring on a hot-plate.  Flash chromatography was performed with the 
indicated solvents using silica gel 60 (particle size 230-400 mesh) with the indicated 
solvent system.  Yields refer to chromatographically and spectroscopically pure 
compounds unless otherwise stated.  Melting points are uncorrected unless otherwise 
noted.  1H and 13C NMR spectra were recorded on Bruker 400, and 500 MHz 
spectrometers at ambient temperature.  1H and 13C NMR data are reported as δ values 
relative to tetramethylsilane or chloroform. High-resolution mass spectra were obtained 
at Texas A&M University Mass Spectrometry Service Center by Dr. Shane Tichy on an 
API QSTAR Pulsar Instrument.  The single-crystal X-ray diffraction analysis was 
performed by Dr. Joseph Reibenspies of Texas A&M University using a Bruker Smart 
1000 CCD single crystal X-ray diffractometer.  
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3.24
I OH
 
To a solution of 3.23 (532 mg, 2 mmol) in CH2Cl2 (20 mL) at -78°C was added 
DIBAL-H (2.2 mL, 2.2 mmol, 2.2 equiv) dropwise.  After the addition was completed, 
the resulting solution was stirred at -78 °C for 1h before quenched with 1 mL MeOH.  
The mixture was poured into a 125 mL beaker containing 50 mL saturated Rochelle’s salt 
(Sodium Potassium Tartrate) solution and stirred at room temperature for 1h.  After 
separated, aqueous layer was extracted with CH2Cl2 (30 mL X 3).  The combined organic 
layer was dried over Na2SO4, concentrated in vacuo. Residue was purified by flash 
chromatography (Hexanes: EtOAc, 2:1) to afford 400 mg (85%) of 3.24 as colorless oil: 
IR: (neat) 3314, 2912, 1439, 1260 cm-1; 1H NMR (400 MHz, CDCl3): δ 6.07 (s, 1H), 5.91 
(s, 1H), 4.06 (s, 2H), 1.95 (s, 3H), 1.76 (s, 3H), 1.55 (s, 1H); 13C NMR (100 MHz, 
CDCl3): δ 144.2, 137.5, 125.4, 79.9, 68.2, 25.0, 15.4 ; HRMS (APCI) m/z 239.1771 
[(M+H)+ calcd for C7H11IO]. 
 
I
OH
3.26  
To a solution of t-BuOK (690 mg, 5.8 mmol, 2 equiv) in THF (15 mL) at -78 °C 
was added cis-2 butene (3 mL, 30 mmol, 10 equiv).  After 5 min, n-BuLi (2.35 mL of 2.5 
M solution in hexanes, 5.8 mmol, 2 equiv) was added dropwise.  5 min later, the reaction 
mixture was warmed up to -45 °C and stirred for 15 min.  The reaction mixture was then 
cooled back to -78 °C and (-)-(ipc)2BOMe (2.2 g, 7.0 mmol, 2.4 equiv) in ether (15 mL) 
was added via cannula.  The resulting mixture was stirred at -78 °C for 30 min and 
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BF3.OEt2 (1.1 mL, 7.9 mmol, 2.68 equiv) were added.  In a meanwhile, to a solution of 
3.24 (700 mg, 2.94 mmol) in CH2Cl2 (20 mL) at room temperature was added MnO2 (21 
g, 30 equiv/m).  The resultant mixture was stired at room temperature for 2h before 
filtered through a short pad of celite and concentrated in vacuo to a solution of crude 3.25 
in CH2Cl2 (ca. 1 mL). After BF3.OEt2 was added 15 min, 3.25 in CH2Cl2 (1 mL) was 
added.  The resulting mixture was stirred at -78 °C overnight and 10 mL NaOH (3 M) 
was added followed by 4 mL H2O2 (30% solution in H2O).  After refluxed at 60 °C for 2 
h, it was cooled down to room temperature and separated, extracted with ether, dried over 
Na2SO4. After filtration and concentration in vacuo, the residue was purified by flash 
chromatography (Hexanes:EtoAc, 30:1) to afford 486 mg (56%) of 3.26 as colorless oil: 
[α]D25 +8.1° (c 1.8, CHCl3); IR (neat) 3410, 2973, 1451, 1296, 1008 cm-1; 1H NMR (400 
MHz, CDCl3): δ 6.03 (s, 1H), 5.88 (s, 1H), 5.75 (m, 1H), 5.06 (m, 2H), 3.89 (d, J = 8 Hz, 
1H), 2.45 (m, 1H), 1.93 (s, 3H), 1.63 (bs, 1H), 1.04 (d, J = 8 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 144.3, 140.7, 138.6, 127.0, 114.8, 78.0, 79.8, 41.1, 25.1, 14.3, 14.2; 
HRMS (ESI) m/z 299.0486[(M+Li)+ calcd for C11H17IO: 299.0484]. The enantiomeric 
excess of 3.26 was examined by 19FNMR analysis after converting to Mosher ester with 
(R)-(+)-α-mehtyoxyl-α-(trifluoro-methyl)phenylacetic acid. (88% ee) 
 
I
OTES
3.27  
To a solution of 3.26 (210 mg, 0.72 mmol) in CH2Cl2 (5 mL) at -78 °C was added 
TESOTf (320 µL, 1.44 mmol, 2 equiv) and 2,6-lutidine (250 µL, 2.16 mmol, 3 equiv).  
The resultant solution was stirred at -78 °C for 3h, quenched with H2O (5 mL), extracted 
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with CH2Cl2 (10 mL x 3), dried over Na2SO4, filtered and concentrated in vacuo.  The 
residue was purified by flash chromatography (Hexanes: EtOAc, 100:1) to afford 260 mg 
(90%) of 3.27 as colorless oil: [α]D25 +4.2° (c 2.1, CHCl3); IR: (neat) 2955, 1457, 1239, 
cm-1; 1H NMR (500 MHz CDCl3): δ 5.97 (s, 1H), 5.74 (s, 1H), 5.67-5.60 (m, 1H), 4.99 
(d, J = 17.5 Hz, 1H), 4.93 (d, J = 10.5 Hz, 1H), 3.73 (d, J = 7.5 Hz, 1H), 2.33 (m, 1H), 
1.91 (s, 3H), 1.67 (s, 3H), 1.03 (d, J = 6.5 Hz, 3H), 0.95 (t, J = 8 Hz, 9H), 0.59 (q, J = 8 
Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 144.5, 141.2, 139.9, 126.9, 113.6, 82.0, 79.4, 
42.6, 15.0, 15.9, 13.7, 6.9, 4.9; HRMS (APSI) m/z 407.0594[(M+Li)+ calcd for 
C17H31IOSi]. 
 
I
CHO
TESO
3.14  
To a solution of 3.27 (180 mg, 0.44 mmol) in CH2Cl2 (3 mL) at room temperature 
was added methacrolein (180 µL, 2.2 mmol, 5 equiv) and Hoveyda-Grubbs secondary 
generation catalyst (27 mg, 0.044 mmol, 0.1 equiv).  After degassed (by freezing in 
Liquid nitrogen under vacuum followed by warm up to room temperature, repeated three 
times), the resulting solution was refluxed at 40 °C overnight.  After removed solvent in 
vacuo, the residue was purified by flash chromatography (Hexanes: EtOAc, 50:1) to 
afford 68 mg (38%, E:Z = 10:1) of 3.14 as colorless oil, after three this cycles, 130 mg 
(66%) of 3.14 was obtained: [α]D25 -6.4° (c 1.8, CHCl3); IR: (neat) 2955, 1689, 1457, 
1258, 1154 cm-1; 1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 6.28 (d, J = 10.5 Hz, 1H), 
5.96 (s, 1H), 5.82 (s, 1H), 3.90 (d, J = 7 Hz, 1H), 2.88 (m, 1H), 1.89 (s, 3H), 1.76 (d, J = 
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1 Hz, 3H), 1.65 (d, J = 1 Hz, 3H), 1.1 (d, J = 6.5 Hz, 3H), 0.96 (t, J = 8 Hz, 9H), 0.62 (q, J 
= 8 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 195.2, 156.5, 144.0, 139.0, 138.2, 127.3, 
80.9, 79.9, 38.3, 29.7, 25.0, 15.5, 13.8, 9.3, 6.8, 4.8; HRMS (ESI) m/z 455.1459[(M+Li)+ 
calcd for C19H33IO2Si 455.1455]. 
I
TESO
MeO
O
OMe
3.46  
To a solution of 3.45 (89 mg, 0.33 mmol, 2.2 equiv) in THF (2 mL) at 0 °C was 
added 18-C-6 (85 mg, 0.32 mmol, 2.15 equiv) followed by KHMDS (0.6 mL of 0.5 M 
solution in toluene, 0.30 mmol, 2.0 equiv).  After 30 min, 3.14 (67 mg, 0.15 mmol) was 
added in THF (1 mL).  The resultant solution was then allowed to warm up to room 
temperature and continue to stir overnight.  The reaction was quenched with NH4Cl (sat. 
5 mL), extracted with Ether (10 mL x 3), dried over Na2SO4, filtered and concentrated in 
vacuo.  The residue was purified by flash chromatography (Hexanes: EtOAc, 40:1) to 
afford 73 mg (91%) of 3.46 (Z:E = 100:6 based on NMR analysis) as colorless oil: [α]D25 
+22.5° (c 3.9, CHCl3); IR: (neat) 2958, 1719, 1244, cm-1; 1H NMR (500 MHz CDCl3): δ 
6.88 (s, 0.06 H), 6.53 (s, 1H), 5.94 (s, 1H), 5.74 (s, 1H), 5.54 (d, J = 10 Hz, 1H), 3.79 (s, 
3H), 3.80-3.75 (m, 1H), 3.64 (s, 3H), 2.70-2.65 (m, 1H), 1.96 (s, 3H), 1.88 (s, 3H), 1.64 
(s, 3H), 1.0 (d, J = 6.5 Hz, 3H), 0.94 (t, J = 8 Hz, 9 H), 0.60 (q, J = 8 Hz, 6H); 13C NMR 
(125 MHz, CDCl3): δ; 165.3, 144.3, 142.9, 141.5, 139.8, 130.5, 129.5, 126.9, 81.8, 79.5, 
60.2, 51.9, 37.6, 24.9, 16.4, 14.7, 13.7, 6.8, 4.8.  
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I
OTES
OMe
3.56  
To a solution of naphthalene (533 mg, 4.16 mmol, 8 equiv) in dry THF (4 mL) at 
room temperature was added potassium metal (162 mg, 4.16 mmol 8 equiv) slowly.  The 
reaction solution became green immediately.  After 1 h stirring at room temperature, 
ether (1 mL) and pentane  (1 mL) were added and the resultant solution was cooled to -
120 °C with liquid nitrogen and pentane.  A solution of (E)-1-methoxy-3-(phenylthio)-
propene 3.50 (375 mg, 2.08 mmol, 4 equiv) and (-)-B-methoxydiisopinocampheyl-
borance ( 658 mg, 2.08 mmol, 4 equiv) in dry THF (4 mL) was added via cannula.  The 
resulting mixture was stirred at -120 °C for 1 h then -78 °C for 3 h before filtered through 
a short pad of celite under nitrogen quickly at -78 °C.  BF3.OEt2 (342 µL, 2.7 mmol, 5.2 
mmol) was then added and the resulting solution was stirred at -78 °C for 15 min.  
Meanwhile, a solution of 3.53 (100 mg, 0.50 mmol) in CH2Cl2 (5 mL) at room 
temperature was added MnO2 (3.5 g, 35 equiv/mass).  The resultant black mixture was 
stirred at room temperature for 2 h before filtered though a celite pad and dried over 
Na2SO4 for 1 h.  After filtration, the solution was concentrated in vacuo to a volume of 1 
mL and the residue was diluted with dry THF (2 mL).  The resultant solution was then 
cannulaed into the reaction solution prepared above at -78 °C and after 2 h the reaction 
mixture was allowed to warm up to room temperature overnight. The mixture was then 
concentrated under vacuum and the residue was dissolved in dry ether (15 mL) and then 
filtered into 25 mL round bottom flask.  The resultant solution was then cooled down to 0 
°C and dry ethanolamine (100 µL) was added and kept at this temperature for 1 h then 
room temperature for 24 h.  After filtration and concentration, the residue was diluted 
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with dry CH2Cl2 (5 mL).  2,6-Lutidine (173 µL, 1.5 mmol, 3 equiv) and TESOTf (225 
µL, 1 mmol, 2 euqiv) were added subsequently at -78 °C.  The resultant solution was 
stirred at -78 °C for 30 min then 0 °C for 2 h.  The reaction was quenched with H2O (5 
mL) and extracted with CH2Cl2 (20 mL x 3), dried Over Na2SO4.  After concentrated in 
vacuum, the residue was purified by flash chromatography (Hexanes: EtOAc, 50:1) to 
afford 60 mg (31%) of 3.56 as colorless oil: [α]D25 -21.6° (c 0.8, CHCl3); IR (neat) 2953, 
1639, 1460, 1239 cm-1; 1H NMR (500 MHz, CDCl3): δ 6.22 (dd, J = 9, 1.5 Hz, 1H), 5.76 
(m, 1H), 5.31 (d, J = 5 Hz, 1H), 5.29 (d, J = 12.5 Hz, 1H), 4.28 (dd, J = 9, 5 Hz, 1H), 3.50 
(dd, J = 10.5, 7 Hz, 1H), 3.32 (s, 1H), 2.45 (s, 3H), 0.97 (t, J = 8 Hz, 9H), 0.63 ( q, J = 8 
Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 141.7, 135,4, 118.8, 96.5, 86.1, 72.3, 57.0, 28.7, 
6.7, 4.9; HRMS (ESI) m/z 389.0929  [(M+Li)+ calcd for C14H27IO2Si : 389.0985]. 
OMe
OH
3.65  
To a suspension of lithium acetylide ethylenediamine complex (3.9 g, 42.8 mmol, 
2 equiv) in DMSO (40 mL) at 0 °C was added a solution of 3.64 (2.44 g, 21.4 mmol) in 
DMSO (20 mL).  The solution was allowed to warm up to room temperature and 
continued to stir for 2 h.  Then the reaction solution was diluted with ether and cooled 
down to 0 °C.  H2O (14 mL) was added followed by adjusting the pH to 3 with 5% HCl.  
Layers were separated and aqueous layer was extracted with ether (50 mL x 3), the 
combined organic layer was dried over Na2SO4. After concentration in vacuo, the residue 
was dissolved in DMSO (50 mL) and cooled down to 15 °C.  t-BuOK (10 g, 85.6 mmol, 
4 equiv) was added carefully.  After 40 min, the reaction solution was diluted with ether 
(100 mL) and cooled down to 0 °C and carefully quenched with 3 M HCl (30 mL).  
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Layers were separated and aqueous layer was extracted with ether (100 mL x 3), the 
combined organic layer was washed with 1:1 mixture of NaHCO3 and brine (200 mL), 
dried over Na2SO4. After concentration in vacuo, the residue was purified by flash 
chromatography (Pentane: ether, 4:1) to afford 1.8 g (60%) of 3.65 as colorless oil: [α]D25 
+66.4° (c 2.1, CHCl3); IR (neat) 3419, 2920, 2361, 1422, 1132 cm-1; 1H NMR (500 MHz 
CDCl3): δ 5.88-5.81 (m, 1H), 5.41 (d, J = 6.5 Hz, 1H), 5.394 (d, J = 14 Hz, 1H), 4.38 (s, 
1H), 3.71 (dd, J = 7.5, 3.5 Hz, 1H), 3.38 (s, 3H), 2.45 (bs, 1H), 1.88 (d, J = 2 Hz, 3H),; 
13C NMR (125 MHz, CDCl3 ): δ 133.9, 120.2, 851, 82.5, 64.9, 56.9, 31.2, 3.7; HRMS 
(ESI) m/z 147.0973 [(M+Li)+ calcd for C8H12O2 : 147.0997]. 
 
OMe
OTES
3.66  
To a solution of 3.65 (280 mg, 2 mmol) in CH2Cl2 (10 mL) at 0 °C was added 2,6-
lutidine (0.7 mL, 6 mmol, 3 equiv) and TESOTf (1.12 mL, 5 mmol, 2.5 equiv).  After 1 h, 
the reaction was quenched with H2O (2 mL) and extracted with CH2Cl2 (10 mL x 3), 
dried over Na2SO4. After concentration in vacuo, the residue was purified by flash 
chromatography (Pentane: ether, 50:1) to afford 0.4 (79%) of 3.66 as colorless oil: [α]D25 
-27.9° (c 5.9, CHCl3); IR (neat) 2953, 1450, 1194 cm-1; 1H NMR (500 MHz CDCl3): δ 
5.83-5.76 (m, 1H), 5.32-5.29 (m, 2H), 4.32 (dd, J = 5, 2 Hz, 1H), 3.59 (dd, J = 7, 5 Hz, 
1H), 3.37 (s, 3H), 1.85 (d, J = 2 Hz, 3H), 0.97 (t, J = 8 Hz, 9H), 0.65 (qd, J = 8, 2.5 Hz, 
6H); 13C NMR (125 MHz, CDCl3): δ 135.0, 118.9, 86.3, 81.2, 78.3, 65.8, 57.2, 6.7, 4.8, 
3.7; HRMS (ESI) m/z 261.1870 [(M+Li)+ calcd for C14H26O2Si: 261.1862]. 
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OMe
OH
Bu3Sn
3.67  
To a solution of 3.65 (140 mg, 1 mmol) in THF (10 mL) at room temperature was 
added PdCl2(PPh3)2 (35 mg, 0.05 mmol, 0.05 equiv) followed by Bu3SnH (325 µL, 1.2 
mmol, 1.2 equiv).  The resultant solution was stirred for 30 min.  Solvent was removed 
under vacuo and the residue was purified by the residue was purified by flash 
chromatography (Pentane: ether, 100:0-30:1) to afford 125 mg (29%) of 3.67 as colorless 
oil: [α]D25 +2.93° (c 2.5, CHCl3); 1H NMR (500 MHz CDCl3): δ 5.78-5.71 (m, 1H), 5.52 
(d, J = 8 Hz, 1H), 5.34 (d,  J = 10.5 Hz, 1H), 5.28 (d, J = 17.5 Hz, 1H), 4.68-4.65 (m, 
1H), 3.61 (dd, J = 8, 3.5 Hz, 1H), 3.33 (s, 1H), 2.24 (d, J = 4.5 Hz, 1H), 1.91 (s, 3H), 
1.51-1.45 (m, 6H), 1.34-1.28 (m, 6H), 0.90-0.87 (m, 15H); 13C NMR (125 MHz, CDCl3): 
δ 143.3, 138.3, 134.3, 119.6, 85.6, 68.8, 56.4, 29.1, 27.3, 13.7, 9.1; HRMS (ESI) m/z 
439.2216 [(M+Li)+ calcd for C20H40O2Sn : 439.2210]. 
 
OMe
OTES
Bu3Sn
3.68  
To a solution of hexabutylditin (2.28 mL, 4.5 mmol, 7.6 equiv) in THF (5 mL) at 
-78 °C was added n-BuLi (1.8 mL, 4.5 mmol, 7.6 equiv) slowly.  After 5 min it was 
warmed up to -40 °C (acetonitrile & dry ice) and stirred for 30 min.  Then the solution 
was added to a suspension of CuCN (0.2 g, 2.24 mmol, 3.8 equiv) in THF (5 mL) at -78 
°C.  After 5 min, the mixture was warmed up to -40 °C and continued to stir for 30 min 
before cooled down to – 78 °C again and MeOH (1.2 mL) was added.  After 5 min, the 
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red slurry was warmed up to -10 °C (wet ice and acetone) and continued to stir for 30 
min.  Then a solution of 3.66 (150 mg, 0.59 mmol, 1 equiv) in THF (1 mL) was added at 
-78 °C and after 5 min it was warmed up to -10 °C and continued to stir for 6 h.   The 
reaction mixture was then cooled down to -20 °C and MeOH (1.2 mL) was added.  After 
15 min, H2O (1.2 mL) was added.  After another 15 min stirring at -20 °C, the reaction 
mixture was diluted with ether (10 mL) and brine (10 mL), extracted with ether, dried 
over Na2SO4. After concentration in vacuo, the residue was purified by flash 
chromatography (Pentane: ether, 100:0 to 30:1) to afford 236 mg (73%) of 3.68 as 
colorless oil: [α]D25 -8.1° (c 1.7, CHCl3); IR (neat) 2955, 1461, 1113cm-1; 1H NMR (500 
MHz CDCl3): δ 5.81-5.74 (m, 1H), 5.54 (dd, J = 8.5, 2 Hz, 1H), 5.25-5.19(m, 2H), 4.58 
(dd, J = 8.5, 4.5 Hz, 1H), 3.45 (dd, J = 7.5, 4.5 Hz, 1H), 3.29 (s, 3H), 1.88 (s, 3H), 1.56-
1.43 (m, 6H), 1.35-1.28 (m, 6H), 0.95 (t, J = 7.5 Hz, 9H), 0.91-0.87 (m, 15H), 0.61(q, J = 
7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ141.1, 139.7, 135.8, 117.9, 86.9, 69.9, 
56.7,29.0, 27.3, 13.6, 9.0, 6.7, 4.9.  
 
OMe
OTES
I
3.71  
To a solution of 3.68 (230 mg, 0.43 mmol) in CH2Cl2 (10 mL) at 0 °C was added 
Na2CO3 (112 mg, 1.06 mmol, 2 equiv) and I2 (270 mg, 1.06 mmol, 2 equiv).  The 
resultant solution was stirred at 0 °C for 1 h before quenched with Na2S2O3 (sat.).  After 
separated, the aqueous layer was extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4. 
After concentration in vacuo, the residue was purified by flash chromatography 
(Hexanes: EtOAc, 50:1) to afford 152 mg (92%) of 3.71 as colorless oil: [α]D25 -21.6° (c 
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0.8, CHCl3); IR (neat) 2953, 1639, 1416, 1193 cm-1; 1H NMR (500 MHz CDCl3): δ 6.22 
(dd, J = 9, 1.5 Hz, 1H), 5.76 (m, 1H), 5.31 (d, J = 5 Hz, 1H), 5.29 (d, J = 12.5 Hz, 1H), 
4.28 (dd, J = 9, 5 Hz, 1H), 3.50 (dd, J = 10.5, 7 Hz, 1H), 3.32 (s, 1H), 2.45 (s, 3H), 0.97 
(t, J = 8 Hz, 9H), 0.63 ( q, J = 8 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 141.7, 135.4, 
118.8, 96.5, 86.1, 72.3, 57.0, 28.7, 6.7, 4.9; HRMS (ESI) m/z 389.0929  [(M+Li)+ calcd 
for C14H27IO2Si : 389.0985]. 
 
I
OH
OTES
OMe
3.73  
To a flame dried round bottom flask charged with BH3.DMS (330 µL, 3.5 mmol, 
5 equiv) was added 2-methyl-2-butene (890 µL, 8.4 mmol, 12 equiv) dropwise at -12 °C.  
After 15 min the reaction solution was warmed up to 0 °C and maintained at this 
temperature for 2 h before ether (2 mL) was added.  The resulting homogenous solution 
was then stirred at 0 °C for 1 h and transferred to a solution of 3.71 (266 mg, 0.70 mmol) 
which has been pre-cooled to 0 °C via cannula.  The resultant solution was stirred at 0 °C 
for 2 h before NaOH (7 mL, 2.5 M) and H2O2 (30% solution in H2O, 5 mL) was added.  
After 20 min, the reaction mixture was warmed up to room temperature and continued to 
stir for 3 h.   The two layers were separated and aqueous layer was extracted with Ether 
(20 mL x 3).   The combined organic layer was then washed by brine, dried over Na2SO4. 
After concentration in vacuo, the residue was purified by flash chromatography 
(Hexanes: EtOAc, 5:1) to afford 160 mg (57%) of 3.73 as colorless oil: [α]D25 -42.3° (c 
5.1, CHCl3); IR (neat) 2954, 1458, 1097 cm-1; 1H NMR (500 MHz CDCl3): δ 6.23 (dd, J 
= 9, 1.5 Hz, 1H), 4.36 (dd, J = 9, 4.5 Hz, 1H), 3.78 (t, J = 5.5 Hz, 2H), 3.47 (s, 3H), 3.32 
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(m, 1H), 2.48 (d, J = 1.5 Hz, 3H), 1.76 (m, 2H), 1.60 (bs, 1H), 0.99 (t, J = 8 Hz, 9H), 0.63 
(q, J = 8 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 141.7, 96.3, 84.0, 71.7, 60.4, 59.0, 
32.9, 28.5, 6.7, 4.8; HRMS (ESI) m/z 407.1108 [(M+Li)+ calcd for C14H29IO3Si: 
407.1091]. 
 
I
O
OTES
OMe
3.8  
To a solution of 3.73 (30 mg, 0.075 mmol, 1 equiv) in CH2Cl2 (2 mL) at room 
temperature was added Dess-martin periodinane (65 mg, 0.15 mmol, 2 equiv).  The 
resultant white slurry was stirred at room temperature for 1 h before evaporate solvent in 
vacuo.  The residue was purified by flash chromatography (Hexanes: EtOAc, 5:1) to 
afford 160 mg (57%) of 3.8 as colorless oil: [α]D25 -29.0° (c 2.7, CHCl3); IR (neat) 2954, 
1725, 1414, 1097cm-1; 1H NMR (500 MHz CDCl3): δ 9.79 (t, J = 2 Hz, 1H), 6.17 (dd, J = 
8.5, 1.5 Hz, 1H), 4.35 (dd, J = 8.5, 5 Hz, 1H), 3.60 (m, 1H), 3.43 (s, 3H), 2.60 (m, 2H), 
2.45 (d, J = 1.5 Hz, 3H), 0.95 (t, J = 8 Hz, 9H), 0.60 ( q, J = 8 Hz, 6H); 13C NMR (125 
MHz, CDCl3): δ 200.7, 141.4, 97.0, 80.0, 71.5, 58.7, 45.2, 28.6, 6.6, 4.7; HRMS (ESI) 
m/z 405.0715 [(M+Li)+ calcd for C14H27IO3Si: 405.0934]. 
 
 
O
NO
Ph
O
OMe
OH
OBn
3.90  
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To a solution of diisopropyl amine (175 µL, 1.25 mmol, 1.6 equiv) in THF (4 mL) 
at 0 °C was added n-BuLi (470 µL, 1.17 mmol, 1.5 equiv).  After 15 min, the reaction 
solution was cooled down to -78 °C and 3.13 (265 mg, 0.78 mmol) in THF (4 mL) was 
added.  The resultant solution was stirred at -78 °C for 30 min before TiCl(O-iPr)3(3.2 
mL, 3.12 mmol, 4 equiv) was added.  The resulting solution was then warmed up to –40 
°C and stirred for 1 h.  It was then cooled down to -78°C again and 3.89 (160 mg, 1.6 
mmol, 2 equiv) in THF (4 mL) was added.  The resultant solution was stirred at -40°C for 
2 h before quenched with saturated NH4Cl (5 mL), and stirred with celite for 30 min.  The 
slurry was then filtered through a celite pad, washed with ether, dried over Na2SO4. The 
combined organic phase was filtered, and concentrated in vacuo.  The residue was 
purified by flash chromatography (Hexanes: EtOAc, 5:1) to afford 282 mg (79%) 3.90 as 
colorless oil: [α]D25 -56.7° (c 1.0, CHCl3); IR (neat) 2932, 1779, 1455, 1102 cm-1; 1H 
NMR (400 MHz C6D6): δ7.43 (d, J=7.6 Hz, 2 H), 7.23-6.96 (m, 8H), 4.94 (s, 1H), 4.82 
(t,6.8 Hz, 1 H), 4.58 (d, J = 11.2 Hz, 1H), 4.53 (d, J = 11.2 Hz, 1 H), 3.25-3.10 ( m, 2H), 
3.05 (s, 3H), 1.90-1.57 ( m, 4H), 1.81 (s, 3H),1.07 (s, 3H), 0.58 (s, 3 H); 13C NMR (100 
MHz, C6D6): δ 174.21, 152.02, 139.11, 137.19, 86.36, 81.60, 73.50, 72.31, 69.12, 66.96, 
58.17,29.41, 28.11, 26.76,23.40, 17.00; HRMS (ESI) m/z 462.2471[(M+Li)+ calcd for 
C26H33NO6 462.2468]. 
 
O
BnO
OMe
OH
OBn
3.91  
To a solution of BnOH (58 µL, 0.56 mmol, 2 equiv) in THF (2 mL) at -78 °C was 
added n-BuLi (168 µL, 0.42 mmol, 1.5 equiv).  After 10 min, 3.90 (130 mg, 0.28 mmol) 
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in THF (2 mL) was added dropwise.  10 min later, the reaction solution was warmed up 
to 0 °C and continued to stir 3 h.  The reaction was quenched with saturated NH4Cl (5 
mL), extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4. The organic phase was 
filtered, concentrated in vacuo. The residue was purified by flash chromatography 
(Hexanes: EtOAc, 6:1) to provide 90 mg (86%) 3.91 as colorless oil: : [α]D25 +12.9° (c 
2.8, CHCl3); IR (neat) 2929, 1751, 1420, 1263cm-1; 1H NMR (500 MHz CDCl3): δ 7.36-
7.23 (m, 10H), 5.24 (d, J = 12.5 Hz, 1H), 5.18 (d, J = 12.5 Hz, 1H), 4.48 (d, J = 10.5 Hz, 
1H), 4.44 (d, J = 10.5 Hz, 1H), 3.80 (d, J = 10.5 Hz, 1H), 3.34 (t, J = 5.5 Hz, 2H), 3.29 (s, 
3H), 2.93 (bs, 1H), 1.80-1.73 (m, 1H), 1.67-1.59 (m, 2H), 1.52 (s, 3H), 1.46-1.39 (m, 
1H); 13C NMR (125 MHz, CDCl3): δ173.0, 138.20, 135.6, 128.5, 128.4, 128.3, 128.2, 
127.6, 127.5, 83.0, 75.8, 72.7, 66.9, 66.8, 58.5, 28.3, 26.6, 16.7; HRMS (ESI) m/z 
379.2133[(M+Li)+ calcd for C22H28O5: 379.2097]. 
 
HO
OMe
OH
OBn
3.92  
To a solution of 3.91  (90 mg, 0.24 mmol) in THF (4 mL) at 0 °C was added LAH 
(20 mg, 0.48 mmol, 2 equiv).  After 10 min, the reaction mixture was warmed up to room 
temperature and continued to stir for 2 h.   The reaction was quenched with NaOH (5 mL, 
3 M) and H2O (2 mL), extracted with ether (10 mL x 3), dried over Na2SO4.  The 
combined organic layer was filtered, concentrated in vacuo.  The residue was purified by 
flash chromatography (Hexanes: EtOAc, 1:2) to afford 52 mg ( 81%) diol 3.92 as 
colorless oil: [α]D25 +19.0° (c 1.7, CHCl3); IR (neat) 3366, 2926, 2360, 1459, 1130 cm-1; 
1H NMR (400 MHz CDCl3): δ 7.36-7.27 (m, 5H), 4.56 (s, 2H), 3.82-3.71 (m, 3H), 3.46 
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(t, J = 8Hz, 2H), 3.36 (s, 3H), 1.90-1.78 (m, 2H), 1.78-1.71 (m, 1H), 1.49-1.43 (m, 1H) 
1.18 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 138.8, 128.4, 127.5, 79.0, 75.9, 72.9, 65.2, 
64.0, 58.6, 28.5, 27.2, 16.2; HRMS (ESI) m/z 275.1828[(M+Li)+ calcd for C15H24O4 
275.1835]. 
 
TBSO
OMe
OH
OBn
3.93  
To a solution of 3.92 (52 mg, 0.19 mmol) in CH2Cl2 (2 mL) at –15 °C was added 
diisopropyl ethylamine (85 µL, 0.48 mmol, 2.5 equiv) and TBSCl (30 mg, 0.20 mmol, 
1.05 equiv).  The resultant solution was stirred at –15 °C for 4 h before quenched with 
H2O (3 mL) and extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4.  After filtration 
and concentration in vacuo, the residue was purified by flash chromatography 
(Hexanes:EtoAc, 5:1) to afford 40 mg(55%) of 3.93 as colorless oil: [α]D25 +9.5° (c 3.2, 
CHCl3); IR (neat) 3366, 2926, 2360, 1459, 1130 cm-1; 1H NMR (500 MHz CDCl3): 
δ7.34-7.25 (m, 5H), 4.63 (d, J = 11.5 Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H), 3.76 (s, 2H), 
3.74 (d, J = 11 Hz, 1H), 3.46-3.43 (m, 2H), 3.35 (s, 3H), 3.10 (bs, 1H), 1.93-1.85 (m, 
1H), 1.80-1.74 (m, 1H), 1.69-1.64 (m, 1H), 1.50-1.42 (m, 1H), 1.25 (s, 3H), 0.92 (s, 9H), 
0.08 (s, 3H), 0.7 (s, 3H); 13C NMR (125 MHz, CDCl3): δ139.6, 128.2, 127.2, 127.1, 78.9, 
75.3, 72.9, 67.0, 64.7, 58.5, 28.2, 27.0, 25.8, 18.1, 16.2; HRMS (ESI) m/z 389.2650 
[(M+Li)+ calcd for C21H38O4Si: 383.2618]. 
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OH
OH
3.94  
To a solution of 3.93 (40 mg, 0.10 mmol) in EtOH (3 mL) at room temperature 
was added Pd/C (11 mg of 10% wt mixture, 0.01 mmol, 0.1 equiv).  The reaction flask 
was equipped with a Hydrogen gas balloon and stirred at room temperature for 16 h. The 
reaction mixture was filtered through a celite pad and washed with ether (10 mL).  The 
combined organic layer was dried over Na2SO4.  After filtration and concentration in 
vacuo, the residue was purified by flash chromatography (Hexanes: EtOAc, 4:1) to afford 
10 mg (34%) of 3.94 as colorless oil: IR (neat) 3366, 2926, 2360, 1459, 1130 cm-1; 1H 
NMR (400 MHz C6D6): δ3.76 (d, J= 10 Hz, 1H), 3.58 (dd, J= 9.6, 4 Hz, 1H), 3.51(d, J = 
10 Hz, 1H), 3.19 (t, J= 6 Hz, 2H), 3.08 (d, 5.2 Hz, 1H), 3.04 (s, 3H), 2.85 (s, 1H), 1.93-
1.79 (m, 2H), 1.69-1.58 (m, 1H), 1.47-1.37 (m, 1H)1.14 (s, 3H), 0.92 (s, (H), -0.01 (s, 
6H); 13C NMR (100 MHz, C6D6): δ 76.6, 73.7, 73.0, 68.8, 58.2, 29.2, 27.7, 25.9, 20.2, 
18.4. 
O O
TBSO
H
OMe
3.95  
To a solution of 3.94 (10 mg, 0.034 mmol) in CH2Cl2 (2 mL) at room temperature 
was added p-TSA (2 mg, 3.4 µmol, 0.1 equiv) and 2,2-dimethoxy propane (10 µL, 50 
µmol, 1.5 equiv).  The resultant solution was stirred at room temperature for 1 h before 
quenched with saturated NaHCO3 (3 mL).  The mixture was separated, extracted with 
CH2Cl2 (10 mL x 3), dried over Na2SO4.  After filtration and concentration in vacuo, the 
residue was purified by flash chromatography (Hexanes: EtOAc, 4:1) to afford 6 mg 
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(53%) of 3.95 as colorless oil: 1H NMR (400 MHz C6D6): δ 3.80 (d, J = 9.6 Hz, 2H), 3.40 
(d, 9.6 Hz, 1 H), 3.32-3.25 (m, 1H), 3.13 (s, 3 H), 1.97 (m, 1H), 1.86-1.79 (m, 2 H), 1.73-
1.68 (m, 1H), 1.34 (s, 3 H), 1.32 (s, 3H), 0.95 (s, 9H), 0.009 (s, 3), 0.003 (s, 3H); 13C 
NMR (100 MHz, C6D6): δ 106.8, 83.7, 81.8, 72.8, 65.9, 58.3, 29.0, 28.2, 26.7, 26.40, 
26.0, 22.0, 18.3. 
O
NO
Ph
O
OMe
OTES
OBn
3.96  
To a solution of 3.90 (320 mg, 0.70 mmol) in CH2Cl2 (10 mL) at -78 °C was 
added TESOTf (320 µL, 1.4 mmol, 2 equiv) and 2,6-Lutidine (240 µL, 2.1 mmol, 3 
equiv). The resultant solution was stirred at -78 °C for 30 min the warmed up to 0 °C and 
stir for 2 h before quenched with H2O (5 mL). Extracted with CH2Cl2 (10 mL x 3), dried 
over Na2SO4.  After filtration and concentration in vacuo, the residue was purified by 
flash chromatography (Hexanes: EtOAc, 10:1) to afford 370 mg (90%) of 3.96 as 
colorless oil: [α]D25 +9.7° (c 1.0, CHCl3); IR(neat) 1954, 1456, 1118 cm-1; 1H NMR (400 
MHz CDCl3): δ 740-7.26 (m, 8H), 7.16 (m, 2H), 5.13 (s, 1H), 4.78 (d, J = 12 Hz, 1H), 
4.69 (t, J = 4 Hz, 1H), 4.53 (d, J = 12 Hz, 1H), 3.27 (s, 3H), 3.26-3.23 (m, 2H), 1.76-1.68 
(m, 1H), 1.58 (s, 3H), 1.56-1.47 (m, 3H), 1.43 (s, 3H), 0.95-0.88 (m, 12H), 0.52 (q, J = 
8Hz, 6H); 13C NMR (100 MHz, CDCl3): δ; 175.8, 151.8, 138.7, 136.5, 128.6, 128.5, 
128.2, 127.2, 127.1, 85.6, 81.7, 76.3, 72.8, 69.2, 67.0, 58.3, 29.8, 28.4, 26.5, 23.8, 16.4, 
7.0, 5.4; HRMS (ESI) m/z 576.3339[(M+Li)+ calcd for C32H47NO6Si: 576.3333]. 
 
 136 
OMe
OTES
BnO
EtS
3.97
O
 
To a solution of EtSH (390 µL, 5.27 mmol, 3 equiv) in THF (5 mL) at -78 °C was 
added n-BuLi (1.4 mL, 3.52 mmol, 2 equiv).  After 10 min, 3.96 (1 g, 1.76 mmol) in THF 
(10 mL) was added dropwise.  The resultant solution was stirred at -78 °C for 10 min 
then warmed up to room temperature and continued to stir for 30 min.  It was then diluted 
with ether (20 mL), washed with NaOH (10 mL of 1M solution) and brine (10 mL), dried 
over Na2SO4.  After filtration and concentration in vacuo, the residue was purified by 
flash chromatography (Hexanes: EtOAc, 15:1) to afford 610 mg (79%) of 3.97 as 
colorless oil: [α]D25 +29.0° (c 1.2, CHCl3); IR (neat) 2954, 1875, 1454, 1120 cm-1; 1H 
NMR (400 MHz, CDCl3): δ 7.43-7.28 (m, 5H), 4.69 (d, J = 12 Hz, 1H), 4.61 (d, J = 12 
Hz, 1H), 4.02 (t, J = 4 Hz, 1H), 3.35-3.32 (m, 2H), 3.30 (s, 3H), 2.84 (m, 2H), 1.72-1.68 
(m, 2H), 1.61-1.53 (m, 2H), 1.47 (s, 3H), 1.26 (t, J = 4 Hz, 3H), 0.97 (t, J= 8 Hz, 9H), 
0.62 (q, J = 8 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 205.0, 138.7, 128.2, 127.2, 87.9, 
77.7, 72.9, 66.6, 58.4, 29.7, 26.7, 22.7, 16.7, 14.4, 7.0, 5.4; HRMS (ESI) m/z 447.2583 
[(M+Li)+ calcd for C23H40O4SSi 447.2577 ]. 
 
3.98
OMe
OTES
BnO
H
O
 
To a solution of 3.97 (620 mg, 1.4 mmol) in CH2Cl2 (10 mL) at -78 °C was added 
DIBAL-H (2.3 mL, 2.3 mmol, 1.65 equiv).  The resultant solution was stirred at -78 °C 
for 2 h before quenched with MeOH (2 mL).  The reaction mixture was then poured into 
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a saturated solution of Rochelle’s salt (50 mL solution of sodium potassium tartrate in 
H2O) and stirred at room temperature for 1 h.  After separated, extracted with CH2Cl2 (10 
mL x 3) and dried over Na2SO4. After concentration in vacuo, the residue was purified by 
flash chromatography (Hexanes: EtOAc, 10:1) to afford 143 mg (90%) of 3.98 as 
colorless oil: [α]D25 +58.5° (c 0.5, CHCl3); IR (neat) 2954, 1737, 1453, 1116 cm-1; 1H 
NMR (400 MHz, CDCl3): δ 9.63 (s, 1H), 7.37-7.28 (m, 5H), 4.58 (d, J = 12 Hz, 1H), 4.38 
(d, J = 12 Hz, 1H), 3.97 (dd, J = 8, 4 Hz, 1H), 3.37 (t, J = 4Hz, 2H), 3.32 9(s, 3H), 1.78-
1.69 (m, 2H), 1.62-1.54 (m, 2H), 1.33 (s, 3H), 0.93 (t, J = 8Hz, 9H), 0.60 (q, J = 8Hz, 
6H); 13C NMR (100 MHz, CDCl3): δ 204.0, 138.3, 128.3, 127.6, 127.5, 84.7, 75.7, 72.7, 
66.5, 58.5, 29.3, 26.5, 12.8, 6.9, 5.3; HRMS (ESI) m/z 387.2584 [(M+Li)+ calcd for 
C21H36O4Si : 387.2543]. 
 
N
OMe
O
OMe
OH OTES
O
S
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3.102  
To a solution of 3.12 (53 mg, 0.2 mmol) in CH2Cl2 (2 mL) at 0 °C was added 
TiCl4 (0.2 mL, 0.2 mmol, 1 equiv).  After 5 min, (-)-sparteine (46 µL, 0.2 mmol, 1 equiv) 
was added.  20 min later, the reaction slurry was cooled down to -78 °C and N-methyl-2-
pyrrolidinone (20 µL, 0.2 mmol, 1 equiv) was added.  After 10 min, 3.98 (100 mg, 
0.26mmol, 1.3 equiv) was added in CH2Cl2 (2 mL).  The resultant solution was stirred at -
78 °C for 1 h, then 0 °C for 1 h, quenched with NH4Cl (sat., 5 mL), extracted with 
CH2Cl2 (10 mL x 3), dried over Na2SO4. After concentration in vacuo, the residue was 
purified by flash chromatography (Hexanes: EtOAc, 5:1) to afford 80 mg (62%) of 3.102 
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as colorless oil: [α]D25 -4.8° (c 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.33-7.06 (m, 
10H), 6.06 (d, J = 4 Hz, 1H), 4.84 (d, J = 8 Hz, 1H), 4.47 (dd, J = 8, 4 Hz, 1H), 4.34 (d, J 
= 8 Hz, 1H), 3.99 (m, 1H), 3.84 (t, J = 4 Hz, 1H), 3.79 (d, J = 8 Hz, 1H), 3.49 (s, 3H), 
3.42 (t, J = 8 Hz, 2H), 3.36 (s, 3H), 3.22 (d, J = 8 Hz, 1H), 3.15-3.07 (m, 2H), 2.50 (dd, J 
= 12, 2 Hz, 1H), 1.88 (m, 2H), 1.68 (m, 2H), 1.51 (s, 3H), 0.97 ( t, J = 8 Hz, 9H), 0.69 (q, 
J = 8 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 184.9, 170.6, 139.4, 135.3, 129.3, 128.7, 
128.3, 128.2, 127.5, 127.2, 81.8, 79.8, 77.9, 73.2, 73.0, 70.2, 66.4, 60.5, 59.0, 58.5, 37.3, 
29.3, 27.3, 14.5, 7.1, 5.4; HRMS (ESI) m/z 652.3319 [(M+Li)+ calcd for C34H51NO7SSi: 
652.3316]. 
 
EtS
OMe
O
OMe
OH OTES
OBn
3.106  
To a solution of EtSH (14 µL, 0.186 mmol, 5 equiv) in THF (1 mL) at -78 °C was 
added n-BuLi (45 µL, 0.111 mmol, 3 equiv).  After 20 min, 3.102 (24 mg, 0.037mmol) in 
THF (1 mL) was added. The resultant solution was stirred at -78 °C for 2 h, quenched 
with NH4Cl (sat., 2 mL), extracted with ether (10 mL x 3), dried over Na2SO4.  After 
concentration in vacuo, the residue was purified by flash chromatography (Hexanes: 
EtOAc, 5:1) to afford 12 mg (63%) of 3.106 as colorless oil: [α]D25 +33.0° (c 1.8, CHCl3); 
IR (neat) 2951, 1686, 1378, 1191cm-1; 1H NMR (500 MHz, CDCl3): δ 7.33-7.21 (m, 5H), 
4.73 (d, J = 11.5 Hz, 1H), 4.65 (d, J = 11.5 Hz, 1H), 4.03 (s, 2H), 3.97 (dd, J = 7, 3 Hz, 
1H), 3.39 (s, 3H), 3.37 (t, J = 6.5 Hz, 2H), 3.32 (s, 3H), 2.99 (d, J = 3.5 Hz, 1H), 2.73 (m, 
2H), 1.88-1.77 (m, 2H), 1.65-1.53(m, 2H), 1.40 (s, 3H), 1.18 (t, J = 7Hz, 3H), 0.97 (t, J = 
8 Hz, 9H), 0.66 (q, J = 8 Hz, 6H) ; 13C NMR (125 MHz, CDCl3): δ 201.9, 139.5, 128.1, 
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127.2, 126.9, 87.4, 81.5, 77.2, 76.2, 73.0, 65.8, 58.9, 58.5, 29.5, 27.4, 22.5, 14.8, 14.2, 
7.0, 5.4; HRMS (ESI) m/z [(M+Li)+ calcd for]. 
 
EtS
OMe
O
OMe
OTESOTES
OBn
3.105  
To a solution of 3.106 (12 mg, 0.023 mmol) in CH2Cl2 (1 mL) at -78 °C was 
added 2,6-Lutidine (8 µL, 0.069 mmol, 3 equiv) followed by TESOTf (10 µL, 0.046 
mmol, 2 equiv).  The resultant solution was stirred at -78 °C for 3 h, quenched with H2O 
(2 mL), extracted with CH2Cl2 (10 mL x 3), dried over Na2SO4.  After concentration in 
vacuo, the residue was purified by flash chromatography (Hexanes: EtOAc, 10:1) to 
afford 13 mg (90%) of 3.105 as colorless oil: [α]D25 +18.6° (c 2.0, CHCl3); IR (neat) 
2954, 1692, 1456, 1079-1; 1H NMR (500 MHz, CDCl3): δ7.30-7.18 (m, 5H), 4.77 (d, J = 
12 Hz, 1H), 4.67 (d, J = 12 Hz, 1H), 4.26 (d, J = 3.5 Hz, 1H), 3.97 (d, J = 3.5 Hz, 1H), 
3.86 (dd, J = 7.5, 3 Hz, 1H), 3.44 (s, 3H), 3.38-3.33 (m, 2H), 3.32 (s, 3H), 2.68-2.60 (m, 
1H), 2.40-2.32 (m, 1H), 1.84-1.73 (m, 2H), 1.58-1.45 (m, 2H), 1.45 (s, 3H), 1.05 (t, J = 
7.5 Hz, 3H), 1.0 (t, J = 8 Hz, 9H), 0.94 (t J = 8 Hz, 9H), 0.67 (q, J = 8 Hz, 6H), 0.54 (q, J 
= 8 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 200.1, 139.9, 127.8, 127.1, 126.6, 89.8, 
82.4, 77.1, 76.9, 73.3, 66.1, 59.5, 58.4, 29.1, 27.5, 22.2, 14.3, 13.9, 7.1, 7.0, 6.8, 6.4; 
HRMS (ESI) m/z  635.3808[(M+Li)+ calcd for C32H60O6SSi2: 635.3809]. 
 
3.9'
OMe
O
OMe
OTESOTES
OBn
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To a solution of suspension of CuI (30 mg, 0.16 mmol, 5 equiv) in ether (1 mL) at 
0 °C was added EtLi (0.64 mL, 0.32 mmol, 10 equiv).  After 15 min, 3.105 (20 mg, 0.032 
mmol, 1 equiv) was added.  The resultant solution was stirred at 0 °C for 20 min, 
quenched with NH4Cl (sat.), extracted with ether, dried over Na2SO4. After concentration 
in vacuo, the residue was purified by flash chromatography (Hexanes: EtOAc, 10:1) to 
afford 15 mg (79%) of 3.9’ as colorless oil: [α]D25 +14.6° (c 0.6, CHCl3); IR (neat) 2955, 
1711, 1456, 1094 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.31-7.21 (m, 5H), 4.75 (d, J = 12 
Hz, 1H), 4.57 (d, J = 12 Hz, 1H), 4.26 (narrow d, 1H), 3.84 (dd, J = 8, 4 Hz, 1H), 3.79 
(narrow d, 1H), 3.40-3.35 (m, 2H), 3.37 (s, 3H), 3.33 (s, 3H), 2.45-2.35 (m, 1H), 2.30-
2.20 (m, 1H), 1.85-1.76 (m,1H), 1.73-1.69 (m, 1H), 1.46 (s, 3H), 1.03-0.96 (m, 18), 0.71-
0.59 (m, 15H); 13C NMR (125 MHz, CDCl3): δ 210.2, 139.3, 128.0, 127.54, 126.86, 89.4, 
82.4, 77.5, 77.2, 73.2, 66.6, 58.9, 58.5, 32.7, 28.9, 27.5, 14.2, 7.1, 7.0, 6.7, 5.8, 5.6; 
HRMS (ESI) m/z 603.4084 [(M+Li)+ calcd for C32H60O6Si2: 603.4089]. 
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CHAPTER IV 
SUMMARY 
Apoptolidin, a specific apoptosis inducer, has attracted extensive attention from 
both biological and synthetic community for its interesting biological activity and 
complex architecture since its isolation in 1997 by Seto’s group in Japan.  Such interests 
has led to Khosla and Wender’s work in Stanford University directed at identification of 
apoptolidin’s biological target for causing apoptosis and quite a few synthetic studies 
towards total synthesis of apoptolidin as described in chapter I.  To date, K. C. Nicolaou 
and Ulrich Koert have achieved two total syntheses of apoptolidin, respectively.  Three 
groups including Koert, Crimmins and Sulikowksi group have completed the total 
synthesis of apoptolidinone.  Several other fragments syntheses were also discussed in 
chapter I including our attempts towards total synthesis of pseudoapoptolidin.  
Chapter II described our efforts towards total synthesis of apoptolidinone based 
on a strategy utilizing a cross metathesis and an intramolecular Horner-Wadsworth-
Emmons reaction.  Also a large-scale preparation of apoptolidinone for biological activity 
test via an intramolecular Suzuki coupling approach featuring asymmetric aldol reactions, 
Yamaguchi esterification reaction and intermolecular Suzuki coupling reaction was 
discussed in chapter II.  
 Ammocidin was another specific apoptosis inducer discovered by Seto’s group.  
Since the isolation in 2001, its structure has not been fully assigned yet.  The ambiguous 
structure and interesting biological activity of ammocidin drew our attention and hence 
led to our selecting ammocidinone as synthetic target.  Chapter III mainly focused on our 
synthetic efforts to build three major building blocks of ammocidinone highlighted by 
 142 
cross metathesis, Horner-Wadsworth-Emmons, asymmetric aldol and asymmetric 
expoxidation reactions.  
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